Conjugate of cytotoxic agent to cell binding molecule with branched linker
Patent Information
- Application Number
- JP2024075879
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-05-08
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing antibody-drug conjugates (ADCs) face issues with off-target toxicity due to systemic exposure and reduced efficacy from hydrolysis by enzymes, leading to failures in clinical trials and limited application of approved drugs.
Development of conjugates with branched side chain linkages that stabilize the cytotoxic agents, preventing hydrolysis by enzymes and minimizing off-target toxicity, thereby extending half-life and improving therapeutic window.
The branched side chain linkages enhance the stability and specificity of ADCs, reducing systemic toxicity and increasing efficacy by maintaining targeted delivery to abnormal cells.
Smart Images

Figure 2024112832000001 
Figure 2024112832000002 
Figure 2024112832000003
Abstract
Description
[Technical Field]
[0001] The present invention relates to conjugates of cell-binding molecules and cytotoxic agents having branched linkers that exhibit better pharmacokinetics in the delivery of the conjugate compounds, resulting in highly precise targeted therapy of abnormal cells. The present invention also relates to side chain linking methods for preparing conjugates of cytotoxic agents and cell-binding ligands, and methods of using the conjugates for the prevention or targeted treatment of cancer, infectious diseases, and autoimmune diseases. [Background technology]
[0002] Antibody-drug conjugates (ADCs), consisting of monoclonal antibodies (mAbs) linked to cytotoxic drugs via specialized linking molecules, have become one of the major biotherapies for the treatment of cancer, infectious diseases, autoimmune diseases, and other drug-resistant diseases (Non-Patent Documents 1-4). This is because antibodies, which are 100 times larger in size, generally have a much longer circulation half-life than cytotoxic drugs. Therefore, systemic exposure and potential toxicity of conventional cytotoxic drugs after conjugation to antibodies are significantly reduced. Furthermore, ADCs can more precisely deliver and release cytotoxic drugs to tumor sites or target tumor cells. This significantly improves the therapeutic window, i.e., the selectivity and specificity of cytotoxic drugs between tumors and normal tissues. Currently, five ADCs—gemtuzumab, ozogamicin, brentuximab vedotin, trastuzumab emtansine, inotuzumab ozogamicin, and moxetumomab pasudotox—have been approved by the U.S. FDA, and more than 100 new promising drugs are in development.
[0003] Among ADC conjugates of cytotoxic agents, releasable conjugates, and antibodies, and in techniques for conjugating components to antibody moieties, the conjugate is known to significantly affect the potency, selectivity, and pharmacokinetics of the resulting ADC conjugate and to overcome multidrug-resistant disease cells that overexpress efflux transporter proteins (Non-Patent Documents 5 to 8). Therefore, optimization of the conjugate is crucial for improving the therapeutic spectrum and safety profile of ADCs.
[0004] Because ADC conjugates must be degradable, the conjugated cytotoxic agent may be released into the blood circulation, potentially increasing systemic toxicity and reducing efficacy. In addition to this type of off-target toxicity, reduced permeability / internalization, metabolic tendency, and target specificity to tumor cells have led to the failure of over 40 ADC drugs in clinical trials over the past 40 years. Off-target toxicity also hinders the widespread application of approved ADC drugs. For example, ado-trastuzumab emtansine (T-DM1, "Kadcyla"®), which uses a stable (non-cleavable) MCC conjugate, has shown significant benefit in clinical trials for patients with HER2-positive metastatic breast cancer (mBC) or for patients who had previously been treated for mBC or whose HER2 tumors recurred within 6 months of adjuvant therapy (Non-Patent Documents 9-11). However, clinical trials of T-DM1 failed because of minimal patient benefit when comparing its efficacy and side effects as a first-line treatment for patients with HER2-positive unresectable locally advanced or metastatic breast cancer and as a second-line treatment for HER2-positive advanced gastric cancer (Non-Patent Documents 12-15).
[0005] To address the issue of off-target toxicity, research and development in ADC chemistry and design is now expanding beyond simply payload potency to encompass the scope of conjugate-payload compartments and conjugation chemistries, specifically addressing the activity of the ADC conjugate-payload toward the target / target disease (Non-Patent Documents 16-17). Today, many drug developers and academic institutions focus on the long circulating half-life, high efficacy, potentially reduced off-target toxicity, narrow range of in vivo pharmacokinetic (PK) properties of ADCs, and the backlog in ADC production. We are focusing on establishing new, reliable and specific conjugates and site-specific ADC conjugation methods that are expected to improve consistency between teams (Non-Patent Documents 18-22). These specific conjugation methods reported so far include the insertion of engineered cysteines (Non-Patent Documents 23-24, Patent Documents 1-5), selenocysteine (Non-Patent Documents 25-26, Patent Document 6), cysteine-containing tags containing perfluoroaromatic reagents (Non-Patent Document 27), thiol fucose (Non-Patent Document 28), unnatural amino acids (Non-Patent Documents 29-32, Patent Documents 7-17), conjugation to reduced intermolecular disulfides by re-bridging dibromomaleimide (Non-Patent Document 33), bis-sulfone reagents (Non-Patent Document 34, Patent Documents 18-19), dibromopyridazinediones (Non-Patent Document 35), galactosyltransferases and sialyltransferases (Non-Patent Document 36, Patent Document 20), formylglycine synthases (FGEs) (Non-Patent Document 37, Patent Documents 21-25), phosphopantetheinyltransferases (PPTases) (Non-Patent Document 38), sortase A (Non-Patent Document 39), and Streptoverticillium These include glutamine tags genetically introduced with mobaraense transglutaminase (mTG) (Non-Patent Documents 40-41, Patent Document 26) or microbial transglutaminase (MTGase) (Non-Patent Documents 42-43, Patent Documents 27-28), and enzymes / bacteria that form isopeptide bonds-peptide bonds on the outside of the protein backbone (Non-Patent Documents 44-46). [Prior art documents] [Patent documents]
[0006] [Patent Document 1] U.S. Patent No. 8,309,300 [Patent Document 2] U.S. Patent No. 7,855,275 [Patent Document 3] U.S. Patent No. 7,521,541 [Patent Document 4] U.S. Patent No. 7,723,485 [Patent Document 5] International Publication No. WO2008 / 141044 [Patent Document 6] U.S. Patent No. 8,916,159 [Patent Document 7] U.S. Patent No. 8,778,631 [Patent Document 8] U.S. Patent Application Publication No. 20100184135 [Patent Document 9] International Publication No. WO2010 / 081110 [Patent Document 10] International Publication No. WO2006 / 069246 [Patent Document 11] International Publication No. WO2007 / 059312 [Patent Document 12] U.S. Patent No. 7,332,571 [Patent Document 13] U.S. Patent No. 7,696,312 [Patent Document 14] U.S. Patent No. 7,638,299 [Patent Document 15] International Publication No. WO2007 / 130453 [Patent Document 16] U.S. Patent No. 7,632,492 [Patent Document 17] U.S. Patent No. 7,829,659 [Patent Document 18] International Publication No. WO2013 / 190272 [Patent Document 19] International Publication No. WO2014 / 064424 [Patent Document 20] U.S. Patent Application Publication No. 20140294867 [Patent Document 21] U.S. Patent No. 7,985,783 [Patent Document 22] U.S. Patent No. 8,097,701 [Patent Document 23] U.S. Patent No. 8,349,910 [Patent Document 24] U.S. Patent Application Publication No. 20140141025 [Patent Document 25] U.S. Patent Application Publication No. 20100210543 [Patent Document 26] U.S. Patent No. 8,871,908 [Patent Document 27] U.S. Patent Application Publication No. 20130189287 [Patent Document 28] U.S. Patent No. 7,893,019
Non-licensed literature
[0007]
Non-patent document 1
Non-patent document 2
Non-patent document 3
Non-patent document 4
Non-patented document 5
Non-patent document 6
Non-patent document 7
Non-patent document 8
Non-licensed literature 9
Non-licensed literature 10
Non-licensed Document 11
Non-licensed Document 12
Non-licensed Document 13
Non-licensed Document 14
Non-licensed Document 15
Non-licensed Document 16
Non-licensed Document 17
Non-licensed Document 18
Non-licensed Document 19
Non-licensed Document 20
Non-licensed Document 21
Non-licensed Document 22
Non-licensed Document 23
Non-licensed Document 24
Non-licensed Document 25
Non-licensed Document 26
Non-licensed Document 27
Non-licensed Document 28
Non-licensed Document 29
Non-licensed Document 30
Non-patent document 31
Non-patent document 32
Non-patent document 33
Non-patent document 34
Non-patented document 35
Non-patent document 36
Non-patent document 37
Non-patent document 38
Non-patent document 39
Non-patent document 40
Non-patent document 41
Non-patent document 42
[0008] Applicant has disclosed several conjugation methods that re-bridge thiol pairs resulting from reduced interchain disulfide bonds in native antibodies, such as using bromomaleimide and dibromomaleimide linkers (WO 2014 / 009774), 2,3-disubstituted succinic acid / 2-monosubstituted / 2,3-disubstituted fumaric acid or maleic acid linkers (WO 2015 / 155753 and WO 20160596228), acetylenedicarboxylic acid linkers (WO 2015 / 151080 and WO 20160596228), or hydrazine linkers (WO 2015 / 151081). ADCs prepared with these linkers and methods have demonstrated superior therapeutic index windows compared to conventional, nonselective conjugation via antibody cysteine or lysine residues. Applicants now disclose the invention of cytotoxic agent conjugates containing long side chain linkers that can protect the antibody-drug conjugates from hydrolysis by hydrolases such as proteinases or esterases, making the conjugates more stable during targeted delivery and minimizing exposure to non-target cells, tissues, or organs in the circulation, resulting in longer blood half-lives, less off-target toxicity, and a wider therapeutic window.
[0009] The present invention provides branched linkages of cytotoxic agents to antibodies, and methods for conjugating cytotoxic agent analogs to antibodies via side chain linkers. [Means for solving the problem]
[0010] In one aspect of the invention, the conjugate containing the side chain linkage is represented by formula (I): [ka]
[0011] During the ceremony, [ka] represents a single bond; n is 1 to 30;
[0012] T stands for antibody; single-chain antibody; antibody fragment that binds to target cells; monoclonal antibody; single-chain a cell-binding agent / molecule selected from the group consisting of a monoclonal antibody; or a monoclonal antibody fragment that binds to a target cell; a chimeric antibody; a chimeric antibody fragment that binds to a target cell; a domain antibody; a domain antibody cross-section that binds to a target cell; an antibody-mimetic adnectin; DARPins; a lymphokine; a hormone; a vitamin; a growth factor; a colony-stimulating factor; or a nutrient transport molecule; transferrin; a binding peptide, or a protein, or an antibody, or a small molecule, polymer, dendrimer, liposome, nanoparticle, vesicle, or (viral) capsid bound to albumin;
[0013] L1 and L2 are chains of atoms, preferably having 0-500 atoms, selected from C, N, O, S, Si, and P, covalently bonded to W and V1, and V1 and V2. The atoms used to form L1 and L2 can be combined in any chemically relevant manner, such as to form alkylenes, alkenylenes, and alkynylenes, ethers, polyoxyalkylenes, esters, amines, imines, polyamines, hydrazines, hydrazones, amides, ureas, semicarbazides, carbazides, alkoxyamines, alkoxylamines, urethanes, amino acids, peptides, acyloxylamines, hydroxamic acids, or combinations thereof. Preferably, L1 and L2 are independently the same or different, O, NH, N, S, P, NNH, NHNH, N(R3), N(R4), N(R5), N(R6), N(R7), N(R8), N(R9), N(R10), N(R11), N(R12), N(R13), N(R14), N(R15), N(R16), N(R17), N(R18), N(R19 ... 12 ), N(R 12 )N(R 12’ ), CH, CO, C(O)NH, C(O)O, NHC(O)NH, NHC(O)O, formula (OCH2CH2) p OR 12 , (OCH2CH-(CH3)) p OR 12 , NH(CH2CH2O) p R 12 , NH(CH2CH(CH3)O) p R 12, N[(CH2CH2O) p R 12 ]-[(CH2CH2O) p’ R 12’ ], (OCH2CH2) p COOR 12 , or CH2CH2(OCH2CH2) p COOR 12 (p and p' are independently an integer selected from 0 to about 1000), or a combination thereof; C1-C8 alkyl; C2-C8 heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or (Aa)r, where r=1-12 (1 to 12 amino acid units) and are composed of natural or unnatural amino acids, or the same or different dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, decapeptide, undecapeptide, or dodecapeptide units;
[0014] W is an extender unit, typically a self-immolative spacer, peptide unit, hydrazone, disulfide, thioether, ester, or amide bond; w is 1, 2, or 3;
[0015] V and V are independently a spacer unit and are O, NH, S, C-C alkyl, C-C heteroalkyl, alkenyl, or alkynyl, C-C aryl, heterocycle, carbocycle, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroaralkyl, heteroalkylcycloalkyl, or alkylcarbonyl, or (Aa) r (r=1-12 (1 to 12 amino acid units) and composed of natural or unnatural amino acids, or the same or different dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, decapeptide, undecapeptide, or dodecapeptide units); or (CHCHO) p(p; 0-1000); and v1 and v2 are independently 0, 1, or 2, but v1 and v2 are not simultaneously 0; when v1 or v2 is 0, it means that one of the side chain Q1 or Q2 fragments is absent;
[0016] Q1 and Q2 are independently represented by formula (I-q1): [ka]
[0017] During the ceremony, [ka] is a bonding site with L1 or L2; G1 and G2 are each independently OC(O), NHC(O), C(O), CH2, NH, OC(O)NH, NHC(O)NH, O, S, B, P(O)(OH), NHP(O)(OH), NHP(O)(OH)NH, CH2P(O)(OH)NH, OP(O)(OH)O, CH2P(O)(OH)O, NHS(O)2, NHS(O)2NH, CH2S(O)2NH, OS(O)2O, CH2S(O)2O, Ar, ArCH2, ArO, ArNH, ArS, ArNR1, or (Aa) q1 ;G3 is OH, SH, OR 12 , S.R. 12 ,OC(O)R 12 , NHC(O)R 12 , C(O)R 12 , CH3, NH2, NR 12 , + NH(R 12 ), + N(R 12 )(R 12’ ), C(O)OH, C(O)NH2, NHC(O)NH2, BH2, BR 12 R 12’ , P(O)(OH)2, NHP(O)(OH)2, NHP(O)(NH2)2, S(O)2(OH), (CH2) q1 C(O)OH, (CH2) q1 P(O)(OH)2, C(O)(CH2)q1 C(O)OH, OC(O)(CH2) q1 C(O)OH, NHC(O)(CH2) q1 C(O)OH, CO(CH2) q1 P(O)(OH)2, NHC(O)O(CH2) q1 C(O)OH, OC(O)NH(CH2) q1 C(O)OH, NHCO(CH2) q1 -P(O)(OH)2, NHC(O)(NH)(CH2) q1 C(O)OH, CONH(CH2) q1 P(O)(OH)2, NHS(O)2(CH2) q1 C(O)OH, CO(CH2) q1 S(O)2(OH), NHS(O)2NH(CH2) q1 C(O)OH, OS(O)2NH(CH2) q1 C(O)OH, NHCO(CH2) q1 S(O)2(OH), NHP(O)(OH)(NH)(CH2) q1 C(O)OH, CONH(CH2) q1 S(O)(OH), OP(O)(OH)2, (CH2) q1 P(O)(NH)2, NHS(O)2(OH), NHS(O)2NH2, CH2S(O)2NH2, OS(O)2OH, OS(O)2OR1, CH2S(O)2OR 12 , Ar, ArR 12 , ArOH, ArNH2, ArSH, ArNHR 12 , or (Aa) q1 p1, p2, and p3 are independently 0 to 100, but not simultaneously 0; q1 and q2 are independently 0 to 24; Q1 and Q2 are independently linear or branched, C2-C 90 Polycarboxylic acids, C2-C 90 Polyalkylamines, C6-C 90 C6-C oligosaccharides or polysaccharides, consisting of quaternary ammonium cations and / or sulfonate anions 90Zwitterionic betaine or zwitterionic poly(sulfobetaine)) (PSB), or poly(lactic / glycolic acid) (PLGA), poly(acrylate), chitosan, copolymer of N-(2-(2-hydroxypropyl)methacrylamide), poly[2-(methacryloyloxy)ethylphosphorylcholine] (PMPC), poly-L-glutamic acid, poly(lactide-co-glycolide) (PLG), poly(lactide-co-glycolide), poly(ethylene glycol) (PEG), poly(propylene glycol) (PPG), poly(lactide-co-glycolide), poly(ethylene glycol)-modified peptides, poly(ethylene glycol) Poly(ethylene glycol)-modified lipids, including poly(ethylene glycol)-amino acids or peptides, poly-glycine, poly-N-methyl-glycine, poly(ethylene glycol)-modified alkyl carboxylic acids, poly(ethylene glycol)-modified alkylamines, poly(lactide-co-glycolide), hyaluronic acid (HA) (glycosaminoglycan), heparin / heparan sulfate (HSGAG), chondroitin sulfate / dermatan sulfate (CSGAG), poly(ethylene glycol) and D is a biodegradable polymer, such as a poly(ethylene glycol)-modified alkyl sulfate, poly(ethylene glycol)-modified alkyl phosphate, or poly(ethylene glycol)-modified alkyl quaternary ammonium; and D is a cytotoxic agent independently selected from calicheamicins, camptothecins, maytansinoids, taxanes, daunorubicin / doxorubicin, vinca alkaloids, auristatins, eribulins, pyrrolobenzodiazepines (PBDs), duocarmycins, kinase inhibitors, MEK inhibitors, KSP inhibitors, nicotinamide phosphoribosyltransferase (NAMPT) inhibitors, immunotoxins, or analogs or prodrugs of these compounds.
[0018] In another aspect of the invention, the conjugates containing side chain linkages are represented by formulas (II) and (III): [ka]
[0019] wherein D, W, L1, L2, Q1, Q2, V1, V2, v1, v2, n, and T are defined as in formula (I); w and w' are independently 1, 2, or 3; and [ka] is a single bond, a double bond, or absent, and D1 and D2 are the same or different and have the same definition as D.
[0020] In another embodiment of the present invention, the side chain binding compound is represented by formula (IV), which can readily react with a cell-binding molecule T to form a conjugate of formula (I): [ka]
[0021] In the formula, D, W, w, L1, L2, Q1, Q2, V1, V2, v1, v2, and n have the same definitions as in formula (I); Lv1 is a functional group described below.
[0022] In another embodiment of the present invention, side chain-binding compounds are represented by formulas (V) and (VI), which can readily react with a pair of sites on a cell-binding molecule T to form conjugates of formulas (II) and (III), respectively: [ka]
[0023] In the formula, D, D1, D2, W, w, w', L1, L2, Q1, Q2, V1, V2, v1, v2, [ka] , and n have the same definitions as above.
[0024] Lv1 and Lv2 represent leaving groups capable of reacting with a thiol, amine, carboxylic acid, selenol, phenol, or hydroxyl group on the cell-binding molecule, and Lv1 and Lv2 are selected from OH; F; Cl; Br; I; nitrophenol; N-hydroxysuccinimide (NHS); phenol, dinitrophenol, pentafluorophenol, tetrafluorophenol; difluorophenol; monofluorophenol; pentachlorophenol; triflate; imidazole; dichlorophenol; tetrachlorophenol; 1-hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5-phenylisoxazolium-3'-sulfonate, anhydrides formed by themselves or with other anhydrides such as acetic anhydride, formyl anhydride, etc.; or intermediate molecules generated by condensation reagents for peptide coupling reactions or Mitsunobu reactions. The condensation reagent is selected from EDC (N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide), DCC (dicyclohexyl-carbodiimide), N,N'-diisopropylcarbodiimide (DIC), N-cyclohexyl-N'-(2-morpholinoethyl)carbodiimide meso-p-toluenesulfonate (CMC, or CME-CDI), 1,1'-carbonyldiimidazole (CDI), TBTU (O-( (benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate), N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU), (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), Pyrrolidinophosphonium hexafluorophosphate (PyBOP), diethyl cyanophosphonate (DEPC), chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU), 1-[(dimethylamino)(morpholino)methylene]-1H-[1,2,3]triazolo[4,5-b]pyridine-1- ium-3-oxide hexafluorophosphate (HDMA), 2-chloro-1,3-dimethylimidazolidinium hexafluorophosphate (CIP), chlorotripyrrolidinophosphonium hexafluorophosphate (PyCloP), fluoro-N,N,N',N'-bis(tetramethylene)formamidinium hexafluorophosphate (BTFFH), N,N,N',N'-tetramethyl-S-(1-oxido-2-pyridyl)thiuronium hexafluorophosphate, O-(2 -oxo-1(2H)pyridyl)-N,N,N',N'-tetramethylthiuronium tetrafluoroborate (TPTU), S-(1-oxido-2-pyridyl)-N,N,N',N'-tetramethylthiuronium tetrafluoroborate, O-[(ethoxycarbonyl)cyanomethyleneamino]-N,N,N',N'-tetramethyluronium hexafluorophosphate (HOTU), (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino-morpholino-carbamate nium hexafluorophosphate (COMU), O-(benzotriazol-1-yl)-N,N,N',N'-bis(tetramethylene)uronium hexafluorophosphate (HBPyU), N-benzyl-N'-cyclohexylcarbodiimide (with or without polymer binding), dipyrrolidino(N-succinimidyloxy)-carbenium hexafluorophosphate (HSPyU), chlorodipyrrolidinocarbenium hexafluorophosphate (PyCIU), 2-chloro-1,3-Dimethylimidazolinium tetrafluoroborate (CIB), (benzotriazol-1-yloxy)dipiperidinocarbenium hexafluorophosphate (HBPipU), O-(6-chlorobenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TCTU), bromotris(dimethylamino)phosphonium hexafluorophosphate (BroP), propylphosphonic anhydride (PPACA, T3P®), 2-morpholinoethyl isocyanide (MEI), N,N,N',N'-tetramethyl-O-(N-succinimidyl)uronium hexafluorophosphate (HSTU), 2-bromo-1-ethyl-pyridinium tetrafluoroborate (BE P), O-[(ethoxycarbonyl)cyanomethyleneamino]-N,N,N',N'-tetramethyluronium tetrafluoroborate (TOTU), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (MMTM, DMTMM), N,N,N',N'-tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate (TSTU), O-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TDBTU), 1,1'-(azodicarbonyl)dipiperidine (ADD), di-(4-chlorobenzyl)azodicarboxylate (DCAD), di-tert-butyl Lv1 and Lv2 are selected from the group consisting of diisopropyl azodicarboxylate (DBAD), diisopropyl azodicarboxylate (DIAD), and diethyl azodicarboxylate (DEAD). Furthermore, Lv1 and Lv2 can be an anhydrides formed by themselves or with other C1-C8 acid anhydrides.
[0025] The present invention further relates to methods for preparing the cell-binding molecule-drug conjugates of formula (I) and formula (II), and applications of the conjugates of formula (I) and formula (II). [Brief explanation of the drawings]
[0026] [Figure 1]1 shows the synthesis of components of tubulysin analogs containing linkers. [Figure 2] The synthesis of the components of the linear linker is shown. [Figure 3] 1 shows the synthesis of tubulysin analogs with side chain linkers. [Figure 4] 1 shows the synthesis of tubulysin analogs with side chain linkers. [Figure 5] 1 shows the synthesis of fragments of tubulysin analogs containing side chain linkers. [Figure 6] 1 shows the synthesis of tubulysin analogue conjugates containing side chain linkers. [Figure 7] 1 shows the synthesis of exatecan and side chain linker fragments. [Figure 8] 1 shows the synthesis of conjugates of exatecan containing side chain linkers. [Figure 9] The synthesis of the components of the linear linker is shown. [Figure 10] A general synthesis of drug-conjugate moieties containing side chain conjugates is shown. [Figure 11] 1 shows the synthesis of drug conjugates containing side chain linkers and maytansinoid-conjugates with side chain linkers. [Figure 12] 1 shows the synthesis of conjugates of exatecan containing maytansinoids and side chain linkers. [Figure 13] 1 shows the synthesis of conjugates of MMAE analogs containing side chain linkers. [Figure 14] 1 shows the synthesis of MMAF analog conjugates containing side chain linkers. [Figure 15] 1 shows the synthesis of conjugable eribulin containing side chain linkers. [Figure 16] 1 shows the synthesis of an eribulin-containing conjugate containing a side chain linker and a conjugable CBI dimer dimer containing a side chain linker. [Figure 17] 1 shows the synthesis of CBI dimer conjugates containing side chain linkers and topotecan analog conjugates containing side chain linkers. [Figure 18] 1 shows the synthesis of tubulysin analogue conjugates containing side chain linkers and MMAE analogue conjugates containing side chain linkers. [Figure 19] 1 shows the synthesis of tubulysin analogue conjugates containing side chain linkers. [Figure 20] Figure 1 shows a comparison of the antitumor effects of conjugate compounds 49 (C-30), 51 (C-48), C-173, C-238, C-312, 132 (C-131), 135 (C-134), C-321, and C-322 with T-DM1 at a single intravenous dose of 6 mg / kg using a human gastric tumor N87 cell model. [Figure 21] Figure 1 shows the results of an acute toxicity study of ADC conjugates 49 (C-30), 51 (C-48), C-173, C-238, C-312, 132 (C-131), 135 (C-134), C-321, C-322, and T-DM1 by monitoring changes in body weight (BW) in mice over a 12-day period. DETAILED DESCRIPTION OF THE INVENTION
[0027] definition
[0028] "Alkyl" refers to an aliphatic hydrocarbon group or monovalent group derived from an alkane by removing one or two hydrogen atoms from a carbon atom. It may be linear or branched, having C1 to C8 (1 to 8 carbon atoms) in the chain. "Branched" refers to a linear alkyl group having one or more lower C alkyl groups, such as methyl, ethyl, or propyl groups, attached to it. Specific examples of alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, 3-pentyl, octyl, nonyl, decyl, cyclopentyl, cyclohexyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, 3,3-dimethylpentyl, 2,3,4-trimethylpentyl, 3-methylhexyl, 2,2-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 3,5-dimethylhexyl, 2,4-dimethylpentyl, 2-methylheptyl, 3-methylheptyl, n-heptyl, isoheptyl, n-octyl, and isooctyl. The C1-C8 alkyl group may be unsubstituted or substituted with one or more substituents (but is not limited to the following substituents). Examples of the substituent include -C1-C8 alkyl, -O-(C1-C8 alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH2, -C(O)NHR', -C(O)N(R')2, -NHC(O)R', -SR', and -S(O)2. Examples include R', -S(O)R', -OH, -halogen, -N3, -NH2, -NH(R'), -N(R')2, and -CN, where each R' is independently selected from C1 to C8 alkyl and aryl.
[0029] "Halogen" refers to fluorine, chlorine, bromine, or iodine atoms, with fluorine and chlorine atoms being preferred.
[0030] "Heteroalkyl" refers to a C2-C8 alkyl in which one to four carbon atoms are independently replaced by a heteroatom selected from the group consisting of O, S, and N.
[0031] "Carbocycle" refers to a saturated or unsaturated monocyclic ring containing 3 to 8 carbon atoms or a bicyclic ring containing 7 to 13 carbon atoms. Monocyclic carbocycles have 3 to 6, more typically 5 or 6, ring atoms. Bicyclic carbocycles have 7 to 12 ring atoms and are arranged as a [4,5], [5,5], [5,6], or [6,6] bicycle, or 9 to 10 ring atoms and are arranged as a [5,6] or [6,6] bicycle. Representative C3-C8 carbocycles include, but are not limited to, -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclopentadienyl, -cyclohexyl, -cyclohexenyl, -1,3-cyclohexadienyl, -1,4-cyclohexadienyl, -cycloheptyl, -1,3-cycloheptadienyl, -1,3,5-cycloheptatrienyl, -cyclooctyl, and -cyclooctadienyl.
[0032] A C3-C8 carbocycle refers to a 3-, 4-, 5-, 6-, 7-, or 8-membered saturated or unsaturated non-aromatic carbocyclic ring compound. A C3-C8 carbocycle can be unsubstituted or substituted with one or more substituents, including, but not limited to, —C1-C8 alkyl, —O—(C1-C8 alkyl), -aryl, —C(O)R′, —OC(O)R′, —C(O)OR′, —C(O)NH2, —C(O)NHR′, —C(O)N(R′)2, —NHC(O)R′, —SR′, —S(O)R′, —S(O)2R′, —OH, -halogen, —N3, —NH2, —NH(R′), —N(R′)2, and —CN, where each R′ is independently selected from C1-C8 alkyl and aryl.
[0033] "Alkenyl" refers to an aliphatic hydrocarbon group that may be straight or branched and has 2 to 8 carbon atoms in the chain and contains a carbon-carbon double bond. Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, hexylenyl, heptenyl, and octenyl.
[0034] "Alkynyl" refers to an aliphatic hydrocarbon group that may be straight or branched and has 2 to 8 carbon atoms in the chain and contains a carbon-carbon triple bond. Examples of alkynyl groups include ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, 5-pentynyl, n-pentynyl, hexynyl, heptynyl, and octynyl.
[0035] "Alkylene" refers to a saturated, straight or branched chain or cyclic hydrocarbon group of 1 to 18 carbon atoms having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. Typical alkylene groups include, but are not limited to, methylene (-CH-), 1,2-ethyl (-CHCH-), 1,3-propyl (-CHCHCH-), 1,4-butyl (-CHCHCHCH-), and the like.
[0036] "Alkenylene" refers to an unsaturated alkyl group having 2 to 18 carbon atoms and two monovalent radical centers derived by removing two hydrogen atoms from the same or two different carbon atoms of a parent alkene. "Alkenylene" refers to a straight or branched chain or cyclic hydrocarbon group of the formula: Typical alkenylene groups include, but are not limited to, 1,2-ethylene (-CH=CH-).
[0037] "Alkynylene" refers to an unsaturated, straight or branched chain or cyclic hydrocarbon group of 2 to 18 carbon atoms having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne. Typical alkynylene groups include, but are not limited to, acetylene, propargyl, and 4-pentynyl.
[0038] "Aryl" or "Ar" refers to an aromatic or heteroaromatic group consisting of one or several rings containing 3 to 14 carbon atoms, preferably 6 to 10 carbon atoms. The term "heteroaromatic group" refers to an aromatic group in which some carbons, preferably 1, 2, 3, or 4 carbon atoms, have been replaced by O, N, Si, Se, P, or S, preferably O, S, and N. The term aryl or Ar also refers to one or more H atoms independently replaced by -R', -halogen, -OR', or -SR', -NR'R'', -N=NR', -N=R', -NR'R'', -NO, -S(O)R', -S(O)R', -S(O)OR', -OS(O)OR', -PR'R'', -P(O)R'R'', -P(OR')(OR''), -P(O)(OR')(OR''), or -OP(O)(OR')(OR''), where R', R'' are independently H, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, arylalkyl, carbonyl, or a pharmaceutical salt.
[0039] "Heterocycle" refers to a ring system in which one to four ring carbon atoms are independently replaced with a heteroatom from the group O, N, S, Se, B, Si, and P. Preferred heteroatoms are O, N, and S. Heterocycles are described in The Handbook of Chemistry and Physics, 78th Edition, CRC Press, Inc., 1997-1998, pp. 225-226, and the disclosure thereof. are incorporated herein by reference. Preferred non-aromatic heterocycles include, but are not limited to, epoxy, aziridinyl, thiiranyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxiranyl, tetrahydrofuranyl, dioxolanyl, tetrahydropyranyl, dioxanyl, dioxolanyl, piperidyl, piperazinyl, morpholinyl, pyranyl, imidazolinyl, pyrrolinyl, pyrazolinyl, thiazolidinyl, tetrahydropyranyl, dihydropyranyl, tetrahydropyridyl, dihydropyridyl, tetrahydropyrimidinyl, dihydrothiopyranyl, azepanyl, as well as fused systems resulting from condensation with a phenyl group.
[0040] The term "heteroaryl" or aromatic heterocycle refers to a 3- to 14-membered, preferably 5- to 10-membered, aromatic hetero, monocyclic, bicyclic, or polycyclic ring. Examples include pyrrolyl, pyridyl, pyrazolyl, thienyl, pyrimidinyl, pyrazinyl, tetrazolyl, indolyl, quinolinyl, purinyl, imidazolyl, thienyl, thiazolyl, benzothiazolyl, furanyl, benzofuranyl, 1,2,4-thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, carbazolyl, benzimidazolyl, isoxazolyl, pyridyl-N-oxide, and fused systems resulting from condensation with a phenyl group.
[0041] "Alkyl," "cycloalkyl," "alkenyl," "alkynyl," "aryl," "heteroaryl," "heterocyclic," and the like, also refer to the corresponding "alkylene," "cycloalkylene," "alkenylene," "alkynylene," "arylene," "heteroarylene," "heterocyclene," and the like, formed by removing two hydrogen atoms.
[0042] "Arylalkyl" refers to an alkyl group consisting of a carbon atom, typically a terminal or sp 3 Water bound to a carbon atom It refers to an acyclic alkyl group in which one of the carbon atoms is substituted with an aryl group. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethene-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl, and the like.
[0043] "Heteroarylalkyl" refers to a heteroaryl group consisting of a carbon atom, typically a terminal or sp 3 It refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom is replaced by a heteroaryl group. Exemplary heteroarylalkyl groups include 2-benzimidazolylmethyl and 2-furylethyl.
[0044] Examples of "hydroxy-protecting groups" include methoxymethyl ether, 2-methoxyethoxymethyl ether, tetrahydropyranyl ether, benzyl ether, p-methoxybenzyl ether, trimethylsilyl ether, triethylsilyl ether, triisopropylsilyl ether, t-butyldimethylsilyl ether, triphenylmethylsilyl ether, acetate ester, substituted acetate ester, pivaloate, benzoate, methanesulfonate, and p-toluenesulfonate.
[0045] "Leaving group" refers to a functional group that can be replaced by another functional group. Such leaving groups are well known in the art and include, for example, halides (e.g., chloride, bromide, and iodide), methanesulfonyl (mesyl), p-toluenesulfonyl (tosyl), trifluoromethylsulfonyl (triflate), and trifluoromethylsulfonate. The leaving group is preferably selected from nitrophenol; N-hydroxysuccinimide (NHS); phenol; dinitrophenol; pentafluorophenol; tetrafluorophenol; difluorophenol; monofluorophenol; pentachlorophenol; triflate; imidazole; dichlorophenol; tetrachlorophenol; 1-hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5-phenylisoxazolium-3'-sulfonate, acid anhydrides formed with itself or other acid anhydrides (e.g., acetic anhydride, formic anhydride); or intermediates generated by condensation reagents for peptide coupling reactions or Mitsunobu reactions.
[0046] The following abbreviations may be used herein and have the definitions set forth below: Boc, tert-butoxycarbonyl; BroP, bromotrispirolizinophosphonium hexafluorophosphate; CDI, 1,1'-carbonyldiimidazole; DCC, dicyclohexylcarbodiimide; DCE, 1,2-dichloroethane; DCM, dichloromethane; DEAD, diethyl azodicarboxylate; DIAD, diisopropyl azodicarboxylate; DIBAL-H, diisobutylaluminum hydride; DIPEA or DEA, diisopropylethylamine; DEPC, diethylphosphoroanidinium; DMA, N,N-dimethylacetamide; DMAP, 4-(N,N-dimethylamino)pyridine; DMF, N,N-dimethylformamide; DMSO, dimethyl sulfoxide; DTPA, diethylenetriaminepentaacetic acid; DTT, dithiothreitol EDC, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; ESI-MS, electrospray mass spectrometry; EtOAc, ethyl acetate; Fmoc, N-(9-fluorenylmethoxycarbonyl); HATU, O-(7-azabenzotriazol-1-yl)-N,N,N'-N'-tetramethyluronium hexafluorophosphate; HOBt, 1-hydroxybenzotriazole; HPLC, high-pressure liquid chromatography; NHS, N-hydroxysuccinimide; MeCN, acetonitrile; MeOH, methanol; MMP, 4-methylmorpholine; PAB, p-aminobenzyl; PBS, phosphate-buffered saline (pH 7.0–7.5); Ph, phenyl; Phe, L-phenylalanine; PyBrop, bromo-tris-pyrrolidino-phosphonium hexafluorophosphate; PEG, polyethylene glycol SEC, size-exclusion chromatography; TCEP, tris(2-carboxyethyl)phosphine; TFA, trifluoroacetic acid; THF, tetrahydrofuran; Val, valine; TLC, thin-layer chromatography; UV, ultraviolet.
[0047] "Amino acids" can be natural and / or unnatural amino acids, preferably α-amino acids. Natural amino acids are those encoded by the genetic code and are alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tyrosine, tryptophan, and valine. Unnatural amino acids are derived forms of protein-forming amino acids. Examples include hydroxyproline, lanthionine, 2-aminoisobutyric acid, dehydroalanine, γ-aminobutyric acid (a neurotransmitter), ornithine, citrulline, β-alanine (3-aminopropanoic acid), γ-carboxyglutamate, selenocysteine (present in most eukaryotes but not directly encoded by DNA), pyrrolysine (found only in some archaea and one bacterium), N-formylmethionine (often the first amino acid in proteins in bacteria, mitochondria, and chloroplasts), 5-hydroxytryptophan, L-dihydroxyphenylalanine, triiodothyronine, L-3,4-dihydroxyphenylalanine (DOPA), and O-phosphoserine. The term amino acid also includes amino acid analogs and mimetics. Analogs are compounds that have the same general HN(R)CHCOH structure as a natural amino acid, except that the R group is not one found in the natural amino acid. Examples of analogs include homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Preferably, an amino acid mimetic is a compound that has a structure different from the general chemical structure of an α-amino acid, but functions similarly to it. The term "unnatural amino acid" is intended to refer to the "D" stereochemical form, whereas natural amino acids are in the "L" form. When 1 to 8 amino acids are used herein, the amino acid sequence is preferably a cleavage recognition sequence for a protease.Many cleavage recognition sequences are known in the art, for example, Matayoshi et al. Science 247: 954 (1990); Dunn et al. Meth. Enzymol. 241: 254 (1994); Seidah et al. Meth. Enzymol. 244: 175 (1994); Thornberry, Meth. Enzymol. 244: 615 (1994); Weber et al. Meth. Enzymol. 244: 595 (1994); Smith et al. Meth. Enzymol. 244: 412 (1994); and Bouvier et al. Meth. Enzymol. 248: 614 (1995). See, e.g., the disclosure of which is incorporated herein by reference. In particular, the sequence is selected from the group consisting of Val-Cit, Ala-Val, Ala-Ala, Val-Val, Val-Ala-Val, Lys-Lys, Ala-Asn-Val, Val-Leu-Lys, Cit-Cit, Val-Lys, Ala-Ala-Asn, Lys, Cit, Ser, and Glu.
[0048] A "glycoside" is a molecule in which a sugar group is linked to another group through its anomeric carbon by a glycosidic bond. Glycosides can be linked by O-(O-glycoside), N-(glycosylamine), S-(thioglycoside), or C-(C-glycoside) glycosidic bonds. Its core empirical formula is C m (H2O) n(where m is different from n and m and n are <36), where glycosides include glucose (dextrose), fructose (levulose), allose, altrose, mannose, gulose, iodose, galactose, talose, galactosamine, glucosamine, sialic acid, N-acetylglucosamine, sulfoquinovose (6-deoxy-6-sulfo-D-glucopyranose), ribose, arabinose, xylose, lyxose, sorbitol, mannitol, sucrose, lactose, maltose, trehalose, maltodextrin, raffinose, glucuronic acid (glucuronide), and stachyose. It may be in the D- or L-form, in the five-atom cyclic furanose form, the six-atom cyclic pyranose form, or in the acyclic form, in the α-isomer (-OH at the anomeric carbon below the plane of the carbon atoms in the Howarth projection), or in the β-isomer (-OH at the anomeric carbon above the plane of the carbon atoms in the Howarth projection). It is used herein to refer to a monosaccharide, disaccharide, polyol, or oligosaccharide containing 3 to 6 sugar units.
[0049] The term "antibody," as used herein, refers to a full-length immunoglobulin molecule or an immunologically active portion of a full-length immunoglobulin molecule, i.e., a molecule that contains an antigen-binding site that immunospecifically binds to an antigen or portion thereof of a target of interest, including, but not limited to, cancer cells or cell populations that produce autoimmune antibodies associated with autoimmune diseases. The immunoglobulins disclosed herein can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecule. The immunoglobulins can be derived from any species. Preferably, however, the immunoglobulins are of human, murine, or rabbit origin. Antibodies useful in the present invention are preferably monoclonal, and include, but are not limited to, polyclonal, monoclonal, bispecific, human, humanized, or chimeric antibodies, single chain antibodies, Fv, Fab fragments, F(ab') fragments, F(ab')2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, CDRs, and epitope-binding fragments of any of the above that immunospecifically bind to a cancer cell antigen, a viral antigen, or a microbial antigen.
[0050] Just as left and right hands are identical except that they are opposites along one axis (simply changing their orientation does not make them appear identical), "enantiomers," also known as "optical isomers," are one of two stereoisomers that are non-superimposable (non-identical) mirror images of each other. A single chiral atom or similar structural feature within a compound causes that compound to have two non-superimposable structures, each a mirror image of the other. The presence of multiple chiral elements in a particular compound increases the number of possible geometric forms, but perfect mirror-image pairs may exist. A pure enantiomer is a sample that, within the limits of detection, has only one chirality. When present in a symmetric environment, enantiomers have identical chemical and physical properties except for their ability to rotate plane-polarized light (+ / -) by equal amounts in opposite directions (although polarized light can be considered an asymmetric medium). For this reason, they are sometimes called optical isomers. A mixture of equal parts of an optically active isomer and its enantiomer is called a racemate; it has zero net rotation of plane-polarized light. This is because the positive rotation of each (+) form is exactly offset by the negative rotation of the (-) form. Enantiomeric members often have different chemical reactions than other enantiomeric substances. Because many biological molecules are enantiomers, there can be significant differences in the effects of the two enantiomers on an organism. For example, in drugs, often only one of the drug's enantiomers is responsible for the desired physiological effect, while the other enantiomer may be less active, inactive, or even have adverse effects. This discovery allows the development of drugs composed of only one enantiomer ("enantiopure") to enhance pharmacological efficacy and sometimes eliminate some side effects.
[0051] Isotopes are variations of a particular chemical element that vary in the number of neutrons. All isotopes of a particular element have the same number of protons in each atom. Each atomic number identifies a particular element, but not an isotope. Atoms of a given element can have a wide range of neutron numbers. The number of nucleons (both protons and neutrons) in the nucleus is the atom's mass number, and each isotope of a particular element has a different mass number. For example, carbon-12, carbon-13, and carbon-14 are three isotopes of carbon with mass numbers 12, 13, and 14, respectively. Carbon has an atomic number of 6. This is because every carbon atom has six protons, so the neutron numbers of these isotopes are 6, 7, and 8, respectively. Hydrogen atoms have protium ( 1 H), deuterium ( 2 H), and tritium ( 3 There are three isotopes of hydrogen (H): deuterium has twice the mass of protium, and tritium has three times the mass of protium. Isotopic substitution can be used to determine the mechanism of a chemical reaction or through kinetic isotope effects. Isotope substitution can affect the metabolic changes of substances in the body (e.g., by metabolic enzymes such as cytochrome P450 or glucuronosyltransferase enzymes), as well as the ability of certain xenobiotics to be absorbed and distributed after administration. It can be used to study how the body interacts with chemicals, as well as the excretion pathways and effects of a drug's metabolites. This study is called pharmacokinetics (PK). Isotope substitution can be used to study the biochemical and physiological effects of a drug. Effects can include those that manifest in animals (including humans), microorganisms, or combinations of organisms (such as an infection). This study is called pharmacodynamics (PD). Effects can include those that manifest in animals (including humans), microorganisms, or combinations of organisms (such as an infection). Together, both influence the administration, benefits, and adverse effects of a drug. Isotopes can be stable (non-radioactive) or unstable elements. Isotopic substitution of a drug may have a different therapeutic effect than the original drug.
[0052] "Pharmaceutically" or "pharmaceutically acceptable" means that the corresponding compound or compound composition does not produce harmful, allergic or other adverse reactions when administered to animals or humans in a suitable manner.
[0053] A "pharmaceutically acceptable solvate" or "solvate" is disclosed as a compound containing one or more solvent molecules. Examples of solvents that form pharmacologically acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.
[0054] Pharmaceutically acceptable auxiliary materials include all carriers, diluents, auxiliaries, or excipients, such as preservatives, antioxidants, fillers, disintegrants, wetting agents, emulsifiers, suspending agents, solvents, dispersion media, coating agents, antibacterial agents, antifungal agents, isotonic agents, absorption delaying agents, etc. In the pharmaceutical field, it is common practice to add these auxiliary materials to active drug components. It is considered reasonable to add auxiliary materials to drug components unless the auxiliary materials are incompatible with the active drug components. To achieve better results, active auxiliary materials may be added to drug components.
[0055] In the present invention, the term "pharmaceutical salt" refers to a salt derivative of the compound of the present invention. By appropriate modification, the compound of the present invention can be converted into a corresponding acid or alkali salt. Pharmaceutical salts include commonly used non-toxic salts or quaternary ammonium salts, which can be prepared with the compound of the present invention using a corresponding non-toxic inorganic or organic acid. For example, inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, aminosulfonic acid, phosphoric acid, and nitric acid. Organic acids include acetic acid, propionic acid, succinic acid, tartaric acid, citric acid, methanesulfonic acid, benzenesulfonic acid, glucuronic acid, glutamic acid, benzoic acid, salicylic acid, toluenesulfonic acid, oxalic acid, fumaric acid, and lactic acid, which can be used to form pharmaceutically acceptable salts. Other salts include ammonium salts such as trometamol, meglumine, and pyrroleethanol, and metal salts such as sodium, potassium, calcium, zinc, and magnesium.
[0056] In the present invention, pharmaceutical salts can be prepared from parent compounds containing acidic or basic residues by conventional chemical methods. Generally, these salts can be obtained by reacting the free acid or free base form of these compounds with a stoichiometric amount of an appropriate base or acid in water, an organic solvent, or a mixture of the two. Generally, ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is preferred as a non-aqueous reaction solvent. A list of suitable salts can be found in "Remington's Pharmaceutical Sciences," 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is incorporated by reference.
[0057] "Administering" or "Administration" means any manner of transferring, delivering, introducing, or transporting a drug or other agent to a subject. Such modes include oral administration, topical contact, intravenous, intraperitoneal, intramuscular, lesional, nasal, subcutaneous, or cavity administration. Also contemplated by the present invention is the use of a device or instrument in administering the drug. Such devices may utilize active or passive transport and may be slow-release or fast-release delivery devices.
[0058] In the context of cancer, the term "treating" includes any or all of the following: inhibiting the growth of tumor or cancer cells, preventing tumor or cancer cell replication, reducing the overall tumor burden, and ameliorating one or more symptoms associated with the disease.
[0059] In the context of autoimmune disease, the term "treating" includes any or all of the following: preventing the replication of cells associated with the pathology of the autoimmune disease, including but not limited to, cells capable of producing autoimmune antibodies, reducing the burden of autoimmune antibodies, and ameliorating one or more symptoms of the autoimmune disease.
[0060] In the context of infectious diseases, the term "treating" includes any or all of preventing the growth, proliferation, or replication of the pathogen causing the infectious disease and ameliorating one or more symptoms of the infectious disease.
[0061] Examples of "mammals" or "animals" include, but are not limited to, humans, rats, mice, guinea pigs, monkeys, pigs, goats, cows, horses, dogs, cats, birds, and poultry.
[0062] The novel conjugates disclosed herein use bridge linkers. Examples of some suitable linkers and their syntheses are shown in Figures 1-26.
[0063] Conjugates of cell-binding agent-ligands and cytotoxic molecules via side chain linkages
[0064] In one aspect of the invention, the conjugates containing side chain linkages are represented by formulas (I), (II), and (III): [ka]
[0065] During the ceremony, [ka] represents a single bond; [ka] is a single bond, a double bond, or absent; n is 1 to 30; w and w' are independently 1, 2, or 3.
[0066] T is a cell binding agent / molecule selected from the group consisting of an antibody; a single chain antibody; an antibody fragment that binds to a target cell; a monoclonal antibody; a single chain monoclonal antibody; or a monoclonal antibody fragment that binds to a target cell; a chimeric antibody; a chimeric antibody fragment that binds to a target cell; a domain antibody; a domain antibody cross-section that binds to a target cell; an antibody-mimetic adnectin; DARPins; lymphokines; hormones; vitamins; growth factors; colony-stimulating factors; or nutrient transport molecules; transferrin; a binding peptide, or protein, or antibody, or a small molecule, polymer, dendrimer, liposome, nanoparticle, vesicle, or (viral) capsid bound to albumin;
[0067] L1 and L2 are chains of atoms, preferably having 0-500 atoms, selected from C, N, O, S, Si, and P, covalently bonded to W and V1, and V1 and V2. The atoms used to form L1 and L2 can be combined in any chemically relevant manner, such as to form alkylenes, alkenylenes, and alkynylenes, ethers, polyoxyalkylenes, esters, amines, imines, polyamines, hydrazines, hydrazones, amides, ureas, semicarbazides, carbazides, alkoxyamines, alkoxylamines, urethanes, amino acids, peptides, acyloxylamines, hydroxamic acids, or combinations thereof. Preferably, L1 and L2 are independently the same or different, O, NH, N, S, P, NNH, NHNH, N(R3), N(R4), N(R5), N(R6), N(R7), N(R8), N(R9), N(R10), N(R11), N(R12), N(R13), N(R14), N(R15), N(R16), N(R17), N(R18), N(R19 ... 12 ), N(R 12 )N(R 12’ ), CH, CO, C(O)NH, C(O)O, NHC(O)NH, NHC(O)O, formula (OCH2CH2) p OR 12 , (OCH2CH-(CH3)) p OR 12 , NH(CH2CH2O) p R 12 , NH(CH2CH(CH3)O) p R 12 , N[(CH2CH2O) p R 12 ]-[(CH2CH2O) p’ R 12’], (OCH2CH2) p COOR 12 , or CH2CH2(OCH2CH2) p COOR 12 (p and p' are independently an integer selected from 0 to about 1000), or a combination thereof; C1-C8 alkyl; C2-C8 heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or (Aa)r, where r=1-12 (1 to 12 amino acid units) and are composed of natural or unnatural amino acids, or the same or different dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, decapeptide, undecapeptide, or dodecapeptide units;
[0068] W is a C1-C8 extender unit, typically a self-immolative spacer, peptide unit, hydrazone, disulfide, thioether, ester, or amide bond.
[0069] V1 and V2 are independently spacer units and are selected from the group consisting of O, NH, S, C1-C8 alkyl, C2-C8 heteroalkyl, alkenyl, or alkynyl, C3-C8 aryl, heterocycle, carbocycle, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heterocyclic, aralkyl, heteroalkylcycloalkyl, or alkylcarbonyl, or (Aa) r (r=1-12 (1 to 12 amino acid units) and composed of natural or unnatural amino acids, or the same or different dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, decapeptide, undecapeptide, or dodecapeptide units); or (CHCHO) p(p; 0-1000); and v1 and v2 are independently 0, 1, or 2, but v1 and v2 are not simultaneously 0; when v1 or v2 is 0, it means that one of the side chain Q1 or Q2 fragments is absent;
[0070] Q1 and Q2 are independently represented by formula (I-q1): [ka]
[0071] During the ceremony, [ka] is a bonding site with L1 or L2; G1 and G2 are each independently OC(O), NHC(O), C(O), CH2, NH, OC(O)NH, NHC(O)NH, O, S, B, P(O)(OH), NHP(O)(OH), NHP(O)(OH)NH, CH2P(O)(OH)NH, OP(O)(OH)O, CH2P(O)(OH)O, NHS(O)2, NHS(O)2NH, CH2S(O)2NH, OS(O)2O, CH2S(O)2O, Ar, ArCH2, ArO, ArNH, ArS, ArNR1, or (Aa) q1 ;G3 is OH, SH, OR 12 , S.R. 12 ,OC(O)R 12 , NHC(O)R 12 , C(O)R 12 , CH3, NH2, NR 12 , + NH(R 12 ), + N(R 12 )(R 12’ ), C(O)OH, C(O)NH2, NHC(O)NH2, BH2, BR 12 R 12’ , P(O)(OH)2, NHP(O)(OH)2, NHP(O)(NH2)2, S(O)2(OH), (CH2) q1 C(O)OH, (CH2) q1 P(O)(OH)2, C(O)(CH2)q1 C(O)OH, OC(O)(CH2) q1 C(O)OH, NHC(O)(CH2) q1 C(O)OH, CO(CH2) q1 P(O)(OH)2, NHC(O)O(CH2) q1 C(O)OH, OC(O)NH(CH2) q1 C(O)OH, NHCO(CH2) q1 -P(O)(OH)2, NHC(O)(NH)(CH2) q1 C(O)OH, CONH(CH2) q1 P(O)(OH)2, NHS(O)2(CH2) q1 C(O)OH, CO(CH2) q1 S(O)2(OH), NHS(O)2NH(CH2) q1 C(O)OH, OS(O)2NH(CH2) q1 C(O)OH, NHCO(CH2) q1 S(O)2(OH), NHP(O)(OH)(NH)(CH2) q1 C(O)OH, CONH(CH2) q1 S(O)(OH), OP(O)(OH)2, (CH2) q1 P(O)(NH)2, NHS(O)2(OH), NHS(O)2NH2, CH2S(O)2NH2, OS(O)2OH, OS(O)2OR1, CH2S(O)2OR 12 , Ar, ArR 12 , ArOH, ArNH2, ArSH, ArNHR 12 , or (Aa) q1 (Aa) q1 are peptides containing the same or different natural or unnatural amino acids; X1 and X2 are independently and O, CH2, S, S(O), NHNH, NH, N(R 12 ), + NH(R 12 ), + N(R 12 )(R 12’ ), C(O), OC(O), OC(O)O, OC(O)NH, NHC(O)NH; Y2 is O, NH, NR 12, CH2, S, NHNH, or Ar; p1, p2, and p3 are independently 0 to 100, but not simultaneously 0; q1 and q2 are independently 0 to 24; R 12 , R 12’ , R 13 , and R 13’ are independently H, C1-C8 alkyl; C2-C8 heteroalkyl, or heterocycle; C3-C8 aryl, Ar-alkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, carbocycle, or alkylcarbonyl;
[0072] Preferably, Q1 and Q2 are independently C2-C 100 Polycarboxylic acids, C2-C 90 Polyalkylamines, C6-C 90 C6-C oligosaccharides or polysaccharides, consisting of quaternary ammonium cations and / or sulfonate anions 100 Zwitterionic betaine or zwitterionic poly(sulfobetaine)) (PSB), or poly(lactic / glycolic acid) (PLGA), poly(acrylate), chitosan, copolymer of N-(2-(2-hydroxypropyl)methacrylamide), poly[2-(methacryloyloxy)ethylphosphorylcholine] (PMPC), poly-L-glutamic acid, poly(lactide-co-glycolide) (PLG), poly(lactide-co-glycolide), poly(ethylene glycol) (PEG), poly(propylene glycol) (PPG), poly(lactide-c), o-glycolide), poly(ethylene glycol)-modified peptides, poly(ethylene glycol)-amino acids or peptides, poly(ethylene glycol)-modified lipids, poly-glycine, poly-N-methyl-glycine, poly(ethylene glycol)-modified alkyl carboxylic acids, poly(ethylene glycol)-modified alkylamines, poly(lactide-co-glycolide), hyaluronic acid (HA) (glycosaminoglycan), heparin / heparan sulfate (HSGAG), chondroitin sulfate / dermatan sulfate (CSGAG), poly(ethylene glycol) C6-C alkyl phosphates, poly(ethylene glycol)-modified alkyl phosphates, or poly(ethylene glycol)-modified alkyl quaternary ammonium salts. 100 It is a biodegradable polymer;
[0073] Examples of structures of Q1 and Q2 are shown below: [ka] TIFF2024112832000016.tif218170
[0074] In the formula, R 25 and R 25’ are independently H;HC(O), CH3C(O), CH3C(NH), NHCH3, COOH, CONH2, CONHCH3, C1-C 18 Alkyl, C1-C 18 Alkyl, alkyl-Y1-SO3H, C1-C 18 Alkyl-Y1-PO 3H2, C1-C 18 Alkyl-Y1-CO2H, C1-C 18 Alkyl-Y1-N + R 12 R 13 R 13’ R 14 , C1-C 18 Alkyl-Y1-CONH2, C2-C 18 Alkylene, C2-C 18 Esters, C2-C 18 Ether, C2-C 18 Amines, C2-C 18 Alkyl carboxylamides, C3-C 18 Aryl, C3-C 18 Cyclic alkyl, C3-C 18 Heterocyclic, 1-24 amino acids; C2-C 18 lipid, C2-C 18 Fatty acids, or C2-C 18 Fatty ammonium lipids; X1 and X2 are independently NH, N(R 12’), O, CH2, S, C(O), S(O), S(O2), P(O)(OH), NHNH, CH=CH, Ar, or (Aa) q1 (q1=0 to 24 (0 to 24 amino acids, q1=0 means absence)); X1, X2, X3, X4, Y1, Y2, and Y3 are independently selected from NH, N(R 12’ ), O, C(O), CH2, S, S(O), NHNH, C(O), OC(O), OC(O)O, OC(O)NH, NHC(O)NH, Ar, or (Aa) q1 wherein X1, X2, X3, X4, Y1, Y2, and Y3 may independently be absent; p1, p2, and p3 are independently 0 to 100, but are not simultaneously 0; and q1, q2, and q3 are independently 0 to 24. 12 , R 13 , R 13’ , and R 14’ are independently selected from H and C1-C6 alkyl; Aa is a natural or unnatural amino acid; Ar or (Aa) q1 are peptides of the same or different sequence; q1=0 is (Aa) q1 means that it does not exist.
[0075] D is a cytotoxic agent independently selected from calicheamicins, maytansinoids, camptothecins, taxanes, anthracyclines (daunorubicin / doxorubicin), vinca alkaloids, auristatins, eribulins, (pyrrolo)benzodiazepines (PBDs), CC-106 / duocarmycins, tubulysins, amatoxins (such as amanitin), protein kinase inhibitors, MEK inhibitors, KSP inhibitors, nicotinamide phosphoribosyltransferase (NAMPT) inhibitors, immunotoxins, analogs or prodrugs of these compounds.
[0076] Calicheamicins and related enediyne antibiotics are described in the following references: Nicolaou, KC et al, Science 1992, 256, 1172-1178; Proc. Natl. Acad. Sci USA. 1993, 90, 5881-5888), US Patent Nos. 4,970,198; 5,053,394; 5,108,912; 5,264,586; 5,384,412; 5,606,040; 5,712,374; 5,714,586; 5,739,116; 5,770,701; 5,770,710; 5,773,001; 5,877,296; 6,015,562; 6,124,310; The calicheamicins preferably have the following structure, or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof; or a polymorphic crystalline structure of these compounds; or an isotope, optical isomer, racemate, diastereomer, or enantiomer thereof: [ka]
[0077] Maytansinoids, including maytansinol and its analogs, are described in the following US patents: U.S. Patents 4,256,746, 4,361,650, 4,307,016, 4,294,757, 4,294,757, 4,371,533, 4,424,219, 4,331,598, 4,450,254, 4,364,866, 4,313,946, 4,315,929, 4,362,663, 4,322,348, 4,371,533, 4,424,219, 5,208,020, 5,416,064, 5,208,020; 5,416,064; 6,333,410; 6,441,163; 6,716,821, 7,276,497, 7,301,019, 7,303,749, 7,368,565, 7,411,063, 7,851,432, and 8,163,888. Maytansinoids preferably have the following structure: [ka]
[0078] Camptothecin (CPT) and its derivatives are topoisomerase inhibitors that prevent DNA religation, thus causing DNA damage and triggering apoptosis, as described in Shang, XF et al, Med Res Rev. 2018, 38(3):775-828; Botella, P. and Rivero-Buceta, E. J Control Release. 2017, 247: 28-54; Martino, E. et al, Bioorg Med Chem Lett. 2017, 27(4):701-707; Lu, A., et al, Acta Pharmacol Sin 2007, 28(2): 307-314. These include SN-38, topotecan, irinotecan (CPT-11), ciratecan (DB-67, AR-67), cositecan (BNP-1350), etirinotecan, exatecan, lurtotecan, gimatecan (ST1481), belotecan (CKD-602), rubitecan, and several others (Shang, XF et al, Med Res Rev. 2018, 38(3):775-828). To date, three CPT analogs, topotecan, irinotecan, and belotecan, have been approved and used in cancer chemotherapy (Palakurthi, S., Expert Opin Drug Deliv. 2015;12(12):1911-21; Shang, X. F. et al, Med Res Rev. 2018, 38(3):775-828), SN-38 and exatecan It has been successfully used as a payload for ADC conjugates in clinical trials (Ocean, AJ et al, Cancer. 2017, 123(19): 3843-3854; Starodub, AN, et al, Clin Cancer Res. 2015, 21(17): 3870-8; Cardillo, TM, et al, Bioconjug Chem.2015, 26(5): 919-31; Ogitani, Y. et al, Bioorg Med Chem Lett.2016, 26(20): 5069-5072; Takegawa, N. et al,Int J Cancer.2017 Oct 15;141(8):1682-1689. U.S. Patent No. 7,591,994; 7,999,083, 8,080,250, 8,268,317; U.S. Patent Application 20130090458, 20140099258, 20150297748, 20160279259).
[0079] Camptothecin (CPT) preferably has the following structure: or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof; or a polymorphic crystalline structure of these compounds; or an isotope, optical isomer, racemate, diastereomer, or enantiomer thereof; [ka]
[0080] wherein R1, R2, and R4 are independently H, F, Cl, Br, CN, NO2, C1-C8 alkyl; O-C1-C8 alkyl; NH-C1-C8 alkyl; C2-C8 heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or ester, ether, amide, carbonate, urea, or carboxylate having 2 to 8 carbon atoms. R3 is H, OH, NH2, C1-C8 alkyl; O-C1-C8 alkyl; NH-C1-C8 alkyl; C2-C8 heteroalkyl, alkylcycloalkyl, heterocycloalkyl; or C2-C8 ester, ether, amide, carbonate, urea, or carbamate; or R1R2, R2R3, and R3R4 independently form a 5-7 membered carbocyclic, heterocyclic, heterocycloalkyl, aromatic, or heteroaromatic ring system;
[0081] The structure of camptothecin is preferably of the following formula, or one or more isotopes of chemical elements, or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof; or a polymorphic crystal structure of these compounds; or an isotope, optical isomer, racemate, diastereomer, or enantiomer thereof: [ka] TIFF2024112832000021.tif249170TIFF2024112832000022.tif199170
[0082] During the ceremony, [ka] is the connection site with W;P 1 are H, OH, NH2, COOH, C(O)NH2, O CH2OP(O)(OR 18 )2, OC(O)OP(O)(OR 18)2, OPO(OR 18 )2, NHPO(OR 18 )2, OC(O)R 18 , OP(O)(OR 18 )OP(O)(OR 18 )2, OC(O)NHR 18 , OC(O)N(C2H4)2NCH3, OSO2(OR 18 ), O-(C4-C 12 -glycosides), OC(O)N(C2H4)2CH2N(C2H4)2CH3, C1-C8 straight or branched alkyl or heteroalkyl; C2-C8 straight or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 straight or branched aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 ) is;R 17 and R 18 are independently H, straight or branched alkyl or heteroalkyl; C2-C8 straight or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 straight or branched aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 )
[0083] Preferred cytotoxic natural product taxanes for conjugation, including paclitaxel (taxol) and the semisynthetic derivative docetaxel (taxotere), and analogs thereof, are described in the following literature: K C. Nicolaou et al., J. Am. Chem. Soc. 117, 2409-2420, (1995); Ojima et al, J. Med. Chem. 39:3889-3896 (1996); 40:267-278 (1997); 45, 5620-5623 (2002); et al., Proc. Natl. Acad. Sci., 96:4256-4261 (1999; Kim et al., Bull. Korean Chem. Soc., 20, 1389-1390 (1999); Miller, et al. J. Med. Chem., 47, 4802-4805 (2004); U.S. Patent Nos. 5,475,011, 5,728,849, 5,811,452; 6,340,701; 6,372,738; 6,391,913, 6,436,931; 6,589,979; 6,596,757; 6,706,708; 7,008,942; 7,186,851; 7,217,819; 7,276,499; 7,598,290; and 7,667,054. The structure of taxanes is The following formula is preferred: [ka]
[0084] Anthracyclines are inhibitors of mammalian DNA topoisomerase II, which can induce DNA strand breaks and stabilize the enzyme-DNA complex by covalently binding to proteins. These anticancer drugs have maintained an important role in the treatment of many forms of solid tumors and acute leukemia over the past several decades. However, anthracyclines cause cardiovascular morbidity and mortality (Sagi, JC, et al, Pharmacogenomics. 2016, 17(9), 1075-87; McGowan, JV, et al, Cardiovasc Drugs Ther. 2017, 31(1), 63-75) Therefore, to increase the specific activity of a molecule while reducing its cardiotoxicity, researchers have have actively used the conjugation of anthracyclines to cell-binding molecules as a general approach to improve the therapeutic index of these drugs (Mollaev, M. et al, Int J Pharm. 2018 Dec 29, pii: S0378-5173(18) 30991-8; Rossin, R., et al, Bioconjug Chem. 2016, 27(7):1697-706; Dal Corso, A., et al, J Control Release. 2017, 264:211-218). The structure of the anthracyclines is preferably of the following formula: [ka] TIFF2024112832000026.tif245170
[0085] Vinca alkaloids are a group of antimitotic and antimicrotubule alkaloids that act by inhibiting the division ability of cancer cells.Vinca alkaloids include vinblastine, vincristine, vindesine, leurosine, vinorelbine, catharanthine, vindoline, vincaminol, vineridine, minovincine, methoxyminovincine, minovincine, vincadifformine, desoxyvincaminol, vincamazine, vincamine, vinpocetine, and vinburnine.The structure of vinca alkaloids is preferably vinblastine and vincristine, which have the following formula: [ka] TIFF2024112832000028.tif70170
[0086] Auristatin and dolastatin analogs are preferred for conjugation via the bis-linkers of this patent.Auristatins (e.g., auristatin E (AE), auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), monomethyl auristatin (MMAF), auristatin F phenylenediamine (AFP), and phenylalanine variants of MMAE) are synthetic analogs of dolastatins and are described in the following documents: Int. J. Oncol. 15:367-72 (1999); Molecular Cancer Therapeutics, vol. 3, No. 8, pp. 921-932 (2004); U.S. Patent Applications 11134826, 20060074008, and 2006022925; U.S. Patent Nos. 4414205, 4753894, 4764368, 4816444, and 4879278. 4943628, 4978744, 5122368, 5165923, 5169774,5286637, 5410024, 5521284, 5530097, 5554725, 5585089, 5599902, 5629197, 5635483, 5654399, 5663149, 5665860, 5708146, 5714586, 5741892, 5767236, 5767237, 5780588, 5821337, 5840699, 5965537, 6004934, 6033876, 6034065, 6048720, 6054297, 6054561, 6124431, 6143721, 6162930, 6214345, 6239104, 6323315, 6342219, 6342221, 6407213, 6569834, 6620911, 6639055, 6884869, 6913748, 7090843, 7091186, 7097840, 7098305, 7098308, 7498298, 7375078, 7462352, 7553816, 7659241, 7662387, 7745394, 7754681, 7829531, 7837980, 7837995, 7902338, 7964566, 7964567, 7851437, 7994135. The structure of the auristatin analog is preferably as follows: Preferred are compounds of the following formulae (Ih-01), (Ih-02), (Ih-03), (Ih-04), (Ih-05), (Ih-06), and (Ih-07), or isotopes of one or more chemical elements, or pharmaceutically acceptable salts, hydrates, or hydrated salts thereof; or polymorphic crystal structures of these compounds; or isotopes, optical isomers, racemates, diastereomers, or enantiomers thereof: [ka]
[0087] In the formula, R 1 , R 2 , R 3 , R 4 , and R 5 are independently H; C1-C8 straight chain or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester, ether, amide, amine, heterocycloalkyl, or acyloxylamine; or a peptide containing 1 to 8 amino acids, or a group of the formula (OCH2CH2) p or (OCH2CH(CH3)) p (p is an integer from 1 to about 5000). 1 R 2 , R 2 R 3 , R 1 R 3 , or R 3 R 4 can form a 3- to 8-membered ring of alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group. X3 is H, CH3, or X 1’ R 1’ where X 1’ is NH, N(CH), NHNH, O, or S, and R 1’ is H or C1-C8 linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl , acyloxylamine; R 3’ is H or C1-C6 linear or branched alkyl; Z 3’is H, COOR1, NH2, NHR1, OR1, CONHR1, NHCOR1, OCOR1, OP(O)(OM1)(OM2), OCH2OP(O)(OM1)(OM2), OSO3M1, R1, or an O-glycoside (glucoside, galactoside, mannoside, glucuronoside / glucuronide, alloside, fructoside, etc.), NH-glycoside, S-glycoside, or CH2-glycoside; M1 and M2 are independently H, Na, K, Ca, Mg, NH4, NR1R2R3; Y1 and Y2 are attachment sites [ka] and, when bonded to, are independently O, NH, NHNH, NR5, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R1), N(R1)C(O)N(R2), C(O)NHNHC(O), and C(O)NR1; [ka] and when not bound to, are independently OH, NH, NHNH, NHR, SH, C(O)OH, C(O)NH, OC(O)NH, OC(O)OH, NHC(O)NH, NHC(O)SH, OC(O)NH(R), N(R)C(O)NH(R), C(O)NHNHC(O)OH, and C(O)NHR; R 12 are OH, NH2, NHR1, NHNH2, NHNHCOOH, O-R1-COOH, NH-R1-COOH, NH-(Aa) n COOH, O(CH2CH2O) p CH2CH2OH, O(CH2CH2O) p CH2CH2NH2, NH(CH2CH2O) p CH2CH2NH2, NR1R 1’ , NHOH, NHOR1, O(CH2CH2O) p CH2CH2COOH, NH(CH2CH2O) pCH2CH2COOH, NH-Ar-COOH, NH-Ar-NH2, O(CH2CH2O) p CH2CH2NH-SO3H, NH(CH2CH2O) p CH2CH2NHSO3H, R1-NHSO3H, NH-R1-NHSO3H, O(CH2CH2O) p CH2-CH2NHPO3H2, NH(CH2CH2O) p CH2CH2NHPO3H2, OR1, R1-NHPO3H2, R1-OPO3H2, O(CH2CH2O) p CH2CH2OPO3H2, OR1-NHPO3H2, NH-R1-NHPO3H2, NH(CH2CH2NH) p CH2-CH2NH2, NH(CH2CH2S) p CH2CH2NH2, NH(CH2CH2NH) p CH2CH2OH, NH(CH2CH2S) p CH2-CH2OH, NH-R1-NH2, or NH(CH2CH2O) p CH2CH2NHPO3H2, where Aa is 1 to 8 identical or different amino acids; p is 1-5000; R1, R2, R3, R4, R5, R 5’ , Z1, Z2, and n have the same definitions as above.
[0088] Eribulin, which binds primarily to a small number of high-affinity sites at the plus ends of pre-existing microtubules, has both cytotoxic and non-cytotoxic mechanisms of action. Its cytotoxic effects are related to its antimitotic activity, where apoptosis of cancer cells is induced after prolonged, irreversible mitotic blockade (Kuznetsov, G. et al., Cancer Research. 2004, 64 (16): 5760-6; Towle, M. J. et al., Cancer Research. 2010, 71 (2): 496-505). Its cytotoxicity In addition to mechanisms based on mitotic inhibition, preclinical studies in human breast cancer models have demonstrated that Evidence suggests that eribulin exerts complex effects on the biology of surviving cancer cells and residual tumors, seemingly unrelated to its antimitotic effect. Eribulin has been approved by the US FDA for the treatment of metastatic breast cancer that has received at least two prior chemotherapy regimens for late-stage disease, including both anthracycline-based and taxane-based chemotherapy, and for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or has progressed (metastatic). Eribulin has been used as a payload in ADC conjugates (US20170252458). The structure of eribulin is preferably of the following formula: Eb01: [ka]
[0089] Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are attractive ADC payloads due to their unique and potent mechanism of action (Sampath D, et al, Pharmacol Ther 2015; 151, 16-31). NAMPT acts by stimulating the production of nicotinamide adenine dinucleotides within cells. NAD regulates niacin (NAD) levels, and NAD functions as a redox cofactor essential for supporting energy and anabolic metabolism. NAD plays several important roles in metabolism: it functions as a coenzyme in redox reactions, as a donor of the ADP-ribose moiety in ADP-ribosylation reactions, and as a precursor of the second messenger molecule cyclic ADP-ribose, as well as in bacterial DNA ligase and NAD + In addition to these metabolic functions, NAD acts as a substrate for a group of enzymes called sirtuins, which use NAD to remove acetyl groups from proteins. +It appears as an adenine nucleotide that can be released from cells spontaneously and by regulated mechanisms (Smyth L. M, et al, J. Biol. Chem. 2004, 279 (47), 48893-903; Billington R. A, et al, Mol Med. 2006, 12, 324-7), and therefore may have important extracellular roles (Billington R. A, et al, Mol Med. 2006, 12, 324-7). In the presence of inhibitors of NAMPT, NAD levels are increased. This causes a drop in NAMPT activity below the metabolically required level, resulting in an energy crisis and subsequent cell death. To date, clinical NAMPT inhibitor candidates FK-866, CHS-828, and GMX-1777 have progressed to clinical trials, but each has encountered dose-limiting toxicity before achieving the desired response (Holen K., et al, Invest New Drugs 2008, 26, 45-51; Hovstadius, P., et al., Clin Cancer Res 2002, 8, 2843-50; Pishvaian, MJ, et al., J Clin Oncol 2009, 27, 3581). Therefore, the use of ADCs for targeted delivery of NAMPT inhibitors may avoid systemic toxicity and achieve a much broader therapeutic index. The structure of the NAMPT inhibitor preferably includes the following formulas: NP01, NP02, NP03, NP04, NP05, NP06, NP07, NP08, and NP09, or one or more isotopes of chemical elements, or pharmaceutically acceptable salts, hydrates, or hydrated salts thereof; or polymorphic crystal structures of these compounds; or isotopes, optical isomers, racemates, diastereomers, or enantiomers thereof: [ka]
[0090] During the ceremony, [ka] has the same definition as above; X5 is F, Cl, Br, I, OH, OR1, R1, OPO3H2, OSO3H, NHR1, OCOR1, NHCOR1.
[0091] Benzodiazepine dimers (e.g., dimers of pyrrolobenzodiazepines (PBD) or (tomaymycin), indolinobenzodiazepines, imidazobenzodiazepines, or oxazolidinobenzodiazepines) that are preferred as cytotoxic agents of the present invention are exemplified by the following: U.S. Patent Nos. 8,163,736; 8,153,627; 8,034,808; 7,834,005; 7,741,319; 7,704,924; 7,691,848; 7,678,787; 7,612,062; 7,608,615; 7,557,099; 7,528,128; 7,528,126; 7,511,032; 7,429,658; 7,407,951; 7,326,700; 7,312,210; 7,265,105; 7,202,239; 7,189,710; 7,173,026; 7,109,193; 7,067,511; 7,064,120; 7,056,913; 7,049,311; 7,022,699; 7,015,215; 6,979,684; 6,951,853; 6,884,799; 6,800,622; 6,747,144; 6,660,856; 6,608,192; 6,562,806; 6,977,254; 6,951,853; 6,909,006; 6,344,451; 5,880,122; 4,935,362; 4,764,616; 4,761,412; 4,723,007; 4,723,003; 4,683,230; 4,663,453; 4,508,647; 4,464,467; 4,427,587; 4,000,304; U.S. Patent Applications 20100203007, 20100316656, 20030195196. Antibody-benzodiazepine dimer conjugates via the linker of the present invention Exemplary structures include PB01, PB02, PB03, PB04, PB05, PB06, PB07, PB08, PB09, PB10, PB11, PB12, PB13, PB14, PB15, and PB16 shown below, or one or more isotopes of chemical elements, or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof; or a polymorphic crystal structure of these compounds; or an isotope, optical isomer, racemate, diastereomer, or enantiomer thereof: [ka] TIFF2024112832000036.tif254170TIFF2024112832000037.tif90170
[0092] In the formula, X1, X2, Y1, Y2, R4, R5, R 5’ , Z1, Z2, and n are the same as defined above. Preferably, X1, X2, Y1, and Y2 are independently O, N, NH, NHNH, NR5, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R1), N(R1)C(O)N(R1), CH, C(O)NHNHC(O), or C(O)NR1; R 1 , R 2 , R 3 , R 1’ , R 2’ , and R 3’ are independently H; F; Cl; ═O; ═S; OH; SH; C1-C8 linear or branched alkyl, aryl, alkenyl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester (COOR5 or -OC(O)R5), ether (OR5), amide (CONR5), carbamate (OCONR5), amine (NHR5, NR5R 5’ ), heterocycloalkyl, or acyloxylamine (—C(O)NHOH, —ONHC(O)R5); or a peptide containing 1 to 20 natural or unnatural amino acids, or a peptide of the formula (OCH2CH2) p or (OCH2CH(CH3)) pwhere p is an integer from 1 to about 5000; 1 R 2 , R 2 R 3 , R 1 R 3 , R 1’ R 2’ , R 2’ R 3’ , or R 1’ R 3’ can independently form a 3- to 8-membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group; X3 and Y3 are independently N, NH, CH2, or CR5, where R4, R5, R6, R 12 , and R 12’ are independently H, OH, NH, NH(CH), NHNH, COOH, SH, OZ, SZ, F, Cl, or C-C linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, acyloxylamine; Z is H, OP(O)(OM)(OM), OCHOP(O)(OM)(OM), OSOM, or an O-glycoside (glucoside, galactoside, mannoside, glucuronoside / glucuronide, alloside, fructoside, etc.), NH-glycoside, S-glycoside, or CH-glycoside; M and M are independently H, Na, K, Ca, Mg, NH, NRRR.
[0093] CC-1065 analogs and Duocarmycin analogs are also preferred for use in the conjugates containing bis-bridged linkages of the present invention. Examples of CC-1065 analogs and Duocarmycin analogs, as well as their synthesis, are described in the following literature: Warpehoski, et al., J. Med. Chem. 31:590-603 (1988), D. Boger et al., J. Org. Chem; 66; 6654-6661, 2001; U.S. Patent Nos.: 4169888, 4391904, 4671958, 4816567, 4912227, 4923990, 4952394, 4975278, 4978757, 4994578, 5037993, 5070092, 5084468, 5101038, 5117006, 5137877, 5138059, 5147786, 5187186, 5223409, 5225539, 5288514, 5324483, 5332740, 5332837, 5334528, 5403484, 5427908, 5475092, 5495009, 5530101, 5545806, 5547667, 5569825, 5571698, 5573922, 5580717, 5585089, 5585499, 5587161, 5595499, 5606017, 5622929, 5625126, 5629430, 5633425, 5641780, 5660829, 5661016, 5686237, 5693762, 5703080, 5712374, 5714586, 5739116, 5739350, 5770429, 5773001, 5773435, 5786377 5786486, 5789650, 5814318, 5846545, 5874299, 5877296, 5877397, 5885793, 5939598, 5962216, 5969108, 5985908, 6060608, 6066742, 6075181, 6103236, 6114598, 6130237, 6132722, 6143901, 6150584, 6162963, 6172197, 6180370, 6194612, 6214345, 6262271, 6281354, 6310209, 6329497, 6342480, 6486326, 6512101, 6521404, 6534660, 6544731, 6548530, 6555313, 6555693, 6566336, 6,586,618, 6593081, 6630579, 6,756,397, 6759509, 6762179, 6884869, 6897034, 6946455, 7,049,316, 7087600, 7091186, 7115573, 7129261, 7214663, 7223837, 7304032, 7329507, 7,329,760, 7,388,026, 7,655,660, 7,655,661, 7,906,545, and 8,012,978. Exemplary structures of antibody-CC-1065 analog conjugates via the carboxyl group are CC01, CC02, CC03, CC04, CC05, CC06, and CC07 shown below: [ka]
[0094] In the formula, X1, X2, Y1, and Y2 are connecting sites. [ka] and, when bonded to, are independently O, NH, NHNH, NR5, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R1), N(R1)C(O)N(R2), C(O)NHNHC(O), and C(O)NR1; [ka] and when not bound to, are independently OH, NH, NHNH, NHR, SH, C(O)OH, C(O)NH, OC(O)NH, OC(O)OH, NHC(O)NH, NHC(O)SH, OC(O)NH(R), N(R)C(O)NH(R), C(O)NHNHC(O)OH, and C(O)NHR; Z is H, PO(O)(OM)(OM), SOMI, CHPO(O)(OM)(OM), CHN(CHCH)NC(O)—, O(CHCH)NC(O)—, R, or a glycoside; R, R, R, M, M, and n are as defined above.
[0095] Tubulysins, which are preferred compounds for the conjugates of the present invention, are well known in the art and can be extracted from natural products according to known methods or synthesized according to known methods (e.g., Balasubramanian, R.; et al. J. Med. Chem., 2009, 52, 238-240. Wipf, P.; et al. Org. Lett., 2004, 6, 4057-4060. Pando, O.; et al. J. Am. Chem. Soc., 2011, 133, 7692-7695. Reddy, JA; et al. Mol. Pharmaceutics, 2009, 6, 1518-1525. Raghavan, B.; et al. al. J. Med. Chem., 2008, 51, 1530-1533. Patterson, AW; et al. J. Org. Chem., 2008, 73, 4362-4369. Pando, O.; et al. Org. Lett., 2009, 11 (24), pp 5567-5569. Wipf, P.; et al. Org. Lett., 2007, 9 (8), 1605-1607. Friestad, GK; Org. Lett., 2004, 6, pp 3249-3252. Hillary M. Peltier, HM; et al. J. Am. Chem. Soc., 2006, 128, 16018-16019. Chandrasekhar, S.; et al. J. Org. Chem., 2009, 74, 9531-9534. Liu, Y.; et al. Mol. Pharmaceutics, 2012, 9, 168-175. Friestad, GK; et al. Org. Lett., 2009, 11, 1095-1098. Kubicek, K.; et al., Angew Chem Int Ed Engl, 2010. 49: p. 4809-12. Chai, Y.; et al., Chem Biol, 2010, 17: 296-309. Ullrich, A.; et al., Angew Chem Int Ed Engl, 2009, 48, 4422-5. Sani, M.; et al. Angew Chem Int Ed Engl, 2007, 46, 3526-9. Domling, A.; et al., Angew Chem Int Ed Engl, 2006. 45, 7235-9. Patent applications: Zanda, M. ; et al, Can. Pat. Appl. CA 2710693 (2011). Chai, Y.; et al. Time. Pat. Appl. 2174947 (2010), WO 2010034724. Leamon, C.; et al, WO 2010033733, WO 2009002993. Ellman, J.; et al, WO 2009134279; WO 2009012958, US appl. 20110263650, 20110021568, Matschiner, G.; et al, WO 2009095447.Vlahov, I.; et al, WO 2009055562, WO 2008112873. Low, P.; et al, WO 2009026177. Richter, W., WO 2008138561. Kjems, J.; et al, WO 2008125116. Davis, M.; et al, WO 2008076333. Diener, J.; et al, US Pat. Appl. 20070041901, WO 2006096754. Matschiner, G.; et al, WO 2006056464. Vaghefi, F.; et al, WO 2006033913. Doemling, A., Ger. Offen. DE 102004030227; WO 2004005327; WO 2004005326; WO2004005269. Stanton, M.; et al, US Pat. Appl. Publ. 20040249130. Hoefle, G.; et al, Ger. Offen. DE 10254439 ; DE 10241152; DE 10008089. Leung, D.; et al, WO 2002077036. Reichenbach, H.; et al, Ger. Offen. DE 19638870; Wolfgang, R.; US 20120129779, Chen, H., US appl. 20110027274.). together with cell-binding molecules Preferred structures of tubulysins for use in the treatment of cancer are described in PCT / IB2012 / 053554. Structures of antibody-tubulysin analog conjugates via linkers include the following: Tb01, Tb02, Tb03, Tb04, Tb05, Tb06, Tb07, Tb08, Tb09, and T10, or one or more isotopes of chemical elements, or a pharmaceutically acceptable salt, hydrate, or hydrated salt thereof; or a polymorphic crystal structure of these compounds; or an isotope, optical isomer, racemate, diastereomer, or enantiomer thereof: [ka] TIFF2024112832000042.tif103170
[0096] wherein X1 and Y1 are independently O, NH, NHNH, NR5, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R1), N(R1)C(O)N(R1), CH, C(O)NHNHC(O), and C(O)NR1; mAb is an antibody, preferably a monoclonal antibody; R 12 are OH, NH2, NHR1, NHNH2, NHNHCOOH, O-R1-COOH, NH-R1-COOH, NH-(Aa) n COOH, O(CH2CH2O) p CH2CH2OH, O(CH2CH2O) p CH2CH2NH2, NH(CH2CH2O) p CH2CH2NH2, NR1R 1’ , NHOH, NHOR1, O(CH2CH2O) p CH2CH2COOH, NH(CH2CH2O) p CH2CH2COOH, NH-Ar-COOH, NH-Ar-NH2, O(CH2CH2O) p CH2CH2NH-SO3H, NH(CH2CH2O) p CH2CH2NHSO3H, R1-NHSO3H, NH-R1-NHSO3H, O(CH2CH2O) p CH2-CH2NHPO3H2, NH(CH2CH2O) p CH2CH2NHPO3H2, OR1, R1-NHPO3H2, R1-OPO3H2, O(CH2CH2O) p CH2CH2OPO3H2, OR1-NHPO3H2, NH-R1-NHPO3H2, NH(CH2CH2NH) p CH2-CH2NH2, NH(CH2CH2S) p CH2CH2NH2, NH(CH2CH2NH) p CH2CH2OH, NH(CH2CH2S) p CH2-CH2OH, NH-R1-NH2, or NH(CH2CH2O) p CH2CH2NHPO3H2, where Aa is 1 to 8 amino acids; n and m1 are independently 1 to 20; p is 1 to 5000; R1, R 1’, R2, R3, and R4 are independently H, C1-C8 straight or branched alkyl, amide, or amine; C2-C8 aryl, alkenyl, alkynyl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester, ether, heterocycloalkyl, or acyloxylamine; or a peptide containing 1 to 8 amino acids, or a group of the formula (OCH2CH2) p or (OCH2CH(CH3)) p where p is an integer from 1 to about 5000; and two R: R1R2, R2R3, R1R3, or R3R4 are independently can form a 3- to 8-membered ring of alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group; X3 can be H, CH3, CH2CH3, C3H7, or X 1’ R 1’ where X 1’ is NH, N(CH), NHNH, O, or S; R 1’ is H or C1-C8 linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, acyloxylamine; R 3’ is H or a C1-C6 straight or branched alkyl; Z3 is H, COOR1, NH2, NHR1, OR1, CONHR1, NHCOR1, OCOR1, OP(O)(OM1)(OM2), OCH2OP(O)(OM1)(OM2), OSO3M1, R1, or an O-glycoside (glucoside, galactoside, mannoside, glucuronoside / glucuronide, alloside, fructoside, etc.), NH-glycoside, S-glycoside, or CH2-glycoside; M1 and M2 are independently H, Na, K, Ca, Mg, NH4, NR1R2R3.
[0097] Amatoxins, a subgroup of at least 10 toxic compounds found in several poisonous mushroom genera, most notably Amanita phalloides, and several other mushroom species, are also preferred for conjugation in this patent. The ten amatoxins, designated α-amanitin, β-amanitin, γ-amanitin, ε-amanitin, amanulin, amanurinic acid, amaninamide, amanine, and proamanulin, are rigid bicyclic peptides synthesized as a 35-amino acid proprotein, from which the last eight amino acids are cleaved by prolyl oligopeptidase (Litten, W. 1975 Scientific American 232 (3): 90-101; H. E. Hallen, et al. 2007 Proc. Nat. Aca. Sci. USA 104, 19097-101; K. Baumann, et al. 1993 Biochemistry 32 (15): 4043-50; Karlson-Stiber C, Persson H. 2003, Toxicon 42 (4): 339-49; Horgen, PA et al. 1978 Arch. Microbio. 118 (3): 317-9). Amatoxins inhibit RNA polymerase II ( It is a potent and selective inhibitor of Pol II and kills cells by halting gene transcription and protein biosynthesis (Brodner, OG and Wieland, T. 1976 Biochemistry,15(16):3480-4; Fiume, L., Curr Probl Clin Biochem,1977,7:23-8; Karlson-Stiber C, Persson H. 2003 Toxicon 42(4):339-49; Chafin, DR, Guo, H. & Price, DH 1995 J. Biol. Chem. 270(32):19114-19; Wieland (1983) Int. J. Pept. Protein Res. 22(3):257-76.). Amatoxins were isolated from collected Amanita phalloides mushrooms (Yocum, RR 1978 Biochemistry 17(18): 3786-9; Zhang, P. et al, 2005, FEMS Microbiol. Lett. 252(2), 223-8) or basidio Fermentation using bacteria (Muraoka, S. and Shinozawa T., 2000 J. Biosci. Bioeng. 89(1): 73-6) or from fermentation using A. fissa (Guo, XW, et al, 2006 Wei Sheng Wu Xue Bao 46(3): 373-8), or from the culture of Galerina fasciculata or Galerina helvoliceps (WO / 1990 / 009799, JP11137291). However, the yields from these isolations and fermentations were very low (less than 5 mg / L in the culture broth).The 30-year-old girl, the girl, the girl, the girl, the girl, the girl. WASHINGTON (WE) Savige, A. Fontana, Chem 1976, 600-1; Int J Pept Protein Res, 1981. 18(2): 162-8; Lett 1982, 23, 619-22; Biochim Biophys Acta, 1986. 870(3): 454-62; Int J Peptide Protein Res 1987, 30, 450-9; Int J Pept Protein Res, 1988. 32(1): 9-20; G., et al., Int J Pept Protein Res, 1990. 35(3): 263-70; Mullersman, JE and JF Preston, 3rd, Int J Pept Protein Res, 1991. 37(6): 544-51; 38(5): 409-16; Zanotti, G., et al, Int J Pept Protein Res, 1992.。; 40(6): 551-8; Schmitt, W. et al, J. Am. Chem. Soc. 1996, 118, 4380-7; Anderson , MO, et al, J. Org. Chem., 2005, 70(12): 4578-84; JP May, et al, J. Org. Chem. 2005, 70, 8424-30; F. Brueckner, P. Cramer, Nat. Struct. Mol. Biol. 2008, 15, 811-8; JP May, DM Perrin, Chem. Eur. J. 2008, 14, 3404-9; JP May, et al, Chem. Eur. J. 2008, 14, 3410-17; Q. Wang, et al, Eur. J. Org. Chem. 2002, 834-9; May, JP and DM Perrin, Biopolymers, 2007. 88(5): 714-24; May, JP, et al., Chemistry, 2008. 14(11): 3410-7; S. De Lamo Marin, et al, Eur. J. Org. Chem. 2010, 3985-9; Pousse, G., et al., Org Lett, 2010. 12(16): 3582-5; Luo, H., et al., Chem Biol, 2014. 21(12): 1610-7; Zhao, L., et al., Chembiochem, 2015. 16(10): 1420-5), most of these preparations were by partial synthesis. Due to their extremely potent and unique cytotoxic mechanism, amatoxins have been used as payloads in conjugates (Fiume, L., Lancet, 1969. 2 (7625): 853-4; Barbanti-Brodano, G. and L. Fiume, Nat New Biol, 1973. 243(130): 281-3; Bonetti, E., M. et al., Arch Toxicol, 1976. 35(1): p. 69-73; Davis, M. T., Preston, J. F. Science 1981, 213, 1385-1388; Preston, J.F., et al, Arch Biochem Biophys, 1981. 209(1): 63-71; H. Faulstich, et al, Biochemistry 1981, 20, 6498-504; Barak, L.S., et al., Proc Natl Acad Sci U S A, 1981. 78(5): 3034-8; Faulstich, H. and L. Fiume, Methods Enzymol, 1985. 112: 225-37; Zhelev, Z., A. et al, Toxicon, 1987. 25(9): 981-7; Khalacheva, K., et al, Eksp Med Morfol, 1990. 29(3): 26-30; U. Bermbach, H. Faulstich, Biochemistry 1990, 29, 6839-45; Mullersman, J. E. and J. F. Preston, Int. J. Peptide Protein Res. 1991, 37, 544-51; Mullersman, J.E. and J.F. Preston, Biochem Cell Biol, 1991. 69(7): 418-27; J. Anderl, H. Echner, H. Faulstich, Beilstein J. Org. Chem. 2012, 8, 2072-84; Moldenhauer, G., et al, J. Natl. Cancer Inst. 2012, 104, 622-34; A. Moshnikova, et al; Biochemistry 2013, 52, 1171-8; Zhao, L., et al., Chembiochem, 2015. 16(10): 1420-5; Zhou, B., et al., Biosens Bioelectron, 2015. 68: 189-96; WO2014 / 043403, US20150218220, EP 1661584). For some time, we have been working on amatoxin conjugates. Examples of structures of antibody-amatoxin conjugates via linkers are preferably the following Am01, Am02, and Am03, or one or more isotopes of chemical elements, or pharmaceutically acceptable salts, hydrates, or hydrated salts thereof; or polymorphic crystal structures of these compounds; or isotopes, optical isomers, racemates, diastereomers, or enantiomers thereof: [ka]
[0098] wherein X1 and Y1 are independently O, NH, NHNH, NR5, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R1), N(R1)C(O)N(R1), CH, C(O)NHNHC(O), and C(O)NR1; R7, R8, and R9 are independently H, OH, OR1, NH2, NHR1, C1-C6 alkyl, or absent; Y2 is O, O2, NR1, NH, or absent; R 10 is CH2, O, NH, NR1, NHC(O), NHC(O)NH, NHC(O)O, OC(O)O, C(O), OC(O), OC(O)(NR1), (NR1)C(O)(NR1), C(O)R1, or absent; R 11 are OH, NH2, NHR1, NHNH2, NHNHCOOH, O-R1-COOH, NH-R1-COOH, NH-(Aa) n COOH, O(CH2CH2O) p CH2CH2OH, O(CH2CH2O) p CH2CH2NH2, NH(CH2CH2O) p CH2CH2NH2, NR1R 1’, NHOH, NHOR1, O(CH2CH2O) p CH2CH2COOH, NH(CH2CH2O) p CH2CH2COOH, NH-Ar-COOH, NH-Ar-NH2, O(CH2CH2O) p CH2CH2NH-SO3H, NH(CH2CH2O) p CH2CH2NHSO3H, R1-NHSO3H, NH-R1-NHSO3H, O(C H2CH2O) p CH2-CH2NHPO3H2, NH(CH2CH2O) p CH2CH2NHPO3H2, OR1, R1-NHPO3H2, R1-OPO3H2, O(CH2CH2O) p CH2CH2OPO3H2, OR1-NHPO3H2, NH-R1-NHPO3H2, NH(CH2CH2NH) p CH2-CH2NH2, NH(CH2CH2S) p CH2CH2NH2, NH(CH2CH2NH) p CH2CH2OH, NH(CH2CH2S) p CH2-CH2OH, NH-R1-NH2, or NH(CH2CH2O) p CH2CH2NHPO3H2, where Aa is 1 to 8 amino acids; n and m1 are independently 1-20; p is 1-5000; R1 and Ar have the same definitions as in formula (I).
[0099] Protein kinase inhibitors can regulate protein function by inhibiting the action of enzymes that add phosphate groups (PO4) to the amino acids serine, threonine, or tyrosine in proteins. Protein kinase inhibitors can be used to treat diseases caused by overactive protein kinases (including mutated or overexpressed kinases) in cancer, or to regulate cellular functions to overcome other disease drivers. The structure of the protein kinase inhibitor is preferably selected from adavosertib, afatinib, axitinib, bafetinib, bosutinib, cobimetinib, crizotinib, cabozantinib, dasatinib, entrectinib, erdafitinib, erlotinib, fostamatinib, gefitinib, ibrutinib, imatinib, lapatinib, lenvatinib, mubritinib, nilotinib, pazopanib, pegaptanib, ponatinib, rebastinib, regorafenib, ruxolitinib, sorafenib, sunitinib, SU6656, tofacitinib, vandetanib, and vemurafenib, which have the following formulae PK01 to PK29: [ka] TIFF2024112832000045.tif254170TIFF2024112832000046.tif254170TIFF2024112832000047.tif238170TIFF2024112832000048.tif168170
[0100] MEK inhibitors inhibit the mitogen-activated protein kinases MEK1 and / or MEK2, which are often overactivated in some cancers. MEK inhibitors are particularly used to treat BRAF-mutant melanoma, KRAS / BRAF-mutant colorectal cancer, breast cancer, and non-small cell lung cancer (NSCLC). MEK inhibitors are selected from PD0325901, selumetinib (AZD6244), cobimetinib (XL518), refametinib, trametinib (GSK1120212), pimasertib, binimetinib (MEK162), AZD8330, RO4987655, RO5126766, WX-554, E6201, GDC-0623, PD-325901, and TAK-733. Preferred MEK inhibitors are selected from trametinib (GSK1120212), cobimetinib (XL518), binimetinib (MEK162), selumetinib, which have the following formula: [ka]
[0101] wherein Z5 is selected from O, NH, NHNH, NR5, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R1), N(R1)C(O)N(R2), C(O)NHNHC(O), and C(O)NR1.
[0102] The proteinase inhibitor used as the payload is preferably selected from carfilzomib, clindamycin, retapamulin, indibulin, of the structures shown below: [ka]
[0103] The immunotoxins herein are macromolecular drugs that are typically cytotoxic proteins derived from bacterial or plant proteins, such as diphtheria toxin (DT), cholera toxin (CT), trichosanthin (TCS), dianthin, Pseudomonas exotoxin A (ETA'), erythrogenic toxin, diphtheria toxin, AB toxin, and type III exotoxin. They may also be highly toxic bacterial pore-forming protoxins that require proteolytic processing for activation. Examples of such protoxins include proerolysin and its recombinant form, topsalysin. Topsalysin is an engineered recombinant protein designed to be selectively activated by prostate enzymes, causing localized cell death and tissue destruction without damaging adjacent tissues and nerves. The immunotoxins herein are preferably conjugated via the side chain linkers of the present application via amino acids bearing free amino, thiol, or carboxylic acid groups, more preferably via the N-terminal amino acid.
[0104] Additionally, W, L1, L2, V1, and V2 may independently comprise one or more of the following structures: 6-maleimidocaproyl (MC), maleimidopropanoyl (MP), valine-citrulline (val-cit or vc), alanine-phenylalanine (ala-phe or af), p-aminobenzyloxycarbonyl (PAB), 4-thiopentanoic acid ester (SPP), 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid ester (MCC), (4-acetyl)aminobenzoic acid (SIAB), 4-thiobutyric acid ester (SPDB), 4-thio-2-hydroxysulfonyl-butyric acid ester (2-sulfo-SPDB), or a linker moiety of a natural or unnatural peptide having 1 to 12 natural or unnatural amino acid units. The natural amino acids are preferably aspartic acid, glutamic acid, guanine, thiamin ... arginine, histidine, lysine, serine, threonine, asparagine, glutamine, cysteine, selenocysteine, tyrosine, phenylalanine, glycine, proline, tryptophan, and alanine;
[0105] [ka] TIFF2024112832000052.tif237170TIFF2024112832000053.tif254170TIFF2024112832000054.tif31170
[0106] During the ceremony, [ka] is a linking moiety; preferably, X2, X3, X4, X5, or X6 is independently NH; NHNH; N(R 12 );N(R 12 )N(R 12’ );O;S;C1-C6 alkyl;C2-C6 heteroalkyl, alkylcycloalkyl, heterocycloalkyl;C3-C8 aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl;CH2OR 12 , CH2SR 12 , CH2NHR 12 or 1 to 8 amino acids; 12 and R 12’ are independently H; C1-C8 alkyl; C2-C8 heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or an ester, ether, or amide having 1 to 8 carbon atoms; or a group of the formula (OCH2CH2) p or (OCH2CH(CH3)) p or a polyethyleneoxy unit (p is an integer from 0 to about 1000), or a combination thereof.
[0107] W, L1, L2, V1, and V2 may also independently comprise a self-immolative or non-self-immolative moiety, a peptide unit, a hydrazone bond, a disulfide, an ester, an oxime, an amide, or a thioether bond, including, but not limited to, aromatic compounds electronically similar to para-aminobenzylcarbamoyl (PAB) groups, 2-aminoimidazole-5-methanol derivatives, heterocyclic PAB analogs, β-glucuronides, and o- or p-aminobenzyl acetals.
[0108] Preferably, the self-immolative linker moiety has one of the following structures: [ka]
[0109] In the formula, ( * Atoms labeled with X are points of attachment to additional spacers or releasable linker units, or cytotoxic agents, and / or binding molecules (CBAs); 1 , Y 1 , Z 2 , and Z 3 are independently NH, O or S; Z 1 are independently H, NHR1, OR1, SR1, COX1R1, where X1 and R1 are as defined above; v is 0 or 1; U 1 are independently H, OH, C1-C6 alkyl, (OCH2CH2) n , F, Cl, Br, I, OR5, SR5, NR5R 5’ ,N=NR5,N=R5,NR 5 R 5’ , NO2, SOR 5 R 5’ , SO2R 5 , SO3R 5 , OSO3R 5 , PR 5 R 5’ , POR 5 R 5’ , PO2R 5 R 5’ , OPO(OR 5 )(OR 5’), or OCH2PO(OR 5 )(OR 5’ ) where R 5 and R 5’ are each independently selected from H, C1-C8 alkyl; C2-C8 alkenyl, alkynyl, heteroalkyl, or amino acid; C3-C8 aryl, heterocycle, carbocycle, cycloalkyl, heterocycloalkyl, heteroaralkyl, alkylcarbonyl, or glycoside; or a medicinal cation salt.
[0110] W, L1, L2, V1, and V2 may also independently comprise a non-self-immolative linker moiety having one of the following structures: [ka] TIFF2024112832000058.tif170170
[0111] In the formula, ( * Atoms labeled with X are points of attachment to additional spacer or releasable linker units, cytotoxic agents, and / or binding molecules; 1 , Y 1 , U 1 , R 5 , R 5’ is as defined above; r is 0 to 100; m and n are independently 0 to 20.
[0112] More preferably, W, L1, L2, V1, and V2 can independently be releasable linker moieties. The term releasable refers to a linker that includes at least one bond that can be cleaved under physiological conditions, such as a pH-labile, acid-labile, base-labile, oxidatively labile, metabolically labile, biochemically labile, or enzyme-labile bond. Such physiological conditions that result in bond rupture do not necessarily involve biological or metabolic processes, but instead may involve standard chemical reactions, such as hydrolysis or substitution reactions, for example, dissociation with intracellular thiols, such as glutathione, which is abundant in endosomes, which have a pH lower than the cytoplasmic pH, and / or in the millimolar range within malignant cells. It is understood that sulfide bond exchange reactions may be involved.
[0113] Examples of releasable components of W, L1, L2, V1, and V2 independently include, but are not limited to: -(CR 15 R 16 ) m (Aa) r (CR 17 R 18 ) n (OCH2CH2) t -,-(CR 15 R 16 ) m (CR 17 R 18 ) n (Aa) r (OCH2CH2) t -, -(Aa) r -(CR 15 R 16 ) m (CR 17 R 18 ) n (OCH2CH2) t -,-(CR 15 R 16 ) m (CR 17 R 18 ) n (OCH2CH2) r (Aa) t -,-(CR 15 R 16 ) m (CR 17 =CR 18 )(CR 19 R 20 ) n (Aa) t (OCH2CH2) r -,-(CR 15 R 16 ) m (NR 11 CO)(Aa) t (CR 19 R 20 ) n (OCH2CH2) r -,-(CR 15 R 16 ) m(Aa) t (NR 21 CO)(CR 19 R 20 ) n (OCH2CH2) r -、-(CR 15 R 16 ) m (OCO)(Aa) t (CR 19 R 20 ) n (OCH2CH2) r -、-(CR 15 R 16 ) m (OCNR 17 )(Aa) t (CR 19 R 20 ) n (OCH2CH2) r -、-(CR 15 R 16 ) m (CO)(Aa) t -(CR 19 R 20 ) n (OCH2CH2) r -、-(CR 15 R 16 ) m (NR 21 CO)(Aa) t (CR 19 R 20 ) n (OCH2CH2) r -、-(CR 15 R 16 ) m (OCO)(Aa) t (CR 19 R 20 ) n -(OCH2CH2) r -、-(CR 15 R 16 ) m (OCNR 17 )(Aa) t (CR 19 R 20 ) n (OCH2CH2) r -、-(CR 15 R 16 ) m(CO)(Aa) t (CR 19 R 20 ) n (OCH2CH2) r -,-(CR 15 R 16 ) m -phenyl-(CO)(Aa) t (CR 17 R 18 ) n -,-(CR 15 R 16 ) m -Frill-(CO)(Aa) t (CR 17 R 18 ) n -,-(CR 15 R 16 ) m -oxazolyl-(CO)(Aa) t (CR 17 R 18 ) n -,-(CR 15 R 16 ) m -thiazolyl-(CO)(Aa) t (CR 17 R 18 ) n -,-(CR 15 R 16 ) t -Thienyl-(CO)(CR 17 R 18 ) n -,-(CR 15 R 16 ) t -imidazolyl-(CO)(CR 17 R 18 ) n -,-(CR 15 R 16 ) t -morpholino-(CO)(Aa) t (CR 17 R 18 ) n -,-(CR 15 R 16 ) t -piperazino-(CO)(Aa) t (CR 17 R 18 ) n-, -(CR 15 R 16 ) t -N-methylpiperazine-(CO)(Aa) t (CR 17 R 18 ) n -, -(CR 15 R 16 ) m -(Aa) t Phenyl-, -(CR 15 R 16 ) m -(Aa) t Frill-,-(CR 15 R 16 ) m -oxazolyl (Aa) t -, -(CR 15 R 16 ) m -Thiazolyl (Aa) t -, -(CR 15 R 16 ) m -Thienyl (Aa) t -, -(CR 15 R 16 ) m -Imidazolyl (Aa) t -,-(CR 15 R 16 ) m -Morpholino-(Aa) t -, -(CR 15 R 16 ) m -Piperazino-(Aa) t -,-(CR 15 R 16 ) m -N-methylpiperazino-(Aa) t -, -K(CR 15 R 16 ) m (Aa) r (CR 17 R 18 ) n (OCH2CH2) t -, -K(CR 15 R 16 ) m (CR 17 R 18 ) n (Aa) r(OCH2CH2) t -、-K(Aa) r (CR 15 R 16 ) m (CR 17 R 18 ) n (OCH2CH2) t -、-K(CR 15 R 16 ) m (CR 17 R 18 ) n (OCH2CH2) r (Aa) t -、-K(CR 15 R 16 ) m (CR 17 =R 18 )(CR 19 R 20 ) n (Aa) t (OCH2CH2) r -、-K(CR 15 R 16 ) m (NR 11 CO)(Aa) t (CR 19 R 20 ) n (OCH2CH2) r -、-K(CR 15 R 16 ) m (Aa) t (NR 21 CO)(CR 19 R 20 ) n (OCH2CH2) r -、-K(CR 15 R 16 ) m (OCO)(Aa) t (CR 19 R 20 ) n (OCH2CH2) r -、-K(CR 15 R 16 ) m (OCNR 17 )(Aa) t (CR 19 R 20 )n (OCH2CH2) r -、-K(CR 15 R 16 ) m (CO)(Aa) t (CR 19 R 20 ) n (OCH2CH2) r -、-K(CR 15 R 16 ) m (No. 21 CO)(Aa) t (CR 19 R 20 ) n (OCH2CH2) r -、-K(CR 15 R 16 ) m (OCO)(Aa) t (CR 19 R 20 ) n (OCH2CH2) r -、-K(CR 15 R 16 ) m (OCNR 17 )(Aa) t (CR 19 R 20 ) n (OCH2CH2) r -、-K(CR 15 R 16 ) m (CO)(Aa) t (CR 19 R 20 ) n (OCH2CH2) r -、-K(CR 15 R 16 ) m -phenyl-(CO)(Aa) t (CR 17 R 18 ) n -、-K(CR 15 R 16 ) m - フリル -(CO)(Aa) t (CR 17 R 18 ) n -、-K(CR15 R 16 ) m -oxazolyl-(CO)(Aa) t (CR 17 R 18 ) n -, -K(CR 15 R 16 ) m -thiazolyl-(CO)(Aa) t (CR 17 R 18 ) n -, -K(CR 15 R 16 ) t -Thienyl-(CO)(CR 17 R 18 ) n -, -K(CR 15 R 16 ) t -imidazolyl-(CO)(CR 17 R 18 ) n -, -K(CR 15 R 16 ) t -morpholino-(CO)(Aa) t (CR 17 R 18 ) n -, -K(CR 15 R 16 ) t -piperazino-(CO)(Aa) t (CR 17 R8) n -, -K(CR 15 R 16 ) t -N-methylpiperazine-(CO)(Aa) t (CR 17 R 18 ) n -, -K(CR 15 R 16 ) m -(Aa) t Phenyl-, -K(CR 15 R 16 ) m -(Aa) t Frill-,-K(CR 15 R 16 ) m -oxazolyl (Aa) t-, -K(CR 15 R 16 ) m -Thiazolyl (Aa) t -, -K(CR 15 R 16 ) m -Thienyl (Aa) t -, -K(CR 15 R 16 ) m -Imidazolyl (Aa) t -, -K(CR 15 R 16 ) m -Morpholino-(Aa) t -, -K(CR 15 R 16 ) m -Piperazino-(Aa) t G-, -K(CR 15 R 16 ) m -N-methylpiperazine No (Aa) t ;In the formula, m, Aa, m, n, R 13 , R 14 , and R 15 are defined as above; t and r are independently 0 to 100. Yes;R 16 , R 17 , R 18 , R 19 , and R 20 are independently H; halide; C1-C8 alkyl or heteroalkyl; C2-C8 aryl, alkenyl, alkynyl, ether, ester, amine, or amide; or one or more of halide, CN, NR 12 R 12’ , CF3, OR 12 , aryl, heterocycle, S(O)R 12 , SO2R 12 , -CO2H, -SO3H, -OR 12 , -CO2R 12 , -CONR 12 , -PO2R 12 R 13 , -PO3H, or P(O)R 12 R 12’ R 13’K is selected from C3-C8 aryl optionally substituted with NR 12 , -SS-, -C(=O)-, -C(=O)NH-, -C(=O)O-, -C=NH-O-, -C=N-NH-, -C(=O)NH-NH-, O, S, Se, B, Het(C3~C 12 or a peptide containing 1 to 20 identical or different amino acids.
[0114] More preferably, the components W, L1, L2, V1, and V2 are independently a straight chain alkyl having 1 to 6 carbon atoms or a group of the formula (OCH2CH2) p or a peptide containing 1 to 4 units of an amino acid (L or D type), or a combination thereof.
[0115] Alternatively, any one or more of W, Q1, Q2, L1, L2, V1, or V2 may be independently absent, but Q1 and Q2 are not simultaneously absent.
[0116] Generally speaking, in another embodiment, when V1 and / or V2 are conjugated to a cell-binding molecule T, or when L1 and / or L2 are directly conjugated to T (V1 and V2 are absent), the covalent bond can be one or more of the following structures: [ka] TIFF2024112832000060.tif251170
[0117] In the formula, R 20 and R 21 are independently C1-C8 alkyl; C2-C8 heteroalkyl, or heterocycle; C3-C8 aryl, Ar-alkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, carbocycle, or alkylcarbonyl; or (CH2CH2O) p C2~C with the formula 100It is polyethylene glycol (where p is defined above), or is absent.
[0118] In another further aspect, Q1 and Q2 are preferably C2 to C 18 Lipids, or C2 to C 18 Fatty acids, or C2-C 18The polyalkylene glycol is selected from polyalkylene glycols containing fatty ammonium lipids. The polyalkylene glycol chain not only helps the conjugate become more hydrophilic during manufacturing, but also protects the conjugate from hydrolysis by hydrolases such as proteinases or esterases. The lipid can help the conjugate bind to albumin in mammalian blood, slowly dissociating the conjugate from this complex during blood circulation. Therefore, the side chain conjugate of the present patent application makes the conjugate more stable during circulation. Here, polyalkylene glycols include, but are not limited to, poly(ethylene glycol) (PEG), poly(propylene glycol), and copolymers of ethylene oxide and propylene oxide. Particularly preferred is PEG, and more particularly preferred is monofunctionally activated hydroxyPEG (e.g., hydroxyPEG-monocarboxylic acid, hydroxyPEG-monoaldehyde, hydroxyPEG-monoamine, hydroxyPEG-monohydrazide, hydroxyPEG-monocarbazate, hydroxylPEG activated at a single end, including reactive esters of hydroxyl, PEG-monoiodoacetamide, hydroxylPEG-monomaleimide, hydroxylPEG-monoorthopyridyl disulfide, hydroxyPEG-monoxime, hydroxyPEG-monophenylcarbonate, hydroxylPEG-monophenylglyoxal, hydroxylPEG-monothiazolidine-2-thione, hydroxylPEG-monothioester, hydroxylPEG-monothiol, hydroxylPEG-monotriazine, and hydroxylPEG-monovinylsulfone). The polyalkylene glycol has a molecular weight of about 10 Da to about 200 kDa, preferably about 88 Da to about 40 kDa; each of the two branched chains has a molecular weight of about 88 Da to about 40 kDa; more preferably, each of the two branched chains has a molecular weight of about 88 Da to about 20 kDa. In a specific embodiment, the polyalkylene glycol is poly(ethylene) glycol and has a molecular weight of about 10 kDa, about 20 kDa, or about 40 kDa. In a specific embodiment, the PEG is PEG 10 kDa (linear or branched), PEG 20 kDa (linear or branched), or PEG 40 kDa (linear or branched).The synthesis of linear or branched "non-antigenic" PEG polymers and their derivatives or conjugates is described in many US patents, for example US Pat. Nos. 5,428,128; 5,621,033. 9;5,622,986;5,643,575;5,728,560;5,730,990;5,738,846;5,811,076;5,824,701;5,840,900;5,880,131;5,900,402;5,902,588;5,919,455;5,95 1,974; 5,965,119; 5,965,566; 5,969,040; 5,981,709; 6,011,042; 6,042,822; 6,113,906; 6,127,355; 6,132,713; 6,177,087; and 6,180,095.
[0119] The cell binding agent / molecule T may be any molecule now known or discovered that binds to, complexes with, or reacts with a moiety of a cell population to be therapeutically or otherwise biologically modified. Preferably, the cell binding agent / molecule is an immunotherapeutic protein, an antibody, a single chain antibody, an antibody fragment that binds to a target cell; a monoclonal antibody; a single chain monoclonal antibody; or a monoclonal antibody fragment that binds to a target cell; a chimeric antibody; a chimeric antibody fragment that binds to a target cell; a domain antibody; a domain antibody fragment that binds to a target cell; an antibody-mimetic adnectin, a DA RPins; lymphokines; hormones; vitamins; growth factors; colony-stimulating factors; or nutrient transport molecules (transferrin); cell-binding peptides with four or more amino acids, or proteins, or antibodies, or small molecules attached to albumin, polymers, dendrimers, liposomes, nanoparticles, vesicles, or (viral) capsids.
[0120] Examples of formulas (I), (II), and (III), or isotopes of one or more chemical elements, or pharmaceutically acceptable salts, hydrates, or hydrated salts thereof; or polymorphic crystal structures of these compounds; or their isotopes, optical isomers, racemates, diastereomers, or enantiomers thereof are shown below: [ka] TIFF2024112832000062.tif251170TIFF2024112832000063.tif251170TIFF2024112832000064.tif234170TIFF2024112832000065.tif251170TIFF2024112832000066.tif225170TIFF2024112832000067.tif252170TIFF2024112832000068.tif223170TIFF2024112832000069.tif230170TIFF2024112832000070.tif254170TIFF2024112832000071.tif254170TIFF2024112832000072.tif254170TIFF2024112832000073.tif235170TIFF2024112832000074.tif254170TIFF2024112832000075.tif254170TIFF2024112832000076.tif236170TIFF2024112832000077.tif236170TIFF2024112832000078.tif249170TIFF2024112832000079.tif251170TIFF2024112832000080.tif224170TIFF2024112832000081.tif250170TIFF2024112832000082.tif252170TIFF2024112832000083.tif210170TIFF2024112832000084.tif249170TIFF2024112832000085.tif234170TIFF2024112832000086.tif234170TIFF2024112832000087.tif234170TIFF2024112832000088.tif224170TIFF2024112832000089.tif245170TIFF2024112832000090.tif245170TIFF2024112832000091.tif211170TIFF2024112832000092.tif213170TIFF2024112832000093.tif231170TIFF2024112832000094.tif211170TIFF2024112832000095.tif243170TIFF2024112832000096.tif248170TIFF2024112832000097.tif215170TIFF2024112 832000098.tif218170TIFF2024112832000099.tif228170TIFF2024112832000100.tif205170TIFF2024112832000101.tif133170.
[0121] In the formula, X8 is O, S, NH, NHNH, NHR 12 , S.R. 12 , SSR 12 , SSCH(CH3)R 12 , SSC(CH3)2R 12 , or R 12 R 1 , R 2 , R 3 , R 4 , R 5 , R4, R5, R7, R8, R9, R 10 ,X1,X2,X3,X4,X5,X6,Y1,Y2,Y3,Y5,R 12 , R 12’ , R 13 , R 13’ , R 25 , R 25’ , p1, p2, q1, q2, m, n, and mAb have the same definitions as above; Aa is a natural or unnatural amino acid; r is 0 to 12; (Aa) r If r>2, then they are peptides containing the same or different amino acid sequences; if r=0, then (Aa) r means that it does not exist.
[0122] In another aspect of the present invention, the side chain linking compounds are represented by formulas (IV), (V), and (VI), which can readily react with the cell-binding molecule T or the modified cell-binding molecule T to form the conjugates of formulas (I), (II), and (III), respectively: [ka]
[0123] In the formula, D, D1, D2, W, w, w', L1, L2, Q1, Q2, V1, V2, v1, v2, [ka] , and n have the same definitions as in formula (I) above.
[0124] Lv1 and Lv2 independently represent reactive groups capable of reacting with a thiol, amine, carboxylic acid, selenol, phenol, or hydroxyl group on a cell-binding molecule. Such reactive groups include, but are not limited to, halide (e.g., fluoride, chloride, bromide, iodide), methanesulfonyl (mesyl), toluenesulfonyl (tosyl), trifluoromethyl-sulfonyl (triflate), trifluoromethylsulfonate, nitrophenoxyl; N-hydroxysuccinimidyloxyl (NHS); phenoxyl, dinitrophenoxyl, pentafluorophenoxyl, tetrafluorophenoxyl, trifluorophenoxyl, difluorophenoxyl, monofluorophenoxyl, pentachlorophenoxyl, 1H-imidazol-1-yl, chlorophenoxyl, and the like. phenyloxadiazole-sulfonyl (-sulfone-ODA), 2-ethyl-5-phenylisoxazolium-yl, phenyloxadiazol-yl (ODA), oxadiazol-yl, unsaturated carbon (carbon-carbon, carbon-nitrogen, carbon-sulfur, carbon-phosphorus, sulfur-nitrogen, phosphorus-nitrogen, oxygen-nitrogen, or carbon-oxygen double or triple bond), or intermediate molecules generated with condensing reagents for the Mitsunobu reaction. Examples of the condensation reagent include EDC (N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide), DCC (dicyclohexylcarbodiimide), N,N'-diisopropylcarbodiimide (DIC), N-cyclohexyl-N'-(2-morpholinoethyl)carbodiimide meso-p-toluenesulfonate (CMC, or CME-CDI), 1,1'-carbonyldiimidazole (CDI), TBTU (O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate), N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU), (benzotriazol-1-yloxy)tris(dimethylamino)methyl (amino)phosphonium hexafluorophosphate (BOP), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), diethyl cyanophosphonate (DEPC), chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU), 1-[(dimethylamino)(morpholino) N,N,N',N'-bis(tetramethylene)formamidinium hexafluorophosphate (BTFFH), N,N,N',N'-tetramethyl-S-(1-oxide-2-pyridyl)-2-methyl-2-methyl-1H-[1,2,3]triazolo[4,5-b]pyridin-1-ium-3-oxide hexafluorophosphate (HDMA), 2-chloro-1,3-dimethylimidazolidinium hexafluorophosphate (CIP), chlorotripyrrolidinophosphonium hexafluorophosphate (PyCloP), fluoro-N,N,N',N'-bis(tetramethylene)formamidinium hexafluorophosphate (BTFFH), N,N,N',N'-tetramethyl-S-(1-oxide-2-pyridyl)-2-methyl-1H-[1,2,3]triazolo[4,5-b]pyridin-1-ium-3-oxide hexafluorophosphate (HDMA), 2-chloro-1,3-dimethylimidazolidinium hexafluorophosphate (CIP), chlorotripyrrolidinophosphonium hexafluorophosphate (PyCloP), ) Thiuronium hexafluorophosphate, O-(2-oxo-1(2H)pyridyl)-N,N,N',N'-tetramethylthiuronium tetrafluoroborate (TPTU), S-(1-oxido-2-pyridyl)-N,N,N',N'-tetramethylthiuronium tetrafluoroborate, O-[(ethoxycarbonyl)cyanomethyleneamino]-N,N,N',N'-tetramethyluronium hexafluorophosphate (HOTU), (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethyl a amino-morpholino-carbenium hexafluorophosphate (COMU), O-(benzotriazol-1-yl)-N,N,N',N'-bis(tetramethylene)uronium hexafluorophosphate (HBPyU), N-benzyl-N'-cyclohexylcarbodiimide (with or without polymer linkage), dipyrrolidino(N-succinimidyloxy)-carbenium hexafluorophosphate (HSPyU), chlorodipyrrolidinocarbenium hexafluorophosphate (PyCIU), 2-chloro-1,3-Dimethylimidazolinium tetrafluoroborate (CIB), (benzotriazol-1-yloxy)dipiperidinocarbenium hexafluorophosphate (HBPipU), O-(6-chlorobenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TCTU), bromotris(dimethylamino)phosphonium hexafluorophosphate (BroP), propylphosphonic anhydride (PPACA, T3P®), 2-morpholinoethyl isocyanide (MEI), N,N,N',N'-tetramethyl-O-(N-succinimidyl)uronium hexafluorophosphate (HSTU), 2-bromo-1-ethyl-pyridinium tetrafluoroborate (BEP ), O-[(ethoxycarbonyl)cyanomethyleneamino]-N,N,N',N'-tetramethyluronium tetrafluoroborate (TOTU), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (MMTM, DMTMM), N,N,N',N'-tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate (TSTU), O-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TDBTU), 1,1'-(azodicarbonyl)dipiperidine (ADD), di-(4-chlorobenzyl)azodicarboxylate (DCAD), di-tert-butyl, azodicarboxylate (DBAD), diisopropyl azodicarboxylate (DIAD), or diethyl azodicarboxylate (DEAD); Lv1 and Lv2 can be anhydrides formed by themselves or with other C1-C8 acid anhydrides.
[0125] Preferably, Lv1 and Lv2 are independently selected from the group consisting of halide (e.g., fluoride, chloride, bromide, iodide), methanesulfonyl (mesyl), toluenesulfonyl (tosyl), trifluoromethyl-sulfonyl (triflate), trifluoromethylsulfonate, nitrophenoxyl; N-hydroxysuccinimidyloxyl (NHS); phenoxyl, dinitrophenoxyl, pentafluorophenoxyl, and tetrafluorophenoxyl. , trifluorophenoxyl, difluorophenoxyl, monofluorophenoxyl, pentachlorophenoxyl, 1H-imidazol-1-yl, chlorophenoxyl, dichlorophenoxyl, trichlorophenoxyl, tetrachlorophenoxyl, N-(benzotriazol-yl)oxyl, 2-ethyl-5-phenylisoxazolium-yl, 3′-sulfonyl, phenyloxadiazole-sulfonyl (-sulfone-ODA), 2-ethyl-5-phenylisoxazolium-yl, phenyloxadiazol-yl (ODA), oxadiazol-yl, unsaturated carbon (carbon-carbon, carbon-nitrogen, carbon-sulfur, carbon-phosphorus, sulfur-nitrogen, phosphorus-nitrogen, oxygen-nitrogen, or carbon-oxygen double or triple bonds), or any of the following structures:
[0126] [ka] TIFF2024112832000105.tif144170
[0127] In the formula, X 1’ is F, Cl, Br, I, or Lv3; X 2’is O, NH, N(R1), or CH2; R3 is independently H, aromatic, heteroaromatic, or an aromatic group in which one or more H atoms are independently replaced by -R1, -halogen, -OR1, -SR1, -NR1R2, -NO2, -S(O)R1, -S(O)2R1, or -COOR1; Lv3 is F, Cl, Br, I, nitrophenol; N-hydroxysuccinimide (NHS); phenol; dinitrophenol; pentafluorophenol; tetrafluorophenol; difluorophenol; a leaving group selected from monofluorophenol; pentachlorophenol; triflate; imidazole; dichlorophenol; tetrachlorophenol; 1-hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5-phenylisoxazolium-3'-sulfonate, anhydrides formed by themselves or with other anhydrides, such as acetic anhydride or formic anhydride; or an intermediate molecule generated by a condensing reagent for a peptide coupling reaction or for a Mitsunobu reaction.
[0128] Formulas (IV), (V), and (VI), or isotopes of one or more chemical elements, or pharmaceutically acceptable salts, hydrates, or hydrated salts thereof; or polymorphic crystal structures of these compounds; or isotopes, optical isomers, racemates, diastereomers, or enantiomers thereof; Examples of thiomers are shown below: [ka] TIFF2024112832000107.tif254170TIFF2024112832000108.tif226170TIFF2024112832000109.tif254170TIFF2024112832000110.tif227170TIFF2024112832000111.tif227170TIFF2024112832000112.tif228170TIFF2024112832000113.tif237170TIFF2024112832000114.tif239170TIFF2024112832000115.tif239170TIFF2024112832000116.tif239170TIFF2024112832000117.tif248170TIFF2024112832000118.tif254170TIFF2024112832000119.tif254170TIFF2024112832000120.tif254170TIFF2024112832000121.tif254170TIFF2024112832000122.tif254170TIFF2024112832000123.tif254170TIFF2024112832000124.tif254170TIFF2024112832000125.tif254170TIFF2024112832000126.tif247170TIFF2024112832000127.tif226170TIFF2024112832000128.tif227170TIFF2024112832000129.tif251170TIFF2024112832000130.tif251170TIFF2024112832000131.tif224170TIFF2024112832000132.tif239170TIFF2024112832000133.tif232170TIFF2024112832000134.tif222170TIFF2024112832000135.tif222170TIFF2024112832000136.tif209170TIFF2024112832000137.tif228170TIFF2024112832000138.tif236170TIFF2024112832000139.tif230170TIFF2024112832000140.tif254170TIFF2024112832000141.tif208170TIFF2024112832000142.tif196170TIFF2024112832000143.tif22 9170TIFF2024112832000144.tif229170TIFF2024112832000145.tif243170TIFF2024112832000146.tif206170TIFF2024112832000147.tif206170.
[0129] In the formula, X8 is O, S, NH, NHNH, NHR 12 , S.R. 12 , SSR 12 , SSCH(CH3)R 12 , SSC(CH3)2R 12 , or R 12 R 1 , R 2 , R 3 , R 4 , R 5 , R4, R5, R7, R8, R9, R 10 ,X1,X2,X3,X4,X5,X6,Y1,Y2,Y3,Y5,R 12 , R 12’ , R 13 , R 13’ , R 25 , R 25’ , Z2, Z3, p, p1, p2, p3, q1, q2, Lv1, Lv2, Lv3, Lv 3’ , m, m1, n, and mAb are defined as above; Aa is a natural or unnatural amino acid; r is 0 to 12; (Aa) r If r>2, the same or different A peptide containing the amino acid sequence (Aa); r means that it does not exist.
[0130] Preferably, Lv1, Lv2, Lv3, and Lv 3’reacts with the thiol of the cell-binding agent / molecule. The thiol is preferably a pair of sulfur atoms obtained by reducing the interchain disulfide bond of the cell-binding agent with a reducing agent selected from dithiothreitol (DTT), dithioerythritol (DTE), L-glutathione (GSH), tris(2-carboxyethyl)phosphine (TCEP), 2-mercaptoethylamine (β-MEA), and / or beta-mercaptoethanol (β-ME, 2-ME). The thiol of the cell-binding agent / molecule can also be generated via Traut's reagent or thiolactone, where Traut's reagent or thiolactone reacts with the amine of the cell-binding agent / molecule to form a thiol, followed by the formation of Lv1, Lv2, Lv3, or Lv4. 3’ React simultaneously or sequentially with:
[0131] [ka]
[0132] The present invention further relates to methods for preparing the cell-binding molecule-amatoxin analog conjugates of formulae (I), (II), and (III), and applications of the conjugates of formulae (I), (II), and (III).
[0133] Preparation of conjugates of cell-binding molecules and drugs via side chain linkages
[0134] The preparation of conjugates of the cell-binding molecules and amatoxin analogs of the present invention, and synthetic routes for generating the conjugates via side chain linkages, are shown in Figures 1-19 and in the Examples section.
[0135] Conjugates of formulas (I), (II), and (III) can be prepared via intermediate compounds of formulas (IV), (V), and (VI), respectively. Generally, compounds of formulas (IV), (V), and (VI) are synthesized to contain maleimide, Lv1, and Lv2 functional groups that can readily react with cell-binding molecules or modified cell-binding molecules. The synthesis of compounds of formulas (IV), (V), and (VI) and some of the preparations of compounds of formulas (I), (II), and (III) are structurally illustrated in Figures 1-19.
[0136] Generally, to synthesize the conjugate of formula (I), the functional group Lv1 of formula (IV) is reacted with one, two, or more residues of a cell-binding molecule in an aqueous medium at 0-60°C, with or without the addition of 0-30% of a water-miscible organic solvent (e.g., DMA, DMF, ethanol, methanol, acetone, acetonitrile, THF, isopropanol, dioxane, propylene glycol, or ethylenediol), at a pH of 5-9, followed by the conjugation of formula (I). Dialysis or chromatographic purification is performed to form the compound. Some of the residues (reactive groups for conjugation) of the cell-binding molecule can be obtained by protein engineering.
[0137] The conjugates of formula (II) and (III) can also be obtained by reacting the functional groups Lv1 and Lv2 of the linker of formula (V) or (VI) with two or more residues on the cell-binding molecule, preferably a pair of free thiols generated through reduction of disulfide bonds of the cell-binding molecule, in an aqueous medium of pH 5 to 9 at 0 to 60°C with or without the addition of 0 to 30% of a water-miscible (miscible) organic solvent to form a conjugate molecule. The thiol pair is preferably a disulfide bond reduced from the interchain disulfide bond of the cell-binding agent by a reducing agent that can be selected from dithiothreitol (DTT), dithioerythritol (DTE), L-glutathione (GSH), tris(2-carboxyethyl)phosphine (TCEP), 2-mercaptoethylamine (β-MEA), and / or β-mercaptoethanol (β-ME, 2-ME) in an aqueous medium of pH 4 to 9 with or without the addition of 0 to 30% of a water-miscible (miscible) organic solvent.
[0138] The reactive groups Lv1 and Lv2 of formulas (IV), (V), and (VI) (independently selected from the group consisting of disulfide, thiol, thioester, maleimide, haloacetyl, azide, 1-yne, ketone, aldehyde, alkoxyamino, triflate, carbonylimidazole, tosylate, mesylate, 2-ethyl-5-phenylisoxazolium-3′-sulfonate, nitrophenol, N-hydroxysuccinimide (NHS), carboxyl ester of phenol; dinitrophenol, pentafluorophenol, tetrafluorophenol, difluorophenol, The reactive groups Lv1 and Lv2 of formulas (IV), (V), and (VI) can be phenol, monofluorophenol, pentachlorophenol, dichlorophenol, tetrachlorophenol, 1-hydroxybenzotriazole, anhydride, or hydrazide groups, or other acid ester derivatives. The reactive groups Lv1 and Lv2 of formulas (IV), (V), and (VI) can react with one, two, or more groups of the cell-binding molecule / agent simultaneously or sequentially in an aqueous medium at pH 4-9.5 with or without 0-30% water-miscible organic solvents after column purification or dialysis to obtain the conjugates of formulas (I), (II), or (III). The reactive groups Lv1 and Lv2 of formulas (IV), (V), and (VI) react with the modified cell-binding molecule in different ways accordingly. For example, the linkage containing a disulfide bond in the cell-binding agent-amatoxin analog of Formula (I) is achieved by disulfide exchange between the disulfide bond in the modified cell-binding agent and Lv1 and Lv2 containing a free thiol group, or by disulfide exchange between the free thiol group in the modified cell-binding agent and the disulfide bond of Lv1 and Lv2. To speed up the disulfide exchange reaction, the disulfide group is usually a group such as disulfanylpyridine, disulfanyl-nitropyridine, disulfanyl-nitrobenzene, disulfanyl-nitrobenzoic acid, or disulfanyl-dinitrobenzene. Linkages involving thioether bonds in the conjugates of formulas (I), (II), and (III) can be achieved by reacting a maleimide or haloacetyl or ethylsulfonyl of the modified cell-binding agent or of the compounds of formulas (IV), (V), and (VI), respectively, with a free thiol group of the compound of formulas (IV), (V), and (VI) or of the modified cell-binding agent.Linkages involving the attachment of acid-labile hydrazones in the conjugate can be carried out by methods known in the art (e.g., P. Hamann et al., Hinman, LM, et al., Cancer Res. 53, 3336-334, 1993; B. Laguzza et al., J. Med. Chem., 32; 548-555, 1959; P. Trail et al., Cancer Res., 57; 100-105, 1997), by reacting a carbonyl group of the drug of formula (IV), (V), and (VI) or of the modified cell-binding agent with a hydrazide residue of the modified cell-binding agent or of the drug of formula (IV), (V), and (VI), respectively, as appropriate. Linkages involving triazole bonds in the conjugates can be achieved by reacting a carbonyl group of the drug of formula (IV), (V), and (VI) or of the modified cell-binding agent with a hydrazide residue of the modified cell-binding agent or of the drug of formula (IV), (V), and (VI), as appropriate, via click chemistry (Huisgen cycloaddition). This can be achieved by reacting the 1-yne group of the drug or cell-binding molecule of (IV), (V), and (VI) with the azide residue of the other (Lutz, JF. et al, 2008, Adv. Drug Del. Rev. 60, 958-970; Sletten, EM et al 2011, Acc Chem. Research 44 , 666-676). Conjugation is achieved by reacting the ketone or aldehyde of the drug or cell-binding molecule of formulas (IV), (V), and (VI) with the oxyamine group of the other, respectively. Thiol-containing cell-binding molecules can be reacted with drug molecule conjugates of formulas (IV), (V), and (VI) bearing maleimide, haloacetyl, or ethylsulfonyl groups in aqueous media at pH 5.5-9.0 to obtain conjugates of formulas (I), (II), and (III) bearing thioether bonds. Thiol-containing cell-binding molecules can undergo disulfide exchange with drug molecule conjugates of formulas (IV), (V), and (VI) bearing pyridyldithiol residues to obtain conjugates bearing disulfide linkages. Cell-binding molecules bearing hydroxyl or thiol groups can be reacted with the drug molecule conjugates of formulas (IV), (V), and (VI) bearing halogens, particularly carboxylic acid α-halides, in the presence of a mild base, e.g., pH 8.0-9.5, to yield modified drugs bearing ether or thiol ether linkages. Hydroxyl or amino groups on cell-binding molecules can be condensed with the crosslinked drug conjugates of formulas (IV), (V), and (VI) bearing carboxyl groups in the presence of a dehydrating agent, such as EDC or DCC, to yield ester linkages. Cell-binding molecules containing an amino group can be condensed with carboxy esters of NHS, imidazole, carboxyl esters of nitrophenol; N-hydroxysuccinimide (NHS); phenol; dinitrophenol; pentafluorophenol; tetrafluorophenol; difluorophenol; monofluorophenol; pentachlorophenol; triflate; imidazole; dichlorophenol; tetrachlorophenol; 1-hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5-phenylisoxazolium-3'-sulfonate on drug linkers of formulas (IV), (V), and (VI) to obtain conjugates via amide bond bridges.
[0139] The synthesized conjugates can be purified by standard biochemical methods, such as gel filtration on a Sephadex G25 or Sephacryl S300 column, adsorption chromatography, ion exchange, or dialysis. In some cases, when small molecules (e.g., folic acid, melanocyte-stimulating hormone, EGF, etc.) are conjugated to small molecule drugs as cell-binding molecules, they can be purified by chromatography, such as HPLC, medium-pressure column chromatography, or ion-exchange chromatography.
[0140] To achieve higher conjugation yields of a pair of free thiol pairs on a cell-binding molecule, preferably an antibody, with Formula (I), (V), or (III), it may be necessary to add a small amount of a water-miscible organic solvent or phase transfer agent to the reaction mixture. First, the cross-linking agent (linker) of Formula (IV), (V), or (VI) is dissolved in a water-miscible polar organic solvent, such as different alcohols, such as methanol, ethanol, propanol, acetone, acetonitrile, tetrahydrofuran (THF), 1,4-dioxane, dimethylformamide (DMF), dimethylacetamide (DMA), or dimethyl sulfoxide (DMSO), at a high concentration, e.g., The antibody or other cell-binding molecule can be dissolved at a concentration of 1 to 800 mM. Alternatively, a cell-binding molecule such as an antibody dissolved at a concentration of 1 to 50 mg / ml in an aqueous buffer solution of pH 4.0 to 9.5, preferably 6.0 to 8.5, is treated with 0.5 to 20 equivalents of TCEP or DTT for 20 minutes to 48 hours. After reduction, DTT can be removed by SEC chromatography purification. TCEP can also be removed by SEC chromatography, if desired, or can be retained in the reaction mixture for the next step without purification. However, TCEP is preferably neutralized with an azide compound such as 4-azidobenzoic acid, 4-(azidomethyl)benzoic acid, or azido-polyethylene glycolyl (e.g., 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanol). Furthermore, reduction of an antibody or other cell-binding agent with TCEP can be carried out in the presence of a pre-existing drug-conjugate molecule of formula (IV), (VI), or (VI) to achieve cross-conjugation of the cell-binding molecule simultaneously with TCEP reduction.
[0141] Aqueous solutions for modifying cell-binding agents are buffered to a pH between 4 and 9, preferably between 6.0 and 8.0, and may contain non-nucleophilic buffer salts useful in these pH ranges. Representative buffers include phosphate, acetate, triethanolamine HCl, HEPES, and MOPS buffers, and may further contain additional components such as cyclodextrin, hydroxypropyl-β-cyclodextrin, polyethylene glycol, sucrose, and salts (e.g., NaCl, KCl). After adding the drug conjugate of Formula (IV), (V), or (VI) to the solution containing the reduced cell-binding molecule, the reaction mixture is incubated at 0°C to 50°C, preferably 15°C to 37.5°C. The progress of the reaction can be monitored by measuring the decrease in absorbance at 252 nm, the increase in absorbance at 280 nm, or other suitable wavelengths. After the reaction is complete, isolation of the modified cell-binding agent can be carried out by conventional methods, such as gel filtration chromatography, ion exchange chromatography, adsorption chromatography, or column chromatography on silica gel or alumina, crystallization, preparative thin layer chromatography, ion exchange chromatography, or HPLC.
[0142] The degree of modification can be assessed by measuring the absorbance of the emitted nitropyridinethione, dinitropyridinedithione, pyridinethione, carboxyamidopyridinedithione, and dicarboxyamidopyridinedithione groups via UV spectroscopy. For conjugates without chromophore groups, the modification or conjugation reaction can be monitored by LC-MS, preferably HPLC-MS / MS, UPLC-QTOF mass spectrometry, or capillary electrophoresis (CEMS). The side-chain crosslinkers described herein have a variety of functional groups that can react with any drug, preferably a cytotoxic drug, bearing the appropriate substituent. For example, modified cell-binding molecules bearing amino or hydroxy substituents can react with drugs bearing N-hydroxysuccinimide (NHS) esters, and modified cell-binding molecules bearing thiol substituents can react with drugs bearing maleimide or haloacetyl groups. Furthermore, modified cell-binding molecules bearing carbonyl substituents (ketones or aldehydes) can react with drugs bearing hydrazides or alkyloxyamines. One of skill in the art can readily determine which linker to use based on the known reactivity of the available functional groups on the linker.
[0143] Cell-binding agents
[0144] The cell-binding molecules, T, Cb, or mAb included in the conjugates and modified cell-binding agents of the present invention can be any molecule now known or discovered that binds to, complexes with, or reacts with a moiety in a cell population to be therapeutically or otherwise biologically modified.
[0145] Cell-binding molecules / agents include, but are not limited to, large molecular weight proteins such as antibodies, antibody-like proteins, full-length antibodies (polyclonal or monoclonal), dimers, multimers, multispecific antibodies (e.g., bispecific antibodies); single-chain antibodies; antibody fragments such as Fab, Fab', F(ab')2, Fv [Parham, J. Immunol. 131, 2895-2902 (1983)], fragments obtained by Fab expression libraries, anti-idiotypic (anti-Id) antibodies, CDRs, bispecific antibodies, trispecific antibodies, cancer cell antigens, viral antigens, microbial antigens, or fragments that recognize, bind to, or bind to specific antigens of a desired organism. epitope-binding fragments of any of the foregoing that immunospecifically bind to proteins produced by the immune system and are capable of expressing activity; interferons (e.g., types I, II, III); peptides; lymphokines, e.g., IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, GM-CSF, or interferon gamma (IFN-γ); hormones, e.g., insulin, TRH (thyrotropin-releasing hormone), MSH (melanocyte-stimulating hormone), or steroid hormones such as androgens, estrogens, or melanocyte-stimulating hormone (MSH); growth factors and colony-stimulating factors, e.g., epidermal growth factor (EFG). , granulocyte-macrophage colony-stimulating factor (GM-CSF); transforming growth factors (TGF), such as TGFα and TGFβ; insulin and insulin-like growth factors (IGF-I, IGF-II), G-CSF, M-CSF, and GM-CSF [Burgess, Immunology Today, 5, 155-158 (1984)]; vaccines fibroblast growth factor (FGF); small molecular weight proteins, polypeptides, peptides, and peptide hormones, such as bombesin, gastrin, and gastrin-releasing peptide; platelet-derived growth factor; interleukins and cytokines, such as interleukin-2 (IL-2), interleukin-6 (IL-6), leukemia inhibitory factor, granulocyte-macrophage colony-stimulating factor (GM-CSF); vitamins such as folic acid; apoproteins and glycoproteins, such as transferrin [O'Keefe et al., J. Bio. Chem. 260, 932-927 (1985)]; carbohydrate-binding proteins or lipoproteins, such as lectins; cellular nutrient transport molecules; and small molecule inhibitors, such as inhibitors of prostate-specific membrane antigen (PSMA), small molecule tyrosine kinase inhibitors (TKIs), non-peptides, or other cell-binding molecules or substances, such as bioactive polymers (Dhar, et al., J. Bio. Chem. 260, 932-927 (1985)). al, Proc. Natl. Acad. Sci. 2008, 105, 17356-61), dendrimers (Lee, et al, Nat. Biotechnol. 2005, 23, 1517-26; Almutairi, et al; Proc. Natl. Acad. Sci. 2009, 106, 685-90), nanoparticles (Liong, et al, ACS Nano, 2008, 19, 1309-12; Medarova, et al, Nat. Med. 2007, 13, 372-7; Javier, et al, Bioconjugate Chem. 2008, 19, 1309-12), liposomes (Medinai, et al, Curr. Phar. Des. 2004, 10, 2981-9), viral capsids (Flenniken, et al, Viruses Nanotechnol. 2009, 327, 71-93). Generally, monoclonal antibodies are preferred as cell surface binding agents, where suitable monoclonal antibodies are available.
[0146] Generally, monoclonal antibodies are preferred as cell surface binding molecules, provided that suitable monoclonal antibodies are available. Antibodies may be murine, human, humanized, chimeric, or of other species origin.
[0147] The production of antibodies used in the present invention can involve in vivo or in vitro production processes, or a combination thereof. Methods for preparing anti-receptor peptide polyclonal antibodies are well known, as shown, for example, in U.S. Patent No. 4,493,795 (Nestor et al.). A typical method for preparing monoclonal antibodies involves fusing mouse spleen cells isolated from mice immunized with a specific antigen with myeloma cells (Kohler, G; Milstein, C. 1975. Nature 256:495-497). Detailed procedures are described in "Antibodies—A Laboratory Manual," Harlow and Lane, eds., Cold Spring Harbor Laboratory Press, New York (1988), the contents of which are incorporated herein by reference. In particular, monoclonal antibodies can be obtained by immunizing mice, rats, hamsters, or other mammals with the antigen of interest, which can be, for example, intact target cells, antigens isolated from target cells, whole viruses, weakened whole viruses, or viral proteins. Spleen cells are fused with myeloma cells using PEG 6000. The resulting hybridomas are screened for their sensitivity to HAT (hypoxanthine-aminopterin-thymine). Hybridomas producing monoclonal antibodies useful in the practice of the present invention are identified by immunoreaction with or inhibition of receptor activity of specific target cell receptors.
[0148] The monoclonal antibodies used in the present invention are those that secrete antibodies with appropriate antigen specificity. Monoclonal hybridoma cells can be obtained by initiating a culture of the hybridoma cells in a nutrient medium containing the hybridoma cells. The culture must be maintained for a time and under conditions sufficient for the hybridoma cells to secrete the antibody into the culture medium. After collecting the antibody-containing culture supernatant, the antibody can be isolated by well-known techniques, such as protein A affinity chromatography; anion exchange chromatography, cation exchange chromatography, hydrophobic interaction chromatography, and molecular sieve chromatography (particularly affinity chromatography and molecular sieve chromatography using antigen-crosslinked protein A); centrifugation, precipitation, or other standard methods for purifying proteins.
[0149] Media useful for preparing these compositions are well known in the art and commercially available, including synthetic media. An exemplary synthetic medium is Dulbecco's Minimum Essential Medium (DMEM; Dulbecco et al., Virol. 8:396 (1959)) supplemented with 4.5 g / L glucose, 0-20 mM glutamine, 0-20% fetal bovine serum, ppm amounts of several heavy metals (e.g., Cu, Mn, Fe, or Zn) or / and heavy metals added in salt form, and an antifoaming agent (e.g., polyoxyethylene-polyoxypropylene block copolymer).
[0150] In addition to cell fusion techniques, cell lines for producing antibodies can also be constructed by the following methods: direct transformation of B lymphocytes with oncogenic DNA or transfection with oncogenic viruses, such as Epstein-Barr virus (EBV, also known as human herpesvirus 4 (HHV-4)) or Kaposi's sarcoma-associated virus (KSHV) (see U.S. Patent Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,451,570; 4,466,917; 4,472,500; 4,491,632; and 4,493,890 for details). Monoclonal antibodies can be prepared using anti-receptor peptides or peptides containing terminal carboxyl groups according to known methods (see Niman et al., Proc. Natl. Acad. Sci. 2002, 103:141-143, for details). Sci. USA, 80:4949-4953 (1983); Geysen et al., Proc. Natl. Acad. Sci. USA, 82:178-182 (1985); Lei et al., Biochemistry 34(20):6675-6688 (1995). The anti-receptor polypeptide or polypeptide analog can be used alone or conjugated to a cross-linked immunogenic carrier as an immunogen to prepare monoclonal antibodies against the anti-receptor polypeptide.
[0151] There are many other well-known methods for producing monoclonal antibodies as binding molecules of the present invention. Of these, the production of fully human antibodies has attracted particular attention. Phage display technology allows for affinity selection of fully human antibodies that specifically bind to known antigens from fully human antibody libraries. The literature provides detailed descriptions of the phage display technology itself, vector construction, and library screening. For details, see Dente et al., Gene. 148(1):7-13 (1994); Little et al., Biotechnol. Adv. 12(3):539-55 (1994); Clackson et al., Nature 352:264-628 (1991); and Huse et al., Science 246:1275-1281 (1989).
[0152] Monoclonal antibodies obtained from non-human species (e.g., mice) using hybridoma technology can be humanized to avoid human anti-mouse antibodies when administered to humans. Among them, well-known methods for antibody humanization are grafting and remodeling of complementarity-determining regions. For details, see U.S. Patent Nos. 5,859,205 and 6,797,492; Liu et al., Immunol Rev. 222:9-27 (2008); Almagro et al., Front Biosci. 1;13:1619-33 (2008); Lazar et al., Mol Immunol. 44(8):1986-98 (2007) ); Li et al. Proc. Natl. Acad. Sci. USA. 103(10):3557-62 (2006), the disclosures of which are incorporated by reference. Fully human antibodies can be prepared by immunizing transgenic mice, rabbits, monkeys, and other mammals that possess large portions of human immunoglobulin light and heavy chains with an antigen. Examples of such mice include the Xenomouse (Abgenix, Inc.), HuMab-Mouse (Medarex / BMS), and VelociMouse (Regeneron). For details, see U.S. Patent Nos. 6,596,541, 6,207,418, 6,150,584, 6,111,166, 6,075,181, 5,922,545, 5,661,016, 5,545,806, 5,436,149, and 5,569,825. In the course of human therapy, chimeric antibodies constructed by integrating mouse antibody variable region genes and human antibody constant region genes are produced in the human body with much lower immunogenicity than mouse antibodies (Kipriyanov et al., Mol Biotechnol. 26:39-60 (2004); Houdebine, Curr Opin Biotechnol. 13:625-9 (2002)). The disclosures of the above documents are incorporated by reference. Furthermore, site-directed mutagenesis of antibody variable regions can improve antibody affinity and specificity (Brannigan et al., Nat Rev Mol Cell Biol. 3:964-70 (2002); Adams et al., J. Immunol. Unol Methods. 231:249-60 (1999)). Cytotoxic effects can be enhanced by partially replacing the constant region of an antibody to effectively enhance its affinity for immune effector cells.
[0153] Immunospecific antibodies against malignant cell antigens can be obtained commercially or by several conventional techniques, such as chemical synthesis or recombinant expression techniques. Similarly, nucleotide sequences encoding immunospecific antibodies against malignant cell antigens can be obtained commercially from the GenBank database or other similar databases, from the literature, or by routine cloning and sequencing.
[0154] In addition to antibodies, polypeptides or proteins can also act as binding molecules, interacting with corresponding receptors or epitopes on the surface of target cells by binding, blocking, attacking, or other means. As long as these peptides or proteins can specifically bind to the epitope or its corresponding receptor, they do not need to belong to the immunoglobulin family. These polypeptides can also be isolated using techniques similar to phage display antibodies (Szardenings, J Recept Signal Transduct Res. 2003;23(4):307-49). Peptide fragments obtained from random peptide libraries have applications similar to antibodies and antibody fragments. Polypeptide or protein molecules maintain their antigen-binding specificity by connecting to several macromolecules or vehicles via binding molecules. These macromolecules include, but are not limited to, albumin, polymers, liposomes, nanoparticles, or dendrimers.
[0155] Antibodies that can be used to conjugate drugs using the conjugates of the present invention to treat cancer, autoimmune diseases, and infectious diseases include, but are not limited to, the following: 3F8 (anti-GD2 antibody), abagovomab (anti-CA-125 antibody), abciximab (anti-CD41 antibody (integrin α-IIb)), adalimumab (anti-TNF-α antibody), adalimumab (anti-EpCAM antibody, CD326), afelimomab (anti-TNF-α); afutuzumab (anti-CD20 antibody), alacizumab pegol (Alacizumab pegol) (anti-VEGFR2 antibody), ALD518 (anti-IL-6 antibody), alemtuzumab (also known as campath, mabcampath, anti-CD52 antibody), altumomab (anti-CEA antibody), anatumomab (anti-tag-72 antibody), anrukinzumab (IMA-638, anti-IL-13 antibody), apolizumab (anti-HLA-DR antibody), arcitumomab (anti-CEA antibody), acelizumab (anti-L-selectin (CD62L) antibody), atlizumab (also known as Tocilizumab, Actemra, RoActemra, anti-IL-6 receptor antibody), Atorolimumab (anti-rhesus factor antibody), Bapineuzumab (anti-β-amyloid antibody), Basiliximab (Simulect, anti-CD25 (IL-2 receptor α chain) antibody), Bavituximab (anti-phosphatidylserine antibody), Bectumomab (also known as LymphoScan, anti-CD22 antibody), Belimumab (also known as BENLYSTA, LymphoStat-B, anti-BAFF antibody), Benralizumab (anti-CD125 antibody), bertilimumab (anti-CCL11 (eotaxin-1) antibody), besilesomab (also known as Scintimun, anti-CEA-related antigen antibody), bevacizumab (also known as Avastin, anti-VEGF antibody), biciromab (also known as FibriScint, anti-fibrin II beta chain antibody), bivatuzumab (anti-CD44v6 antibody), blinatumomab (also known as BiTE, anti-CD19 antibody), brentuximab (cAC10, anti-CD30 TNFRSF8 antibody), Briakinumab (anti-IL-12, IL-23 antibody), Canakinumab (also known as Ilaris, anti-IL-1 antibody), Cantuzumab (also known as C242, anti-CanAg antibody), Capromab, Catumaxomab (also known as removeb, anti-EpCAM, anti-CD3 antibody), CC49 (anti-TAG-72 antibody), Cedelizumab (anti-CD4 antibody), Certolizumab pegol (also known as CIMZIA, anti-TNF-α antibody), Cetuximab (also known as Erbitux, IM C-C225, anti-EGFR antibody), sitatuzumab (anti-EpCAM antibody), cixutumumab (anti-IGF-1 antibody), clenoliximab (anti-CD4 antibody), clivatuzumab (anti-MUC1 antibody), conatumumab (anti-TRAIL-R2 antibody), CR6261 (anti-influenza A hemagglutinin antibody), dacetuzumab (anti-CD40 antibody), daclizumab (also known as Zenapax, anti-CD25C (IL-2 receptor alpha chain) antibody), Dara Daratumumab (anti-CD38 (cyclic ADP-ribose hydrolase) antibody), denosumab (also known as Prolia, anti-RANKL antibody), detumomab (anti-B-lymphoma cell antibody), dorlimomab, dorxizumab, ecromeximab (anti-GD3 ganglioside antibody), eculizumab (also known as Soliris, anti-C5 antibody), edovacomab (anti-endotoxin antibody), edrecolomab (also known as Panorex, MAb17-A1, anti-EpCAM antibody), F Alizumab (also known as Raptiva, anti-LFA-1 (CD11a) antibody), Efungumab (also known as Mycograb, anti-Hsp90 antibody), Elotuzumab (anti-SLAMF7 antibody), Elsilimomab (anti-IL-6 antibody), Enlimomab pegol (anti-ICAM-1 (CD54) antibody), Epitumomab (anti-episialin antibody), Epratuzumab (anti-CD22 antibody), Erlizumab (anti-ITGB2 (CD18) antibody),Ertumaxomab (also known as Rexomun, anti-HER2 / neu, CD3 antibody), etaracizumab (also known as Abegrin, anti-integrin αvβ3), exibirmab (anti-hepatitis B surface antigen antibody (HBs antibody)), fanolesomab (also known as NeutroSpec, anti-CD15 antibody), faralimomab (anti-interferon receptor antibody), farletuzumab (anti-folate receptor 1 antibody), felvizumab (antibody against respiratory syncytial virus), fezakinumab kinumab (anti-IL-22 antibody), Figitumumab (anti-IGF-1 receptor antibody), Fontolizumab (anti-IFN-γ antibody), Foravirumab (anti-rabies virus glycoprotein antibody), Fresolimumab (anti-TGF-β antibody), Galiximab (anti-CD80 antibody), Gantenerumab (anti-β-amyloid antibody), Gavilimomab (anti-CD147 (basigin) antibody), Gemtuzumab (anti-CD33 antibody), G, Girentuximab (anti-carbonic anhydrase 9 antibody), Glembatumumab (also known as CR011, anti-GPNMB antibody), Golimumab (also known as Simponi, anti-TNF-α antibody), Gomiliximab (anti-CD23C (IgE receptor) antibody), Ibalizumab (anti-CD4 antibody), Ibritumomab (anti-CD20 antibody), Igovomab (also known as Indimacis-125, anti-CA-125 antibody), Imciromab (also known as Myoscint, an anti-cardiac myosin antibody), infliximab (also known as Remicade, an anti-TNF-α antibody), intetumumab (anti-CD51 antibody), inolimomab (anti-CD25 (IL-2 receptor α chain) antibody), inotuzumab (anti-CD22 antibody), ipilimumab (anti-CD152 antibody), iratumumab (anti-CD30 (TNFRSF8) antibody), keliximab (anti-CD4 antibody) ), Labetuzumab (also known as CEA-Cide, anti-CEA antibody), Lebrikizumab (anti-IL-13 antibody), Lemalesomab (anti-NCA-90 (granulocyte antigen) antibody), Lerdelimumab (anti-TGFβ-2 antibody), Lexatumumab (anti-TRAIL-R2 antibody), Ribivirumab (anti-hepatitis B surface antigen antibody), Lintuzumab (anti-CD33 antibody), Lucatumumab (anti-CD40 antibody), Lumiliximab (anti-CD23 (IgE receptor) antibody), Mapatumumab (anti-TRAIL-R1 antibody), Maslimomab (anti-T cell receptor antibody), Matuzumab (anti-EGFR antibody), Mepolizumab (also known as Bosatria, anti-IL-5 antibody), Metelimumab (anti-TGFβ-1 antibody), Milatuzumab (anti-CD74 antibody), Minretumomab (anti-TAG-72 antibody),Mitumomab (also known as BEC-2, anti-ganglioside antibody-GD3), Morolimumab (anti-rhesus factor antibody), Motavizumab (also known as Numax, anti-RS virus antibody), Muromonab-CD3 (also known as Orthoclone OKT3, anti-CD3 antibody), nacolomab (anti-C242 antibody), naptumomab (anti-5T4 antibody), natalizumab (also known as Tysabri, anti-integrin α4 antibody), nebacumab (anti-endotoxin antibody), necitumumab (anti-EGFR antibody), nerelimomab (anti-TNF-α antibody), nimotuzumab (also known as Theracim, Theraloc , anti-EGFR antibody), nofetumomab, ocrelizumab (anti-CD20 antibody), odulimomab (also known as afolimomab, anti-LFA-1 (CD11a) antibody), ofatumumab (also known as Arzerra, anti-CD20 antibody), olaratumab (anti-PDGF-Rα antibody), omalizumab (also known as Xolair, anti-IgEFc region antibody), oportuzumab (anti-EpCAM antibody) , Oregovomab (also known as OvaRex, anti-CA-125 antibody), Otelixizumab (anti-CD3 antibody), Pagibaximab (anti-LTA antibody), Palivizumab (also known as Synagis, Abbosynagis, anti-RS virus antibody), Panimumab (also known as Vectibix, ABX-EGF, anti-EGFR antibody), Panobacumab (anti-Pseudomonas aeruginosa antibody), Pascolizumab Pascolizumab (anti-IL-4 antibody), Pemtumomab (also known as Theragyn, anti-MUC1 antibody), Pertuzumab (also known as Omnitarg, 2C4, anti-HER2 / neu antibody), Pexelizumab (anti-C5 antibody), Pintumomab (anti-adenocarcinoma antigen antibody), Priliximab (anti-CD4 antibody), Pritumumab (anti-vimentin antibody),PRO140 (anti-CCR5 antibody), , racotumomab (also known as 1E10, anti-(N-glycolylneuraminic acid (NeuGc, NGNA)-ganglioside (GM3) antibody), rafivirumab (anti-rabies virus glycoprotein antibody), ramucirumab (anti-VEGFR2 antibody), ranibizumab (also known as Lucentis, anti-VEGF-A antibody), raxibacumab (anti-anthrax toxin, protective antigen antibody), regavirumab (anti-CMV glycoprotein B antibody), reslizumab (anti-IL-5 antibody), rilotumumab (anti-HGF antibody), rituximab (also known as MabThera, Rituxanmab, anti-CD20 antibody), Robatumumab (anti-IGF-1 receptor antibody), Rontalizumab (anti-IFN-α antibody), Rovelizumab (also known as LeukArrest, anti-CD11, CD18 antibody), Ruplizumab (also known as Antova, anti-CD154 (CD40L) antibody), Satumomab (anti-TAG-72 antibody), Sevirumab (anti-CMV antibody), Sibrotuzumab (anti-FAP antibody), Sifalimumab (anti-IFN-α antibody), Siltuximab (anti-IL-6 antibody), Siplizumab (anti-CD2 antibody), (Smart) MI95 (anti-CD33 antibody), Solanezumab ( Anti-β-amyloid antibody), Sonepcizumab (anti-sphingosine-1-phosphate antibody), Sontuzumab (anti-episialin antibody), Stamulumab (anti-myostatin antibody), Sulesomab (also known as LeukoScan, (anti-NCA-90 (granulocyte antigen) antibody)), Tacatuzumab (anti-α-fetoprotein antibody) Antibody to protein), tadocizumab (anti-integrin αIIbβ3 antibody), talizumab (anti-IgE antibody), tanezumab (anti-NGF antibody), taplitumomab (anti-CD19 antibody), tefibazumab (also known as Aurexis, anti-clumping factor A antibody), telimomab, tenatumomab natumomab (anti-tenascin C antibody), teneliximab (anti-CD40 antibody), teplizumab (anti-CD3 antibody), TGN1412 (anti-CD28 antibody) ), Ticilimumab (also known as Tremelimumab, anti-CTLA-4 antibody), Tigatuzumab (anti-TRAIL-R2 antibody), TNX-650 (anti-IL-13 antibody), Tocilizumab (Also known as Atlizumab, Actemra, RoActemra, (anti-IL-6 receptor antibody), Toralizumab (anti-CD154 (CD40L) antibody), Tositumomab (anti-CD20 antibody), Trastuzumab (also known as Herceptin, anti-HER2 / neu antibody), Tremelimumab (anti-CTLA-4 antibody), TucotuzumabCelmoleukin (anti-EpCAM antibody), Tuvirumab (anti-hepatitis B antibody), Urtoxazumab (anti-Escherichia coli antibody), Ustekinumab (also known as Stelara, anti-IL-12, IL-23 antibody), Vapaliximab (anti-AOC3 (VAP-1) antibody), Vedolizumab (anti-integrin α4β7 antibody), Veltuzumab (anti-CD20 antibody), Bepalimomab Vepalimomab (anti-AOC3 (VAP-1) antibody), Visilizumab (also known as Nuvion, anti-CD3 antibody), Vitaxin (anti-angiogenic integrin avb3 antibody), Volociximab (anti-integrin α5β1), Votumumab (also known as HumaSPECT, anti-tumor antigen CTAA16.88 antibody), Zalutumumab (also known as HuMax-EGFr, (anti-EGFR antibody), Zanolimumab (also known as HuMax-CD4, anti-CD4 antibody), Ziralimumab (anti-CD147 (basic immunoglobulin) antibody), zolimomab (anti-CD5 antibody), etanercept (registered trademark "Enbrel"), alefacept (registered trademark "Amevive"), abatacept (registered trademark "Orencia"), rilonacept (Arcalyst), 14F7 [anti-IRP-2 (iron regulatory protein 2) antibody], 14G2a (anti-ganglioside GD2 antibody for melanoma and solid tumors from Nat. Cancer Inst.), J591 (anti-PSMA antibody for treating prostate cancer from Weill Cornell Medical School), 225.28S [anti-HMW-MAA (high molecular weight melanoma-associated antigen) antibody for melanoma, Sorin Radiofarmaci SRL (Milan, Italy)], COL-1 (Nat. Cancer Inst., Milan, Italy). Anti-CEACAM3 antibody, CGM1, for colon and gastric cancer from Inst., CYT-356 (registered trademark "Oncoltad"), for prostate cancer, HNK20 (for respiratory syncytial virus from Ora Vax Inc.), ImmuRAIT (for non-Hodgkin's lymphoma from IMMUNOMEDICS), Lym-1 (anti-HLA-DR10 antibody, for oncology from Peregrine Pharm), MAK-195F [anti-TNF (tumor necrosis factor; TNFA, TNF-α; TNFSF2) antibody for sepsis and toxic shock from Abbott / Knoll], MEDI-500 [also known as T10B9, an anti-CD3 antibody, TRαβ (T-cell receptor α / β), for graft-versus-host disease from MediImmune Inc.], RING SCAN [Neoprobe Corp. for breast cancer, colon cancer, and colorectal cancer)], Avicidin (anti-EPCAM (epithelial cell adhesion molecule) antibody), anti-TACSTD1 (tumor-associated calcium signal transducer 1) antibody, anti-GA733-2 (gastrointestinal tumor-associated protein 2) antibody, anti-EGP-2 (epithelial glycoprotein 2) antibody; anti-KSA antibody; KS1 / 4 antigen; M4S; tumor antigen 17-1A; CD326 for colon cancer, ovarian cancer, prostate cancer, and non-Hodgkin's lymphoma from NeoRx Corp.; LYMPHOCIDE (IMMUNOMEDICS, NJ), Smart ID10 (Protein Design Labs), Oncolym (Techniclone Inc, CA), Allomune (BioTransplant, CA), anti-VEGF antibody (Genentech, CA); CEAcide (Immunomedics, NJ), IMC-1C11 (ImClone Systems, NJ), and cetuximab (ImClone, NJ).
[0156] Other antibodies that function as binding ligands include, but are not limited to, antibodies against the following antigens: aminopeptidase N (CD13), annexin A1, B7-H3 (CD276, various cancers), CA125 (ovarian), CA15-3 (carcinoma), CA19-9 (carcinoma), L6 (carcinoma), Lewis Y (carcinoma), Lewis X (carcinoma), alpha-fetoprotein (carcinoma), CA242 (colorectal), placental alkaline phosphatase. (carcinoma), prostate-specific antigen (prostate), prostatic acid phosphatase (prostate), epidermal growth factor (carcinoma), CD2 (Hodgkin's disease, NHL lymphoma, multiple myeloma), CD3ε (T-cell lymphoma, lung cancer, breast cancer, gastric cancer, ovarian cancer, autoimmune diseases, malignant ascites), CD19 (B-cell malignancies), CD20 (non-Hodgkin's lymphoma), CD22 (leukemia, lymphoma, multiple myeloma, systemic lupus erythematosus), CD30 (Hodgkin's lymphoma) , CD33 (leukemia, autoimmune diseases), CD38 (multiple myeloma), CD40 (lymphoma, multiple myeloma, leukemia (CLL)), CD51 (metastatic melanoma, sarcoma), CD52 (leukemia), CD56 (small cell lung cancer, ovarian cancer, Merkel cell carcinoma and liquid tumors, multiple myeloma), CD66e (cancer), CD70 (metastatic renal cell carcinoma and non-Hodgkin's lymphoma), CD74 (multiple myeloma), CD80 (lymphoma), CD98 (cancer), mucin (carcinoma), CD221 (solid tumors), CD227 (breast cancer, ovarian cancer), CD262 (non-small cell lung cancer and other cancers), CD309 (ovarian cancer), CD326 (solid tumors), CEACAM3 (colorectal cancer, gastric cancer), CEACAM5 (carcinoembryonic antigen; CEA, CD66e) (breast cancer, colorectal cancer and lung cancer), DLL4 (Δ-like-4), EGFR (epidermal growth factor receptor, various cancers), CTLA4 (melanoma), CXCR4 (CD184, Heme tumors, solid tumors), endoglin (CD105, solid tumors), EPCAM (epithelial cell adhesion molecule, bladder, head, neck, colon cancer, NHL prostate cancer, and ovarian cancer), ERBB2 (epidermal growth factor receptor 2; lung cancer, breast cancer, prostate cancer), FCGR1 (autoimmune disease), FOLR (folate receptor, ovarian cancer), GD2 ganglioside (cancer), G-28G (cell surface antigen glycolipid, melanoma), GD3 idiotype (cancer), heat shock protein (cancer), HER1 (lung cancer, gastric cancer), HER2 (breast cancer, lung cancer, and ovarian cancer), HLA-DR10 (NHL), HLA-DRB (N HL, B-cell leukemia), human chorionic gonadotropin (carcinoma), IGF1R (insulin-like growth factor-1 receptor, solid tumors, blood cancers), IL-2 receptor (interleukin-2 receptor, T-cell leukemia and lymphoma), IL-6R (interleukin-6 receptor, multiple myeloma, RA, Castleman's disease, IL6-dependent tumors), integrins (αVβ3, α5β1, α6β4, αIIβ3, α5β5, αVβ5 for various cancers), MAGE-1 (carcinoma), MAGE-2 (carcinoma), MAGE-3 (carcinoma), MAGE-4 (carcinoma), anti-transferrin receptor (carcinoma), p97 (melanoma), MS4A1 (transmembrane 4-domain family A member 1, non-Hodgkin's B-cell lymphoma, leukemia), MUC1 or MUC1-KLH (breast, ovarian, cervical, bronchial and gastrointestinal cancer), MUC16 (CA125) (ovarian cancer), CEA (colon), gp100 (melanoma), MART1 (melanoma), MPG (melanoma), MS4A1 (transmembrane 4-domain family A member 1, small cell lung cancer, NHL), nucleolin, neural oncogene product (carcinoma), P21 (carcinoma), anti-(N-glycolylneuraminic acid paratope (breast cancer, melanoma) tumor cancer), PLAP-like testicular alkaline phosphatase (ovarian cancer, testicular cancer), PSMA (prostate cancer), PSA (prostate), ROBO4, TAG72 (tumor-associated glycoprotein 72, leukemia (AML), gastric cancer, colorectal cancer, ovarian cancer), T cell transmembrane protein (cancer), Tie (CD202b), TNFRSF10B (tumor necrosis factor receptor superfamily member 10B, cancer), TNFRSF13B (tumor necrosis factor receptor superfamily member 13B, multiple myeloma, NHL, other cancers, RA and SLE), TPBG (trophoblast glycoprotein, renal cell carcinoma),Other tumor-associated antigens recognized by antibodies have been reported (Gerber, et al., mAbs 1:3, 247-253 (2009); Novellino et al., Cancer Immunol Immunother. 54 (3), 187-207 (2005); Franke et al., Cancer Biother Radiopharm. 2000, 15, 459-76). (See Gerber, et al, mAbs 1:3, 247-253 (2009); Novellino et al, Cancer Immunol Immunother. 54(3), 187-207 (2005). Franke, et al, Cancer Biother Radiopharm. 2000, 15,459-76). ,
[0157] The cell binding agent, more preferably an antibody, can be any agent capable of binding to tumor cells, virus-infected cells, microbial-infected cells, parasite-infected cells, autoimmune cells, activated cells, myeloid cells, activated T cells, B cells, or melanocytes. More specifically, the cell binding agent can be any agent / molecule capable of binding to any one of the following antigens or receptors: CD1, CD1a, CD1b, CD1c, CD1d, CD1e, CD2, CD3, CD3d, CD3e, CD3g, CD4, CD5, CD6, CD7, CD8, CD8a, CD8b, CD9, CD10, CD11a, CD11b, CD11c, CD12w, CD14. , CD15, CD16, CD16a, CD16b, CDw17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD3 0, CD31, CD32, CD32a, CD32b, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42, CD42a, CD42b, CD42c, CD42d、CD43、CD44、CD45、CD46、CD47、CD48、CD49b、CD49c、CD49c、CD49d、CD49f、CD50、CD51、CD52、CD53、CD54、CD55、CD56、CD57、CD58、CD59、CD60、CD60a、CD60b、CD60c、CD61、CD62E、CD62L、CD62P、CD63、CD64、CD65、CD65s、CD66、CD66a、CD66b、CD66c、CD66d、CD66e、CD66f、CD67、CD68、CD69、CD70、CD71、CD72、CD73、CD74、CD74、CD75、CD75s、CD76、CD77、CD78、CD79、CD79a、CD79b、CD80、CD81、CD82、CD83、CD84、CD85、CD85a、CD85b、CD85c、CD85d、CD85e、CD85f、CD85g、CD85g、CD85i、CD85j、CD85k、CD85m、CD86、CD87、CD88、CD89、CD90、CD91、CD92、CD93、CD94、CD95、CD96、CD97、CD98、CD99、CD100、CD101、CD102、CD103、CD104、CD105、CD106、CD107、CD107a、CD107b、CD108、CD109、CD110、CD111、CD112、CD113、CD114、CD115、CD116、CD117、CD118、CD119、CD120a、CD120b、CD121、CD121a、CD121b、CD122、CD123、CD123a、CD124、CD125、CD126、CD127、CD128、CD129、CD130、CD131、CD132、CD133、CD134、CD135、CD136、CD137、CD138、CD139、CD140、CD140a、CD140b、CD141、CD142、CD143、CD144、CD145、CDw145、CD146、CD147、CD148、CD149、CD150、CD151、CD152、CD153、CD154、CD155、CD156a、CD156b、CD156c、CD156d、CD157、CD158、CD158a、CD158b1、CD158b2、CD158c、CD158d、CD158e1、CD158e2、CD158f2、CD158g、CD158h、CD158i、CD158j、CD158k、CD159、CD159a、CD159b、CD159c、CD160、CD161、CD162、CD163、CD164、CD165、CD166、CD167、CD167a、CD167b、CD168、CD169、CD170、CD171、CD172、CD172a、CD172b、CD172g、CD173、CD174、CD175、CD175s、CD176、CD177、CD178、CD179、CD179a、CD179b、CD180、CD181、CD182、CD183、CD184、CD185、CD186、CDw186、CD187、CD188、CD189、CD190、CD191、CD192、CD193、CD194、CD195、CD196、CD197、CD198、CDw198、CDw199、CD200、CD201、CD202(a,b)、CD203、CD203c、CD204、CD205、CD206、CD207、CD208、CD209、CD210、CDw210a、CDw210b、CD211、CD212、CD213、CD213a1、CD213a2、CD214、CD215、CD216、CD217、CD218、CDw218a、CD218、CD21b9、CD220、CD221、CD222、CD223、CD224、CD225、CD226、CD227、CD228、CD229、CD230、CD231、CD232、CD233、CD234、CD235a、CD235b、CD236、CD236R、CD238、CD239、CD240、CD240ce、CD240d、CD241、CD242、CD243、CD244、CD245、CD246、CD247、CD248、CD249、CD250、CD251、CD252、CD253、CD254、CD255、CD256、CD257、CD258、CD259、CD260、CD261、CD262、CD263、CD264、CD265、CD266、CD267、CD268、CD269、CD270、CD271、CD272、CD273、CD274、CD275、CD276、CD277、CD278、CD279、CD281、CD282、CD283、CD284、CD285、CD286、CD287、CD288、CD289、CD290、CD291、CD292、CD293、C、 D294, CD295, CD296, CD297, CD298, CD299, CD300, CD300a, CD300b, CD300c, CD301, CD302, CD303, CD304, CD305, CD306, CD307, CD307a, CD307b, CD307 c, CD307d, CD307e, CD307f, CD308, CD309, CD310, CD311, CD312, CD313, CD314, CD315, CD316, CD317, CD318, CD319, CD320, CD321, CD322, CD323, CD324 , CD325, CD326, CD327, CD328, CD329, CD330, CD331, CD332, CD333, CD334, CD335, CD336, CD337, CD338, CD339, CD340, CD341, CD342, CD343, CD344, CD3 45, CD346, CD347, CD348, CD349, CD350, CD351, CD352, CD353, CD354, CD355, CD356, CD357, CD358, CD359, CD360, CD361, CD362, CD363, CD364, CD365, C D366, CD367, CD368, CD369, CD370, CD371, CD372, CD373, CD374, CD375, CD376, CD377, CD378, CD379, CD381, CD382, CD383, CD384, CD385, CD386, CD387, CD388, CD389, CRIPTO, CRIPTO, CR, CR1, CRGF, CRIPTO, CXCR5, LY64, TDGF1, 4-1BB, APO2, ASLG659, BMPR1B, 4-1BB, 5AC, 5T4 (trophoblast glycoprotein), TPBG, 5T4, Wnt activation inhibitor 1 or WAIF1), adenocarcinoma antigen, AGS-5, AGS-22M6, activin receptor-like kinase 1, AFP, AKAP-4, ALK, α integrin, αvβ6, aminopeptidase N, amyloid beta, androgen receptor, angiopoietin 2, angiopoietin 3, annexin A1, anthrax toxin protective antigen, anti-transferrin receptor, AOC3 (VAP-1), B7-H3, anthrax, BAFF (B-cell activating factor), BCMA, B-lymphoma cells, bcr-abl, bombesin, BORIS, C5, C242 antigen,CA125 (carbohydrate antigen 125, MUC16), CA-IX (or CAIX, carbonic anhydrase 9), CALLA, CanAg, canine IL31, carbonic anhydrase IX, cardiac myosin, CCL11 (CC motif chemokine 11), CCR4 (CC chemokine receptor type 4, CD194), CCR5, CD3E (epsilon), CEA (carcinoembryonic antigen), CEACAM3, CEACAM5 (carcinoembryonic antigen), CFD (factor D), Ch4D5, cholecystokinin 2 (CCK2R), CLDN18 (claudin- 18), CLDN18.1 (claudin-18.1), CLDN18.2 (claudin-18.2), clumping factor A, cMet, CRIPTO, FCSF1R (colony-stimulating factor 1 receptor, CD115), CSF2 (colony-stimulating factor 2, granulocyte-macrophage colony-stimulating factor (GM-CSF)), CSP4, CTLA4 (cytotoxic T-lymphocyte-associated protein 4), CTAA16.88 tumor antigen, CXCR4, CXC chemokine receptor type 4, cADP-ribose hydrolase, Cyclin B1, CYP1B1, cytomegalovirus, cytomegalovirus glycoprotein B, dabigatran, DLL3 (delta-like ligand 3), DLL4 (delta-like ligand 4), DPP4 (dipeptidyl peptidase 4), DR5 (death receptor 5), Escherichia coli Shiga toxin type 1, Escherichia coli Shiga toxin type 2, ED-B, EGFL7 (EGF-like domain containing protein 7), EGFR, EGFRII, EGFRvIII, endoglin, endothelin B receptor, endotoxin, EpCAM (epithelial cell adhesion molecule), EphA2, episialin, ERBB2 (epidermal growth factor receptor 2), ERBB3, ERG (T MPRSS2ETS fusion gene), E. coli, ETV6-AML, FAP (fibroblast activation protein α), fibroblast surface antigen, FCGR1, α-fetoprotein, fibrin II, β chain, fibronectin ectodomain B, FOLR (folate receptor), folate receptor α, folate hydrolase, respiratory syncytial virus Fos-related antigen 1F protein, Frizzled receptor, fucosyl GM1, GD2 ganglioside, G-28 (cell surface glycolipid antigen), GD3 idiotype, GloboH, glypican 3, N-glycolylneuraminic acid, GM3, GMCSF receptor α chain, growth differentiation factor, GP100,GPNMB (transmembrane protein NMB), GUCY, 2C (guanylate cyclase 2C, guanylate cyclase C (GC-C), intestinal guanylate cyclase, guanylate cyclase-C receptor, heat-stable enterotoxin receptor (hSTAR)), heat shock protein, hemagglutinin, hepatitis B surface antigen, hepatitis B virus, HER1 (human epidermal growth factor receptor 1), HER2, HER2 / neu, HER3 (ERBB-3), IgG4, HGF / SF (stem cell growth factor / scatter factor), HHGFR, HIV-1, histone complex, HLA-DR (human leukocyte antigen), HLA-DR10, HLA-DRB, HMWMAA, human chorionic gonadotropin, HNGF, human cell scatter factor receptor kinase, HPV E6 / E7, Hsp90, hTERT, ICAM-1 (intercellular adhesion molecule 1), idiotype, IGF1R (IGF-1, insulin-like growth factor 1 receptor), IGF-1 receptor, IFN-γ, influenza hemagglutinin, IgE, IgE Fc region, IGF-1 receptor, interleukins (including IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-6R, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-17A, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-27, or IL-28), IL-31RA, ILGF2 (insulin-like growth factor 2), integrins (α4, α IIIb β3, αvβ3, α4β7 , α5β1, α6β4, α7β7, αIIβ3, α5β5, αvβ5), interferon-γ-inducible protein, ITAGA2, ITGB2, KIR2D, Kappa Ig, LCK, Le, legumain, Lewis-Y antigen, LFA-1 (lymphocyte function-associated antigen 1, CD11a), LHRH, LINGO-1, lipoteichoic acid, LIV1A, LMP2, LTA, MAD-CT-1, MAD-CT-2, MAGE-1, MAGE-2, MAGE-3, MAGEA1, MAGEA3, MAGE4, MART1, MCP-1, MIF (macrophage migration inhibitory factor or glycosylation inhibitory factor (GIF)), MS4A1 (transmembrane 4 domain subfamily A member 1), MSLN (mesothelin), MUC1 (mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM), MUC1-KLH, MUC16 (CA125), MCP1 (monocyte chemoattractant protein 1), MelanA / MART1, ML-IAP, MPG, MS4A1 (transmembrane 4 domain subfamily A), MYCN, myelin-associated glycoprotein, myostatin, NA17, NARP-1, NCA-90 (granulocyte antigen), Nectin-4 (ASG-22ME), NGF, neuronal apoptosis-regulating proteinase 1, NOGO-A, Notch receptor, nucleolin, Neu oncogene product, NY-BR-1, NY-ESO-1, OX-40, OxLDL (oxidized low-density lipoprotein), OY-TES1, P21, non-mutant p53, P9 7, Page 4, PAP, anti-(N-glycolylneuraminic acid) paratope, PAX3, PAX5, PCSK9, PDCD1 (PD-1, programmed cell death protein 1), PDGF-Rα (platelet-derived growth factor receptor α), PDGFR-β, PDL-1, PLAC1, PLAP-like testicular alkaline phosphatase, platelet-derived growth factor receptor β, sodium phosphate cotransporter, PMEL17, polysialic acid, proteinase 3 (PR1), prostate cancer, PS (phosphatidylserine), prostate cancer cells, Pseudomonas aeruginosa, PSMA, PSA, PSCA, rabies virus glycoprotein, RHD (Rh polypeptide 1 (RhPI)), rhesus factor, RANKL, PhoC,Ras mutant, RGS5, ROBO4, respiratory syncytial virus, RON, ROR1, sarcoma metastatic breakpoint, SART3, sclerostin, SLAMF7 (SLAM family member 7), selectin P, SDC1 (syndecan 1), sLe(a), somatomedin C, SIP (sphingosine-1-phosphate), somatostatin, sperm protein 17, SSX2, STEAP1 (six-transmembrane epithelial antigen of prostate 1), STEAP2, STn, TAG-72 (tumor-associated glycoprotein 72), survivin, T cell receptor, T cell transmembrane protein, TEM1 (tumor epithelial marker 1), TENB2, tenascin-C (TN-C), TGF-α, TGF-β (transforming growth factor β), TGF-β1, TGF-β2 (transforming growth factor beta 2), Tie (CD202b), Tie2, TIM-1 (CDX-014), TN, TNF, TNF-α, TNFRSF8, TNFRSF10B (tumor necrosis factor receptor superfamily member 10B), TNFRSF13B (tumor necrosis factor receptor superfamily member 13B), TPBG (trophoblast glycoprotein), TRAIL-R1 (tumor necrosis-inducing ligand receptor 1), TRAILR2 (cell death receptor Cells expressing receptor 5 (DR5), tumor-associated calcium signal transducer 2, tumor-specific glycosylation of MUC1, TWEAK receptor, TYRP1 (glycoprotein 75), TRP-1 (Trop1), TRP-2 (Trop2), tyrosinase, VCAM-1, VEGF, VEGF-A, VEGF-2, VEGFR-1, VEGFR2, or vimentin, WT1, XAGE1, or any insulin growth factor receptor, or any epidermal growth factor receptor.
[0158] In another specific embodiment, the cell-binding molecule can be a ligand or receptor agonist selected from the following: Folic acid derivatives (binding to folate receptors, proteins overexpressed in ovarian cancer and other malignancies) (Low, PS et al 2008, Acc. Chem. Res. 41, 120-129); glutamic acid urea derivatives (binding to prostate-specific membrane antigen, a surface marker of prostate cancer cells) (Hillier, SM et al, 2009, Cancer Res. 69, 6932-6940); somatostatin (also known as growth hormone-inhibiting hormone (GHIH), somatotropin-releasing inhibitory factor (SRIF), or somatotropin-releasing inhibitory hormone) and its derivatives, such as octreotide (sandostatin) and lanreotide (somatulin) (particularly in neuroendocrine tumors, GH-producing pituitary adenomas, paraganglionic tumors, dysfunctional pituitary adenomas, and pheochromocytomas) (Ginj, M., et al, 2006, Proc. Natl. Acad. Sci. USA 103, 16436-16441); In general, Tomatostatin and its receptor subtypes (sst1, sst2, sst3, sst4, and sst5) are involved in many types of tumors, including neuroendocrine tumors, especially GH-secreting pituitary adenomas (Reubi JC, Landolt, AM 1984 J. Clin. Endocrinol Metab 59: 1148-51; Reubi JC, Landolt AM 1987 J. Clin. Endocrinol Metab 65: 65-73; Moyse E, et al., J. Clin. Endocrinol Metab 61: 98-103) and gastroenteropancreatic tumors (Reubi JC, et al, 1987 J Clin Endocrinol Metab 65: 1127-34; Reubi, J. C, et al, 1990 Cancer Res 50: 5969-77) , pheochromocytoma (Epel-baum J, et al 1995 J Clin Endocrinol Metab 80:1837-44; Reubi JC, et al, 1992 J Clin Endocrinol Metab 74: 1082-9), neuroblastoma (Prevost G, 1996 Neuroendocrinology 63:188-197; Moertel, C. L, et al 1994 Am J Clin Path 102:752-756), medullary thyroid carcinoma (Reubi, J. C, et al 1991 Lab Invest 64:567-573), Small cell lung cancer (Sagman U, et al, 1990 Cancer 66:2129-2133), meningioma, medulloblastoma, neuro Non-neuroendocrine tumors, including brain tumors such as gliomas (Reubi JC, et al 1986 J Clin Endocrinol Metab 63: 433-8; Reubi JC, et al 1987 Cancer Res 47: 5758-64; Fruhwald, M. C, et al 1999 Pediatr Res 45: 697-708), breast cancer (Reubi JC, et al 1990 Int J Cancer 46: 416-20; Srkalovic G, et al 1990 J Clin Endocrinol Metab 70: 661-669), lymphoma (Reubi JC, et al 1992, Int J Cancer50: 895-900), renal cell carcinoma (Reubi JC, et al 1992, Cancer Res 52: 6074-6078), mesenchymal tumors (Reubi JC, et al 1996 Cancer Res 56: 1922-31), prostate (Reubi JC, et al 1995, J. Clin. Endocrinol Metab 80: 2806-14; et al 1989, Prostate 14:191-208; Halmos G, et al J. Clin. Endocrinol Metab 85: 2564-71), ovary (Halmos, G, et al, 2000 J Clin Endocrinol Metab 85: 3509-12; Reubi JC, et al 1991 Am J Pathol 138:1267-72), stomach (Reubi JC, et al 1999, Int J Cancer 81: 376-86; Miller, G. V, 1992 Br J Cancer 66: 391-95), hepatocellular (Kouroumalis E, et al 1998 Gut 42: 442-7; Reubi JC, et al 1999 Gut 45: 66-774), and nasopharyngeal cancer (Loh K. S, et al, 2002 Virchows Arch 441: 444-8); specific for carbonic anhydrase IX (a marker of hypoxia and renal cell carcinoma) aromatic sulfonamides (Neri, D., et al, Nat. Rev. Drug Discov. 2011, 10, 767-777); pituitary adenylate cyclase activating peptides for pheochromocytoma and paraganglioma tumors; PACAP (PAC1); lung, stomach, colon, rectum, breast, prostate, pancreatic duct, liver, bladder Vasoactive intestinal peptide (VIP) and its receptor subtypes (VPAC1, VCAP2) for epithelial cancers; alpha-melanocyte-stimulating hormone (alpha-MSH) receptor for various tumors; small cell lung cancer, medullary thyroid carcinoma, astrocytoma, insulinoma, and ovarian cancer. Cholecystokinin (CCK) / gastrin receptors and their receptor subtypes (CCK1 (formerly CCK-A) and CCK2) for renal cell carcinoma, breast cancer, lung cancer, gastric cancer, and prostate cancer; bombesin (Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2) / gastrin-releasing peptide for neuroblastoma (neuroblastoma) GRP receptor subtypes (GRP) and their receptor subtypes (BB1, GRP receptor subtype (BB2), BB3, and BB4) (Ohlsson, B., et al, 1999, Scand. J. Gastroenterology 34 (12): 1224-9; Weber, HC, 2009, Cur. Opin. Endocri. Diab. Obesity 16(1): 66-71; Gonzalez N, et al, 2008, Cur. Opin. Endocri. Diab. Obesity 15(1), 58-64); Neurotensin (NTR1, NTR2, NTR3) for alveolar lung cancer, neuroblastoma, pancreatic cancer, and colon cancer; substance P and its receptor subtypes for glial tumors (NK1 receptor for glial tumors, etc., Hennig IM, et al 1995 Int. J. Cancer 61, 786-792); Neuropeptide Y and its receptor subtypes (Y1-Y6) for breast cancer; dimeric and multimeric cyclic RGD peptides (e.g., cRGDfV) that recognize RGD (Arg-Gly-Asp), NGR (Asn-Gly-Arg), and receptors (integrins) on the tumor surface (Laakkonen P, Vuorinen K. 2010, Integr Biol (Camb). 2(7-8): 326-337; Chen K, Chen X. 2011, Theranostics. 1:189-200; Garanger E, et al., Anti-Cancer Agents Med Chem. 7 (5): 552-558; Kerr, JS et al., Anticancer Research, 19(2A), 959-968; Thumshirn, G, et al., 2003 Chem. Eur. J. 9, 2717-2728). 2725), and TAASGVRSMH and LTLRWVGL Homing peptides include MS (chondroitin sulfate proteoglycan NG2 receptor) and F3 peptide (a 31-amino acid peptide that binds to cell surface-expressed nucleolin receptors) (Zitzmann, S., 2002 Cancer Res., 62, 18, pp. 5139-5143; Temminga, K., 2005, Drug Resistance Updates, 8, 381-402; P. Laakkonen and K. Vuorinen, 2010 Integrative Biol, 2(7-8), 326-337; MA Burg, 1999 Cancer Res., 59(12), 2869-2874; K. Porkka, et al. 2002, Proc. Nat. Acad. Sci. USA 99(11), 7444-9); cell-penetrating peptides (CPPs) (Nakase I, et al., 2012, J. Control Release. 159(2),181-188); Peptides Hormones such as luteinizing hormone-releasing hormone (LHRH) agonists and antagonists, which act by targeting follicle-stimulating hormone (FSH) and luteinizing hormone (LH), as well as testosterone production, and gonadotropin-releasing hormone (GnRH) agonists, such as buserelin (Pyr-His-Trp-Ser-Tyr-D-Ser(OtBu)-Leu-Arg-Pro-NHEt), gonadorelin (Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH), goserelin (Pyr-His-Trp-Ser-Tyr- yr-D-Ser(OtBu)-Leu-Arg-Pro-AzGly-NH2), histrelin (Pyr-His-Trp-Ser-Tyr-D-His(N-benzyl)-Leu-Arg-Pro-NHEt), leuprolide (Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt), nafarelin (Pyr-His-Trp-Ser-Tyr-2Nal-Leu-Arg-Pro-Gly-NH2), triptorelin (Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2), nafarelin Phosphorin, deslorelin, abarelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-(N-Me)Tyr-D-Asn-Leu-isopropylLys-Pro-DAla-NH2), cetrorelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2), degarelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-4-aminoPhe(L-hydroxamic acid) (carbamoyl)-D-4-aminoPhe(carbamoyl)-Leu-isopropylLys-Pro-D-Ala-NH2), and Rix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-Tyr-D-(N9,N10-diethyl) Boccon-Gibod, L.; et al, 2011, Therapeutic Advances in Urology 3 (3): 127-140; Debruyne, F., 2006, Future Oncology, 2(6), 677-696; Schally A. V; Nagy, A. 1999 Eur J Endocrinol 141:1-14; Koppan M, et al 1999 Prostate 38:151-158; and, for example, from small molecules (imiquimod, guanidine and adenosine analogues) to lipopolysaccharide (LPS), nucleic acids (CpG DNA, poly I;C) and lipopeptides (Pam3CSK4) (Kasturi, SP, et al, 2011, Nature 470, 543-547; Lane, T., 2001, J. R. Soc. Med. 94, 316; Hotz, C., and Bourquin, C., 2012, Oncoimmunology 1, 227-228; Dudek, A. Z., et al., 2007, Clin. Cancer Res. 13, 7119-7125), which recognize large and complex biopolymers such as Toll-like receptors (TLRs), C-type lectins, and Nod-like receptors (NLRs) (Fukata, M., et al, 2009, Semin. Immunol. 21, 242-253; Maisonneuve, C., et al, 2014, Proc. Natl. Acad. Sci. USA 111, 1-6; Botos, I., et al, 2011, Structure 19, 447-459; Means, TK, et al, 2000, Life Sci. 68, 241-258) and other pattern recognition receptors (PRRs). RRs), a 32-amino acid neuropeptide that is widely involved in regulating calcium levels through its effects in osteoclasts and the kidney (Zaidi M, et al, 1990 Crit Rev Clin Lab Sci 28, 109-174; Gorn, AH, et al, 1995 J Clin Invest 95:2680-91); integrin receptors and their receptor subtypes (e.g., αVβ1, αVβ3, αVβ5, αVβ6, α6β4, α7β1, αLβ2, αIIbβ3) that are expressed on the surface of various cells, particularly osteoclasts, endothelial cells, and tumor cells, and generally play an important role in angiogenesis (Ruoslahti, E. et al, 1994 Cell 77, 477-8; Albelda, SM et al, 1990 Cancer Res., 50, 6757-64). Short peptides and GRGDSPK, as well as cyclic RGD pentapeptides such as cyclo(RGDfV)(L1) and their derivatives [cyclo(-N(Me)R-GDfV), cyclo(R-Sar-DfV), cyclo-(RG-N(Me)D-fV), cyclo(RGD-N(Me)fV), cyclo(RGDf-N(Me)V-)(Cilengitide)], which showed high binding affinity to integrin receptors (Dechantsreiter, M. A. et al, 1999 J. Med. Chem. 42, 3033-40, Goodman, SL, et al, 2002 J. Med. Chem. 45, 1045-51).
[0159] The cell-binding molecule / ligand or cell receptor agonist can be an Ig-based or non-Ig-based protein scaffold molecule. Ig-based scaffolds include, but are not limited to, nanobodies (VHH (camelid Ig) derivatives) (Muyldermans S., 2013 Annu Rev Biochem. 82, 775-797); domain antibodies (dAbs, VH or VL domain derivatives) (Holt, L. J. et al., 2003, Trends Biotechnol. 21, 484-490); bispecific antibodies (dAbs, VH or VL domain derivatives) (Holt, L. J. et al., 2003, Trends Biotechnol. 21, 484-490); Specificity T cell induction (BiTE, bispecific dimer) (Baeuerle, P. A, et al, 2009, Curr. Opin. Mol. Ther. 11, 22-30); Dual affinity retargeting (DART, bispecific dimer) (Moore PA P, et al. 2011, Blood 117(17), 4542-4551);Tetravalent tandem antibody (Tan Non-Ig scaffolds can be selected from, but are not limited to, anticalins (derivatives of lipocalins) (Skerra A. 2008, FEBS J., 275(11): 2677-2683; Beste G, et al., 1999 Proc. Nat. Acad. USA. 96(5):1898-1903; Skerra, A. 2000 Biochim Biophys Acta, 1482(1-2):337-350; Skerra, A. 2007, Curr Opin Biotechnol. 18(4):295-304; Skerra, A. 2008, FEBS J. 275(11):2677-2683); Adnectins (10FN3 (fibronectin)) (Koide, A, et al., 1998 J. Mol. Biol., 284(4):1141-1151; Batori V, 2002, Protein Eng. 15(12): 1015-1020; Tolcher, A. W, 2011, Clin. Cancer Res. 17(2):363-371; Hackel, B. J, 2010, Protein Eng. Des. Sel. 23(4):211-219; designed ankyrin repeat proteins (DARPins) (derivatives of ankyrin repeat (AR) proteins) (Boersma, Y. L., et al., 2011 Curr Opin Biotechnol. 22(6): 849-857), such as DARPinC9, DARPinEc4, and DARPinE69_LZ3_E01 (Winkler J, et al., 2009 Mol Cancer Ther. 8(9), 2674-2683; Patricia M. K. M., et al., Clin Cancer Res. 2011;17(1):100-110; Boersma Y. L, et al., 2011 J. Biol. Chem. 286(48),41273-41285; Avimer (Domain A / LDL receptor) (Boersma Y. L, 2011 J. Biol. Chem. 286(48): 41273-41285; Silverman J, et al, 2005 Nat. Biotechnol., 23(12):1556-1561) You can choose from:
[0160] Examples of small molecule structures of cell binding molecules / ligands or cell receptor agonists of the present application are as follows: These include: LB01 (folic acid), LB02 (PMSA ligand), LB03 (PMSA ligand), LB04 (PMSA ligand), LB05 (somatostatin), LB06 (somatostatin), LB07 (octreotide, growth factor receptor (GFRP), LB08 (lanreotide, somatostatin analog), LB09 (vapreotide (sambar), somatostatin analog), LB10 (CAIX ligand), LB11 (CAIX ligand), LB12 (gastrin-releasing peptide receptor (GRPr), MBA), LB13 (luteinizing hormone-releasing hormone (LH-RH) ligand and and GnRH), LB14 (luteinizing hormone-releasing hormone (LH-RH) and GnRH ligand), LB15 (GnRH antagonist, abarelix), LB16 (cobalamin, vitamin B12 analog), LB17 (cobalamin, vitamin B12 analog), LB18 (for αvβ3 integrin receptor, cyclic RGD pentapeptide), LB19 (heterobivalent peptide ligand for VEGF receptor), LB20 (for neurotonin B), LB21 (glycoprotein for G protein-coupled receptor), LB22 (Toll-like receptor TLR2), LB23 (and for αv integrin receptors), LB24 (for αv integrin receptors), cilengitide / cyclo(-RGDfV-), LB23 (flucortisone), LB25 (rifabutin analog), LB26 (rifabutin analog), LB27 (rifabutin analog), LB28 (flucortisone), LB29 (dexamethasone), LB30 (fluticasone propionate), LB31 (dichlobate), LB32 (acetonide), LB33 (prednisone), LB34 (prednisolone), LB36 (prednisolone), LB37 (irino) Tecan analog), LB38 (crizotinib analog), LB39 (bortezomib analog), LB40 (carfilzomib analog), LB41 (carfilzomib analog), LB42 (leuprolide analog), LB43 (triptorelin analog), LB44 (clindamycin), LB45 (liraglutide analog), LB46 (semaglutide analog), LB47 (retamulin analog), LB48 (indigosine analog), LB49 (vinblastine analog), LB50 (lixisenatide analog), LB51 (ositinib analog), LB52 (nucleoside analog),LB53 (an erlotinib analog) and LB54 (a lapatinib analog), the structures of which are as follows: [ka] TIFF2024112832000150.tif253170TIFF2024112832000151.tif238170TIFF202 4112832000152.tif240170TIFF2024112832000153.tif255170TIFF20241128320 00154.tif254170TIFF2024112832000155.tif219170TIFF2024112832000156.t if224170TIFF2024112832000157.tif199170TIFF2024112832000158.tif103170
[0161] During the ceremony, [ka] is the linking site to the side chain linker of the present patent; X4 and Y1 are independently O, NH, NHNH, NR1, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R1), N(R1)C(O)N(R1), CH2, C(O)NHNHC(O), and C(O)NR1; X1 is H, CH2, OH, O, C(O), C(O)NH, C(O)N(R1), R1, NHR1, NR1, C(O)R1, or C(O)O; X5 is H, CH3, F, or Cl; M1 and M2 are independently H, Na, K, Ca, Mg, NH4, N(R 12 R 12’ R 13 R 13’ ) is;R 12 , R 12’ , R 13 , and R 13’ is defined in formula (I).
[0162] In another embodiment, the above-described ligands can be used as payloads for conjugation to cell-binding molecules (e.g., antibodies) via the side chain linkers of the present application for the targeted treatment or prevention of cancer, infectious diseases, and autoimmune diseases.
[0163] In yet another embodiment, one, two, or more of DNA, RNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA), and PIWI-interacting RNA (piRNA) can be conjugated to the cell-binding molecule via the side chain conjugate of the present application. Small RNAs (siRNA, miRNA, piRNA) and long non-coding antisense RNAs are known to be involved in epigenetic changes in cells (Goodchild, J (2011), Methods in molecular biology (Clifton, NJ). 764: 1-15). The DNA, RNA, mRNA, siRNA, miRNA, or piRNA in this specification may be single-stranded or double-stranded, with from 3 to 1 million nucleotide units, some of whose nucleotides are linked by phosphorothioate bonds rather than the phosphodiester bonds of natural RNA and DNA, as exemplified by phosphorothioate-linked oligonucleotides such as Fomivirsen, or mipomersen, and the sugar moiety in the center of the molecule is deoxyribonucleotide. The oligonucleotide may be a nucleotide with a 2'-O-methoxyethyl modified ribose at both ends, or a non-natural (synthetic) form such as peptide nucleic acid (PNA), morpholino, phosphorothioate, thiophosphoramidate, or oligonucleotides made with 2'-O-methoxyethyl (MOE), 2'-O-methyl, 2'-fluoro, locked nucleic acid (LNA), or bicyclic nucleic acid (BNA) with ribose sugars, or nucleic acids modified to remove the 2'-3' carbon bond in the sugar ring structure (Whitehead, KA; et al (2011), Annual Review of Chemical and Biomolecular Engineering 2: 77-96; Bennett, CF; Swayze, EE (2010), Annu. Rev. Pharmacol. Toxicol. 50: 259-29). Preferably, the length of the oligonucleotide ranges from about 8 to 200 nucleotides or more. Exemplary conjugate structures are shown below:
[0164] [ka]
[0165] In the formula, X1, [ka] is the same as defined in formula (I) or above; [ka] is single-stranded or double-stranded DNA, RNA, mRNA, siRNA, miRNA, or piRNA; Y is preferably O, S, NH, or CH2.
[0166] Application of conjugates
[0167] In certain embodiments, the cell-binding ligand-drug conjugates of the present invention via side chain linkers is used in the targeted treatment of cancers, including but not limited to adrenocortical carcinoma, anal cancer, bladder cancer, brain tumors (adult, brainstem glioma, childhood, cerebellar astrocytoma, cerebral astrocytoma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal and pineal tumor, visual pathway and hypothalamic glioma), breast cancer, carcinoid tumor, gastrointestinal, carcinoma of unknown primary, cervical carcinoma, colorectal carcinoma, endometrial cancer, esophageal cancer, extrahepatic bile duct cancer, and Ewing family tumors. Tumor (PNET), extracranial malignant germ cell tumor, eye cancer, intraocular melanoma, gallbladder cancer, gastric cancer (stomach), germ cell tumor, extragonadal, gestational trophoblastic tumor, head and neck cancer, hypopharyngeal cancer, pancreatic islet cell carcinoma, kidney cancer (renal cell carcinoma), laryngeal carcinoma, leukemia (acute lymphoblastic, acute myeloid, chronic lymphocytic, chronic myeloid, hairy cell), lip and oral cancer, liver cancer, lung cancer (non-small cell, small cell, lymphoma (AIDS-related, central nervous system, skin T-cell) alveolar sarcoma, Hodgkin's disease, non-Hodgkin's disease, malignant mesothelioma, melanoma, Merkel cell carcinoma, metastatic squamous neck cancer of unknown primary site, multiple myeloma and other plasma cell neoplasms, mycosis fungoides, myelodysplastic syndrome, myeloproliferative syndrome, nasopharyngeal cancer, neuroblastoma, oral cancer, pharyngeal cancer, osteosarcoma, ovarian cancer (epithelial, germ cell tumor, low malignant potential tumor), pancreatic cancer (exocrine gland, islet cell carcinoma), paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer , pheochromocytoma cancer, pituitary cancer, plasmacytoma, prostate cancer, rhabdomyosarcoma, rectal cancer, renal cell carcinoma (kidney cancer), renal pelvis and ureter (transitional cell), salivary gland cancer, Sezary syndrome, skin cancer, skin cancer (cutaneous T-cell lymphoma, Kaposi's sarcoma, melanoma), small intestine cancer, soft tissue sarcoma, stomach cancer, testicular cancer, thymoma (malignant), thyroid cancer, urethral cancer, uterine cancer (sarcoma), abnormal cancers of children, vaginal cancer, vulvar cancer, Wilms' tumor.
[0168] In another specific embodiment, the cell-binding-drug conjugate of the present invention is used to treat or prevent autoimmune diseases, including, but not limited to, autoimmune gastric achlorhydria, chronic active hepatitis, acute disseminated encephalomyelitis, acute hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, amyotrophic lateral sclerosis, ankylosing spondylitis, anti-GMB / TBM nephritis, antiphospholipid syndrome, antisynthetase syndrome, arthritis, atopic allergy, atopic dermatitis, autoimmune aplastic anemia, autoimmune cardiomyopathy, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, autoimmune peripheral nervous system disease, Autoimmune pancreatitis, multiple autoimmune endocrinopathy types I, II, and III, autoimmune progesterone dermatitis, autoimmune thrombocytopenic purpura, autoimmune uveitis, Barlow's disease / Barlow's concentric sclerosis, Behçet's disease, Berger's disease, Bickerstaff's encephalitis, Blau syndrome, bullous pemphigoid, Castleman's disease, Chagas' disease, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, chronic relapsing multifocal osteomyelitis, chronic Lyme disease, chronic obstructive pulmonary disease, allergic granulomatous vasculitis, cicatricial pemphigoid, celiac disease Crohn's disease, Cogan's syndrome, cold agglutinin disease, complement component C2 deficiency, cranial arteritis, CREST syndrome, Crohn's disease (idiopathic inflammatory bowel disease), Cushing's syndrome, cutaneous leukocytoclastic vasculitis, malignant atrophic papulosis, painful adiposity, dermatitis herpetiformis, dermatomyositis, type 1 diabetes, diffuse cutaneous scleroderma, myocardial infarction, discoid lupus erythematosus, eczema, endometriosis, enthesitis-associated arthritis, eosinophilic fasciitis, epidermolysis bullosa acquisita, erythema nodosum, idiopathic mixed cryoglobulinemia, Evans syndrome, fibrodysplasia ossificans progressiva, fibromyalgia, fibromyositis, fibrosing alveolar septa inflammation, gastritis, gastrointestinal pemphigoid, giant cell arteritis, glomerulonephritis, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome, Hashimoto's encephalopathy, Hashimoto's thyroiditis, hemolytic anemia, allergic purpura, herpes gestationis, hidradenitis suppurativa, Hughes' syndrome (antiphospholipid antibody syndrome), hypogammaglobulinemia, idiopathic inflammatory demyelinating disease, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (autoimmune thrombocytopenic purpura), IgA nephropathy (Berger's disease), inclusion body myositis, inflammatory demyelinating polyneuropathy, interstitial cystitis, irritable bowel syndrome, juvenile idiopathic arthritis,Juvenile rheumatoid arthritis, mucocutaneous lymph node syndrome, Lambert-Eaton myasthenic syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, linear immunoglobulin A disease (LAD), Lou Gehrig's disease (amyotrophic lateral sclerosis), lupus-like hepatitis, lupus erythematosus, Blau syndrome, Meniere's disease, microscopic polyangiitis, Miller-Fisher syndrome, mixed connective tissue disease, scleroderma, Mucha-Jakob disease, Muckle-Wells syndrome, multiple myeloma, multiple sclerosis, myasthenia gravis, Myositis, narcolepsy, neuromyelitis optica (Devic's disease), neuromuscular diseases, ocular cicatricial pemphigoid, opsoclonus-myoclonus syndrome, Ord's thyroiditis, relapsing rheumatoid arthritis, Panda syndrome (childhood autoimmune neuropsychiatric disorder complicated by streptococcal infection), oncocerebellar degeneration, paroxysmal nocturnal hemoglobinuria, Parry-Romberg syndrome, Parsonage-Georgia syndrome, pars plana inflammation, pemphigus, pemphigus vulgaris, pernicious anemia, perivenous encephalomyelitis, POEMS syndrome, polyarteritis nodosa, polymyalgia rheumatica, polymyositis, primary biliary cirrhosis, primary sclerosing cholangitis, progressive inflammatory neuropathies, psoriasis, psoriatic arthritis, pyoderma gangrenosum, pure red cell aplastic anemia, Rasmussen's encephalitis, Raynaud's disease, recurrent These include: polychondritis recurrentis, Reiter's syndrome, restless legs syndrome, retroperitoneal fibrosis, rheumatoid arthritis, rheumatic fever, sarcoidosis, schizophrenia, Schmidt's syndrome, Schnitzler's syndrome, scleritis, scleroderma, Sjögren's syndrome, spondyloarthropathy, sticky blood syndrome, Still's disease, stiff-man syndrome, subacute bacterial endocarditis, Susac's syndrome, acute febrile neutrophilic dermatosis, Sydenham's chorea, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis (giant cell arteritis), Tolosa-Hunt syndrome, transverse myelitis, ulcerative colitis (idiopathic inflammatory bowel disease), undifferentiated connective tissue disease, undifferentiated spondyloarthropathy, vasculitis, vitiligo, Wegener's granulomatosis, Wilson's syndrome, and Westcott-Aldrich syndrome.
[0169] In another specific example, binding molecules used to conjugate via the side chain linkers of the invention for the treatment or prevention of autoimmune diseases include, but are not limited to, anti-elastin antibodies; Abys anti-epithelial cell antibodies; anti-basement membrane type IV collagen protein antibodies; anti-nuclear antibodies; anti-double-stranded DNA antibodies, anti-single-stranded DNA antibodies, anti-cardiolipin antibodies IgM, IgG; anti-celiac antibodies; anti-phospholipid antibodies IgK, IgG; anti-SM antibodies; anti-mitochondrial antibodies; thyroid antibodies; microsomal antibodies, T-cell antibodies; thyroglobulin antibodies, anti-scleroderma-70 antibodies (AntiSCL-70). ; anti-Jo antibody (Anti-Jo), anti-U1RNP antibody (Anti-U1RNP); anti-La / SSB antibody; anti-SSA antibody; anti-SSB antibody; anti-parietal cell antibody; anti-histone antibody; anti-RNP antibody; C-ANCA; P-ANCA; anti-centromere antibody; anti-fibrin antibody, anti-GBM antibody, anti-ganglioside antibody; anti-desmosomal glycoprotein 3 core antibody (anti-Desmogein3); anti-p62 antibody; anti-sp100 antibody; anti-mitochondrial (M2) antibody; rheumatoid factor antibody; anti-MCV antibody; anti-topoisomerase antibody; and anti-neutrophil cytoplasmic (cANCA) antibody.
[0170] In a preferred embodiment, the binding molecule used in the conjugate of the invention is capable of binding to a receptor or receptor complex expressed by activated lymphocytes associated with autoimmune disease. The receptor or receptor complex may be, for example, a member of the immunoglobulin gene superfamily (e.g., CD2, CD3, CD4, CD8, CD19, CD20, CD22, CD28, CD30, CD33, CD37, CD38, CD56, CD70, CD79, CD90, CD125, CD147, CD152 / CTLA-4, PD-1, or ICOS), the TNF receptor superfamily (e.g., CD27, CD40, CD95), or a receptor complex expressed by activated lymphocytes associated with autoimmune disease. / Fas, CD134 / OX40, CD137 / 4-1BB, INF-R1, TNFR-2, RANK, TACI, BCMA, osteoprotegerin, Apo2 / TRAIL-R1, TRAIL-R2, TRAIL-R3, TRAIL-R4, and APO-3), integrins, cytokine receptors, chemokine receptors, major histocompatibility proteins, lectins (C-type, S-type, or I-type), or complement regulatory proteins.
[0171] In another specific embodiment, useful cell-binding ligands immunospecific for viral or microbial antigens are humanized or human monoclonal antibodies. As used herein, the term "viral antigen" includes, but is not limited to, any viral peptide, polypeptide protein (e.g., HIV gp120, HIV nef, RSV F glycoprotein, influenza virus neuraminidase, influenza virus hemagglutinin, HTLV tax, herpes simplex virus glycoproteins (e.g., gB, gC, gD, and gE), and hepatitis B surface antigen) that can elicit an immune response. The term "microbial antigen" as used herein includes, but is not limited to, any microbial peptide, polypeptide, protein, saccharide, polysaccharide, or lipid molecule capable of eliciting an immune response (e.g., bacterial, fungal, pathogenic protozoan, yeast polypeptides (e.g., LPS and capsular polysaccharide 5 / 8)). Examples of antibodies useful in treating viral or microbial infections include, but are not limited to, palivizumab (a humanized anti-respiratory syncytial virus monoclonal antibody used to treat RVS infections), PRO542 (a CD4 fusion antibody used to treat HIV infections), Ostavir (a human antibody used to treat hepatitis B virus), PROTVIR (a humanized IgG1 antibody used to treat cytomegalovirus), and anti-LPS antibodies.
[0172] The cell-binding molecule-drug conjugates of the present invention via side chain linkers can be used to treat infectious diseases, including, but not limited to, Acinetobacter infection, actinomycosis, African sleeping sickness (African trypanosomiasis), AIDS (acquired immunodeficiency syndrome), amebiasis, Anaplasmosis, Bacillus anthracis, bacterial tuberculosis infection, Argentine hemorrhagic fever, ascariasis, aspergillosis, astrovirus infection, babesiosis, Bacillus cereus infection, bacterial pneumonia, bacterial vaginosis, Bacteroides infection, Balantidiosis, Baileyi roundworm infection, BK virus infection, black sand mites, Blastocystis hominis infection, Blastomyces, Bolivian hemorrhagic fever, Borrelia infection, botulism (and infant botulism), Brazilian hemorrhagic fever, brucellosis, Burkholderia infection, Buruli ulcer, Calicivirus infection (norovirus, sapovirus), Campylobacter infection, Candida infection (candidiasis, thrush), cat scratch disease, cellulitis, Chagas disease (American trypanosomiasis), chancroid, chickenpox, Clonorchiasis, Pneumoniae infection, cholera, chromomycosis, Clonorchiasis, Clostridium difficile infection, coccidioidomycosis, Colorado tick fever, cold (acute viral nasopharyngeal rhinitis, acute rhinitis), Creutzfeldt-Jakob disease, Crimean-Congo hemorrhagic fever, cryptococcosis, cryptosporidium, cutaneous larval migration, cyclospora infection, cysticercosis, cytomegalovirus infection, dengue fever, dientamebiasis, diphtheria, diphyllobothriasis, dracunculiasis, Ebola hemorrhagic fever, hydatid disease, ehrlichiosis, pinworms (pinworm infection), enterococcus infection, enterovirus infection, typhus, erythema infectiosum (fifth disease), acute exanthema in children, trematodiasis, fluke disease, fatal familial insomnia, filariasis, foodborne illness caused by Clostridium perfringens Venom, non-parasitic amoeba infections, Fusobacterium infections, gas gangrene (Clostridial myonecrosis), diotrichosis, Gerstmann-Straussler-Scheinker syndrome, Giardiasis, glanders, gnathostomiasis, gonorrhea, inguinal granuloma (donovanosis), group A streptococcal infections, group B streptococcal infections, Haemophilus influenzae infections, hand, foot and mouth disease (HFMD), hantavirus pulmonary syndrome, Helicobacter pylori infection, hemolytic uremic syndrome, hemorrhagic fever with renal syndrome, hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E, herpes simplex, histoplasmosis,Hookworm infection, human Balkan virus infection, human ehrlichiosis Evans, human granulocytic anaplasmosis, human metapneumovirus infection, human monocytic ehrlichiosis, human papillomavirus infection, human parainfluenza virus infection, microtaeniasis, influenza, isosporiasis, Kawasaki disease, mononucleosis, Mycobacterium kumamotoi infection, kuru, Lassa fever, Legionnaires' disease, Legionnaires' disease, leishmaniasis, leprosy, leptospirosis, listeriosis, Lyme disease, lymphatic filariasis, lymphocytic choriomeningitis, malaria, Marburg hemorrhagic fever, measles, melioidosis (Whitmore disease), meningitis, meningococcal disease, metagonism, microsporidiosis, molluscum contagiosum, epidemics parotitis, typhus (endemic typhus), mycoplasma pneumonia, mycetoma, myiasis, neonatal conjunctivitis (ophthalmia neonatorum), Creutzfeldt-Jakob disease (vCJD, nvCJD), nocardiosis, onchocerciasis (blinding filariasis), paracoccidioidomycosis (South American blastomycosis), paragonimiasis, pasteurellosis, head lice (head lice), body lice Body lice, Crarbice, Pelvic inflammatory disease, Whooping cough, Plague, Pneumococcal infection, Pneumocystis carinii pneumonia, Pneumonia, Polio, Prevotella infection, PAME, Progressive multifocal leukoencephalopathy, Psittacosis, Q fever, Rabies, Rat bite fever, Respiratory syncytial virus infection, Rhinovirus infection, Rickettsia infection, , Rickettsia, Rift Valley fever, Rocky Mountain spotted fever, Rotavirus infection, Rubella, Salmonellosis, SARS (Severe Acute Respiratory Syndrome), Scabies, Schistosomiasis, Septicemia, Diarrhea (Dysentery), Shingles (Herpeszoster), Smallpox, Sporotrichosis, Staphylococcus aureus food poisoning, Staphylococcus aureus infection, Strongyloides, Syphilis, Taeniasis, Tetanus (Opening disorder), Barber's sitch, Tinea manus, Black shingles Includes herpes, tinea pedis, tinea unguium, tinea versicolor, toxocariasis (ocular larva migrans), toxocariasis (visceral larva migrans), toxoplasmosis, trichinella, trichomoniasis, cryptobiosis (whipworm infection), pulmonary tuberculosis, tularemia, urea-degrading Mycoplasma infection, Venezuelan equine encephalitis, Venezuelan hemorrhagic fever, viral pneumonia, West Nile fever, rhizobacterium tuberculosis, Mycobacterium pseudotuberculosis, yersiniosis, yellow fever, and zygomycosis.
[0173] More preferably, the conjugates of the present invention are capable of combating pathogenic strains, including but not limited to Acinetobacter baumannii, Actiomyces israelii, Actinomyces odontolyticus, Propionibacterium propionicus, Trypanosoma brucei, HIV (human immunodeficiency virus), Entamoeba histolytica, Anaplasma spp., Bacillus anthracis, Arcanobacterium haemolyticum, Junin virus, Ascaris lumbricoides, and Arthrobacter pneumoniae. Spergillus, Astroviridae, Babesia, Bacillus cereus, Multiplex bacteria, Bacteroides, Colonic pouch ciliates, Roundworm, Nematode, BK virus, Piedraia hortae, Blastocystis hominis, Dermatophagoides, Macubo virus, Borrelia, Clostridium botulinum, Sabia, Brucella, typically Burkholderia cepacia and other Burkholderia species, Mycobacterium ulcerans, Caliciviridae family, Campylobacter, typically Candida albicans and other Candida species Dida species, Bartonella henselae, Group A Streptococci and Staphylococci, Trypanosoma cruzi, Haemophilus ducreyi, Varicella-zoster virus (VZV), Chlamydia trachomatis, Chlamydia pneumoniae, Vibrio cholerae, Fonsecae pedrosoi, Clonorchiasis, Clostridium difficile, Coccidioides immitis, Coccidioides posadaci, Colorado tick fever virus, rhinovirus, coronavirus, Creutzfeldt-Jakob disease prion, Crimean-Congo hemorrhagic fever virus, Cryptococcus S. neoformans, Cryptosporidium spp., Cat hookworm, Co-parasites, Cyclospora, Taenia solium, Cytomegalovirus, Dengue virus (DEN-1, DEN-2, DEN-3 and DEN-4)-Flavivirus, Dictyonamoeba, Corynebacterium diphtheriae, Diphyllobothrix spp., Dracunculus medinensis, Ebola virus, Echinococcus spp., Ehrlichia spp., Pinworms, Enterococcus spp., Enterovirus spp., Typhi Rickettsia, Parvovirus B19, Human herpesvirus type 6, Human herpesvirus type 7,Flukes, Fasciola hepatica and Fasciola gigantica, FFI prions, Filarioidea, Clostridium perfringens, Fusobacterium, Clostridium perfringens, other Clostridium species, Geotrichum candidum, GSS prions, Giardia lamblia, Burkholderia mallei, Gnathostoma nematode, Gnathostoma spp., Neisseria gonorrhoeae, Bordetella granulomatosis, Streptococcus pyogenes, Streptococcus agalactiae, Haemophilus influenzae, enteric viruses, most Coxsackievirus A viruses, enteric virus 71, Sin Nombre virus, Helicobacter pylori, Escherichia coli O158:H7, Bunyaviridae, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus Herpes simplex virus type 1, Herpes simplex virus type 2, Histoplasma capsulatum, Ancylostoma nigra, American hookworm, Haemophilus influenzae, Boca human virus, Ehrlichia ewingii, Anaplasma phagocytophilum, Human metapneumovirus, Ehrlichia chaffeensis, Human papillomavirus, Human parainfluenza virus, Tapeworm dwarf, Tapeworm diminutum, Epstein-Barr virus, Orthomyxoviridae, Isospora belli, Kingella kingae, Klebsiella pneumoniae, Klebsiella otsena, Klebsiella rhinocerosella, Klebsiellarhinoscleromotis, Couloury poultry, Lassa fever virus, Legionella pneumophila, Leishmania, Mycobacterium leprosum and Mycobacterium lepromatosis, Leptospira, Listeria monocytogenes, Borreliosis and other Borrelia species, Wuchereria bancrofti and Brugia malayi, Lymphocytic choriomeningitis virus (LCMV), Plasmodium genus, Marburg virus, Measles virus , Burkholderia pseudomallei, Neisseria meningitidis, Fluke yokogawai, Microsporidia, Molluscum contagiosum virus (MCV), Mumps virus, Rickettsia typhi, Mycoplasma pneumoniae, various bacteria (actinomycetoma) and fungi (mycosis), Diptera parasitic fly larvae, Chlamydia trachomatis and Neisseria gonorrhoeae, vCJD prion, Nocardia asteroides and other Nocardia species, Onchocerca volvulus, Blastomyces brasiliensis, Paragonimus and other Paragonimus genera, Pasteurella spp., head lice, body lice, Phthirus puvis ( Phthiruspubis), Bordetella pertussis, Yersinia pestis, Streptococcus pneumoniae, Pneumocystis cysticercosis, Poliovirus, Prevotella spp., Naegleria ameba, JC virus, Chlamydia psittacosis, Coxiella burnetii, Rabies virus, Bead-chain Escherichia coli and Rat Bite Fever spirochetes, Respiratory Respiratory Syncytial Virus, Rhinosporidium sayberi, Rhinovirus, Rickettsia spp., Rickettsia mites, Rift Valley fever virus, Rocky Mountain spotted fever rickettsia, Rotavirus, Rubella virus, Salmonella spp., Atypical pneumonia coronavirus, Scabies mites, Schistosoma spp. Shigella, Varicella-zoster virus, Variola major or minor, Sporothrix schenckii, Staphylococcus spp., Staphylococcus aureus, Streptococcus pyogenes, Strongyloides stercoralis, Syphilis spirochete, Cestodes spp., Clostridium tetani, Ringworm, Trichophyton tonsurans, Ringworm, Epidermophyton floccosum, Trichophyton rubrum and Trichophyton mentagrophytes, Trichophyton rubrum, Holtea werneckii, Ringworm, Malassezia spp., Roundworm, Toxoplasma gondii, Trichinella spiralis, Trichomonas vaginalis, Trichuris trichiura, Mycobacterium tuberculosis, Tula hot francis bacteria, Ureaplasma urealyticum, Venezuelan equine encephalitis virus, Vibrio cholerae,Guanarito virus, West Nile virus, Trichosporonium spp., Yersinia pseudotuberculosis, Yersinia enterocolitica, Yellow fever virus, Mucorales (mucormycosis) and Entomophthora entomophthora, Pseudomonas aeruginosa, Campylobacter fetus (Vibrio), Aeromonas bacteria, Edwardsiella spp., Tarda, Yersinia pestis, Shigella dysenteriae, Shigella sonnei, Salmonella typhimurium, Treponema pertenue, Treponema carateneum, Phenyx burgdorferi, Borrelia burgdorferi, Leptospira hemorrhagic jaundice, Pneumocystis carinii, Brucella abortus, Brucella abortus, Mycoplasma malta, Mycoplasma These include: Rickettsia typhi, Rickettsia tsutsugamushi, Chlamydia; pathogenic fungi (Aspergillus fumigatus, Candida albicans, Histoplasma capsulatum); protozoa (Entamoeba histolytica, Trichomonas vaginalis, Trichomonas mansoni, Trypanosoma gambiens, Trypanosoma rhodesiense, Leishmania donovani, Leishmania tropicalis, Leishmania braziliensis, Pneumocystis carinii pneumoniae, Plasmodium vivax, Plasmodium falciparum, malignant malaria); or helminths (Schistosoma japonicum, Schistosoma mansoni, Schistosoma haematobium, and hookworms).
[0174] Additionally, the conjugates of the present invention are for the treatment of viral diseases, including, but not limited to, Poxyiridae, Herpesviridae, Adenoviridae, Papovaviridae, Enteroviridae, Picornaviridae, Parvoviridae, Reoviridae, Retroviridae, influenza virus, parainfluenza virus, mumps, measles, respiratory syncytial virus, rubella, arbovirus, rhabdovirus, arenavirus, and the like. Viral diseases, non-A / non-B hepatitis viruses, rhinoviruses, coronaviruses, rotaviruses, tumor viruses [e.g., HBV (hepatocellular carcinoma), HPV (cervical cancer, anal cancer), Kaposi's sarcoma-associated herpesvirus (Kaposi's sarcoma), EB virus (nasopharyngeal carcinoma, Burkitt's lymphoma, primary central nervous system lymphoma), MCPyV (Merkel cell carcinoma), SV40 (simian virus 40), HCV (hepatocellular carcinoma), HTLV-I (adult T-cell leukemia / lymphoma)]; immune diseases caused by viruses : [e.g., human immunodeficiency virus (AIDS)], CNS viruses: [e.g., JCV (progressive multifocal leukoencephalopathy), MeV (subacute sclerosing panencephalitis), LCV (lymphocytic choriomeningitis), arboviral encephalitis, Orthomyxoviridae (presumed) (encephalitis lethargica), RV (rabies), vesicular stomatitis, herpesvirus meningitis, Ramsay-Hunt syndrome type II; poliovirus (acute poliomyelitis, post-polio syndrome), HTLV-I (tropical spastic paraparesis)]; cytomegalovirus (CMV retinitis, HSV (herpetic keratitis)); cardiovascular viruses [e.g., CBV (pericarditis, myocarditis)]; respiratory system / acute nasopharyngitis / viral pneumonia: [EB virus (EBV infection / infectious mononucleosis), cytomegalovirus, SARS coronavirus (severe acute respiratory syndrome), These pathogenic viral diseases include Orthomyxoviridae: influenza viruses A / B / C (influenza / avian influenza), Paramyxovirus: human parainfluenza virus (parainfluenza), RSV (human respiratory syncytial virus), hMPV; digestive system viruses [MuV (mumps), cytomegalovirus (CMV esophagitis); adenovirus (adenovirus infection); rotavirus, norovirus, astrovirus, coronavirus, HBV (hepatitis B virus), CBV, HAV (hepatitis A virus), HCV (hepatitis C virus), HDV (hepatitis D virus), HEV (hepatitis E virus), HGV (hepatitis G virus)]; and urogenital viruses [e.g., BK virus, MuV (mumps)].
[0175] According to a further object, the present invention also relates to a pharmaceutical composition for the treatment of cancer or autoimmune diseases, comprising the conjugate of the present invention together with a pharmaceutically acceptable carrier, diluent, or excipient. Methods for treating cancer, infectious diseases, and autoimmune diseases can be performed in vitro, in vivo, or ex vivo. An example of in vitro therapy includes cell culture treatment to kill all cells except for desired variants that do not express the target antigen, or to kill variants that express undesired antigens. An example of ex vivo therapy includes treatment of hematopoietic stem cells (HSCs) prior to transplantation (HSCT) and their return to the same patient to kill diseased or malignant cells. For example, clinical ex vivo treatments for removing cancer or lymphocyte cells from bone marrow prior to autologous transplantation in the treatment of cancer and autoimmune diseases, or for removing T cells and other lymphocytes from allogeneic bone marrow or tissue prior to transplantation to prevent graft-versus-host disease, can be performed as follows: After obtaining bone marrow cells from a patient or other individual, they are cultured in serum-containing medium containing the conjugate of the present invention at a concentration ranging from 1 pM to 0.1 mM at 37°C for 15 minutes to approximately 48 hours. The exact concentration conditions and culture time (= dose) can be easily determined by an experienced clinician. After culture, the bone marrow cells are washed with serum-containing medium and returned to the body by known methods, such as intravenous injection. If the patient is undergoing other treatments (e.g., ablative chemotherapy or total body irradiation) between the time of bone marrow cell acquisition and reinfusion treatment, the processed bone marrow cells are cryopreserved in liquid nitrogen using standard medical equipment.
[0176] Chemotherapeutic / cytotoxic agents for use as payloads for conjugation with conjugates or for synergistic effects
[0177] Chemotherapeutic agents that can be used as payloads for the conjugates of the present invention or can be used together with the conjugates of the present invention for synergistic effects are small molecule drugs, including cytotoxic agents. Here, "small molecule drugs" generally refer to organic, inorganic, or organometallic compounds with molecular weights of, for example, 100 to 2500, more appropriately, 200 to 2000. Small molecule drugs are described in WO05058367A2 and U.S. Pat. No. 4,956,303, as well as Chessum, N., et al., Prog Med Chem. 2015, 54: 1-63; Eder, J., et al., Nat Rev Drug Discov. 2014, 13(8): 577-87. Zhang, M.-Q., et al., Curr Opin Biotechnol. 2007, 18(6): 478-88, etc. The drugs listed above include known drugs and and potential drugs.
[0178] Known drugs include, but are not limited to:
[0179] 1) Chemotherapeutic agents: a) Alkylating Agents: Nitrogen mustards: chlorambucil, chlornaphazine, cyclophosphamide, dacarbazine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, mannomustine, mitobronitol, melphalan, mitolactol, pipobroman, nobembine, phenesterine, prednimustine, thiotepa, trofosfamide, uracil mustard; CC-1065 and synthetic analogs of adozelesin, carzelesin, and bizelesin; duocarmycin and its synthetic analogs KW-2189 and CBI-TMI; benzodiazepine dimers or pyrrolobenzodiazepine (PBD) dimers, tomaymycin dimers, indolinobenzodiazepine dimers, imidazobenzyl benzothiadiazepine dimers or oxazolidinobenzodiazepine dimers; nitrosourea compounds including carmustine, lomustine, chlorozotocin, fotemustine, nimustine, ranimustine; alkylsulfonates including busulfan, treosulfan, improsulfan, and piposulfan; triazenes or dacarbazine; platinum-containing compounds including carboplatin, cisplatin, and oxaliplatin; aziridines, benzodopa, carboquone, metledopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramine, trimethylolomelamine, and the like; b) Plant Alkaloids: Vinca alkaloids including vincristine, vinblastine, vindesine, vinorelbine, and navelbine; taxoids including paclitaxel and docetaxel and their analogs; maytansinoids including DM1, DM2, DM3, DM4, DM5, DM6, DM7, maytansine, and ansamitocin and their analogs; cryptophycins such as cryptophycin 1 and cryptophycin 8; epothilones, eluterobin, discodermolide, bryostatins, dolostatins, auristatins, tubulysins, and cephalostatins; pancratistatin; sarcodictyin; and spongistatin sugars. c) DNA topoisomerase inhibitors: epipodophyllins including 9-aminocamptothecin, camptothecin, crisnatol, daunomycin, etoposide, etoposide phosphate, irinotecan, mitoxantrone, novantrone, retinoic acid (retinolic acid), teniposide, topotecan, 9-nitrocamptothecin, or RFS 2000; and mitomycins, and their analogs, etc.; d) Antimetabolites: {[Antifolates: (e.g., DHFR inhibitors: methotrexate, trimetrexate, denopterin, pteropterin, aminopterin (4-aminopteroic acid), or other folic acid analogs); IMP dehydrogenase inhibitors (e.g., mycophenolic acid, tiazofurin, ribavirin, EICAR); ribonucleotide reductase inhibitors (e.g., hydroxyurea, deferoxamine)]; [Pyrimidine analogs: uracil analogs (e.g., ancitabine, azacitidine, 6-azauridine, capecitabine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, 5-fluorouracil, floxuridine, raltitrexed; cytosine analogs (e.g., cytarabine, cytosine arabinoside, fludarabine); purine analogs (e.g., azathioprine, fludarabine, mercaptopurine, thiamiprine, thioguanine); folic acid supplements such as folinic acid, etc.; e) Hormone therapy agents: receptor antagonists: [Antiestrogens: (e.g., megestrol, raloxifene, tamoxifen); LHRH agonists: (including goserelin and leuprolide acetate); Antiandrogens: (e.g., bicalutamide, flutamide, calcineurin, dromostanolone propionate, epithiostanol, goserelin, leuprolide , mepitiostane, nilutamide, testolactone, trilostane, and other similar androgen inhibitors)]; retinoids / deltoids: [e.g., vitamin D3 analogs: (CB1093, EB1089, KH1060, cholecalciferol, ergocalciferol); photodynamic therapy agents: (e.g., verteporfin, phthalocyanines, photosensitizer Pc4, demethoxyhypocrelin A); cytokines: (e.g., interferon alpha, interferon gamma, tumor necrosis factor (TNF), TNF domain-containing human proteins)]}, etc.; f) Kinase inhibitors: BIBW2992 (anti-EGFR / Erb2), imatinib, gefitinib, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, axitinib, pazopanib, vandetanib, E7080 (anti-VEGFR2), mubritinib, ponatinib, bafetinib, bosutinib, cabozantinib, vismodegib, iniparib, ruxolitinib, CYT387, axitinib, tivozanib, sorafenib, bevacizumab, cetuximab, trastuzumab, ranibizumab, panitumumab, ispinesib, etc.; g) poly(ADP-ribose) polymerase (PARP) inhibitors such as olaparib, niraparib, iniparib, talazoparib, veliparib, CEP9722 (Cephalon), E7016 (Eisai), BGB-290 (Beigene), or 3-aminobenzamide; h) Enediyne antibiotics (e.g., calicheamicins, particularly calicheamicin γ1, δ1, α1, or β1 (J. Med. Chem., 39(11), 2103-2117(1996), Angew. Chem. Intl. Ed. Engl. 33:183-186 (1994); dynemicins, including dynemicin A and deoxydynemicin; esperamicin, kedarcidin, C-1027, maduropeptin, or neocarzinostatin chromophores and related chromoprotein enediyne antibiotic chromophores), aclacinomycins, actinomycin, anthramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin; chromomycins, dactinomycin, daunorubicin antibiotics such as detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin, epirubicin, eribulin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfilomycin, puromycin, queramycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, etc.; i) Others: polyketides (acetogenins), especially bullatacin and bullatacinone; gemcitabine, epoxomicins (e.g., carfilzomib), bortezomib, thalidomide, lenalidomide, pomalidomide, tosedostat, zybrestat, PLX4032, STA-9090, Stimuvax, allovectin-7, Zygeba, Provenge, Elvoy, isoprenylation inhibitors (e.g., lovastatin), dopaminergic neurotoxins (e.g., 1-methylpropional), -4-phenylpyridine ion), cell cycle inhibitors (e.g., staurosporine), actinomycins (e.g., actinomycin D, dactinomycin), amanitins, bleomycins (e.g., bleomycin A2, bleomycin B2, peplomycin), anthracyclines (e.g., daunorubicin, doxorubicin (adriamycin), idarubicin, epirubicin, pirarubicin, zorubicin), mitoxantrone, MDR inhibitors (e.g., verapamil), Ca 2+ ATP inhibitors (e.g., thapsigargin), histone deacetylase inhibitors (including vorinostat, romidepsin, panobinostat, valproic acid, mocetinostat (MGCD0103), belinostat, PCI-24781, entinostat, SB939, resminostat, gibinostat, AR-42, CUDC-101, sulforaphane, and trichostatin A); thapsigargin, celecoxib, glitazones, epigallocatechin gallate, disulfiram, salinosporamide A, and antiadrenal agents (aminoglutethimide). selected from the group consisting of acetaminophen, mitotane, and trilostanol; aceglatone; aldophosphamide glucoside; aminolevulinic acid; amsacrine; arabinoside, bestravcil; bisantrene; edatrexate; defofamine; demecolcine; diaziquone; elfornithine (DFMO), elfomitine; elliptinium acetate; etocluzide, gallium nitrate, gacytosine, hydroxyurea; ibandronate, lentinan; lonidamine; mitoguazo amine; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllic acid; 2-ethylhydrazide; procarbazine; PSK (registered trademark); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triazicon; 2,2',2''-trichlorotriethylamine; trichothecenes (including, inter alia, T2 toxin, verrucarin A, roridin A, and anguidine); urethanes, siRNA, antisense drugs, and nucleases;
[0180] 2) Anti-autoimmune disease medications include, but are not limited to, cyclosporine, cyclosporine A, aminocaproic acid, azathioprine, bromocriptine, chlorambucil, chloroquine, cyclophosphamide, corticoids (e.g., amcinonide, betamethasone, budesonide, hydrocortisone, flunisolide, fluticasone propionate, fluocortolone danazol, dexamethasone, triamcinolone acetonide, beclomethasone dipropionate), DHEA, etanercept, hydroxychloroquine, infliximab, meloxicam, methotrexate, mofetil, mycophenolate, prednisone, sirolimus, and tacrolimus.
[0181] 3) Anti-infectives include, but are not limited to: a) Aminoglycosides: amikacin, astromycin, gentamicin (netilmicin, sisomicin, isepamicin), hygromycin B, kanamycin (amikacin, arbekacin, bekanamycin, dibekacin, tobramycin), neomycin (framycin, paromomycin, ribostamycin), netilmicin, spectinomycin, streptomycin, tobramycin, verdamycin; b) Amphenicols: azidamphenicol, chloramphenicol, florfenicol, thiamphenicol; c) Ansamycins: geldanamycin, herbimycin; d) Carbapenems: biapenem, doripenem, ertapenem, imipenem, cilastatin, meropenem, panipenem; e) Cephems: carbacephem (loracarbef), cephacetrile, cefaclor, cephradine, cefadroxil, cephalonium, cephaloridine, cephalothin or cephalothin, cephalexin, cephaloglycin, cefamandole, cephapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefbuperazone, cefcapene, cefdaloxime, cefepime, cefminox, cefoxitin, cefprozil, cefroxadine, ceftezole, cefuroxime, cefixime, cefdinir, cefditoren, cefepime, fetamet, cefmenoxime, cefodizime, cefonicid, cefoperazone, ceforanide, cefotaxime, cefotiam, cefozopran, cephalexin, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefprozil, cefquinome, cefsulodin, ceftazidime, cefteram, ceftibuten, ceftiolene, ceftizoxime, ceftobiprol, ceftriaxone, cefuroxime, cefuzonam, cephamycins (including cefoxitin, cefotetan, cefmetazole), oxacephems (flomoxef, latamoxef); f) Glycopeptides: bleomycin, vancomycin (including oritavancin, telavancin), teicoplanin (dalbavancin), ramoplanin; g) Glycylcyclines: for example, tigecycline; h) β-lactamase inhibitors: penams (sulbactam, tazobactam), clavams ( clavulanic acid); i) Lincosamides: clindamycin, lincomycin; j) Lipopeptides: daptomycin, A54145, calcium-dependent antibiotics (CDA); k) Macrolides: azithromycin, cethromycin, clarithromycin, dirithromycin, erythromycin, flurithromycin, josamycin, ketolides (telithromycin, cethromycin), midecamycin, miokamycin, oleandomycin, rifamycins (rifampicin, rifampin, rifabutin, rifapentine), rokitamycin, roxithromycin, spectinomycin, spiramycin, tacrolimus (FK506), troleandomycin, telithromycin; l) Monobactams: aztreonam, tigemonam; m) Oxazolidinones: Linezolid; n) Penicillins: amoxicillin, ampicillin, pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin, azidocillin, azlocillin, benzylpenicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, clometocillin, procaine benzylpenicillin, carbenicillin (carindacillin), cloxacillin, dicloxacillin, epicillin, flucloxacillin, mecillinam (pivmecillinam), mezlocillin, methicillin, nafcillin, oxacillin, penamecillin, penicillin, phenethicillin, phenoxymethylpenicillin, piperacillin, propicillin, sulbenicillin, temocillin, ticarcillin; o) Polypeptides: bacitracin, colistin, polymyxin B; p) Quinolones: alatrofloxacin, balofloxacin, ciprofloxacin, clinafloxacin, danofloxacin, difloxacin, enoxacin, enrofloxacin, floxin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, canotrovafloxacin, levofloxacin, lomefloxacin, marbofloxacin, moxifloxacin, nadifloxacin, norfloxacin, orbifloxacin, ofloxacin, pefloxacin, trovafloxacin, grepafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tosufloxacin, trovafloxacin; q) Streptogramins: Pristinamycin, quinupristin / dalfopristin; r) Sulfonamides: mafenide, prontosil, sulfacetamide, sulfamethizole, sulfanilamide, sulfasalazine, sulfisoxazole, trimethoprim, trimethoprim-sulfamethoxazole (co-trimoxazole); s)Steroidal antibacterial drugs: selected from fusidic acid; t) Tetracyclines: doxycycline, chlortetracycline, clomocycline, demeclocycline, lymecycline, meclocycline, methacycline, minocycline, oxytetracycline, penimepicycline, rolitetracycline, tetracycline, glycylcyclines (e.g., tigecycline); u) Other antibiotics: annonacin, arsphenamine, bactoprenol inhibitors (bacitracin), DADAL / AR inhibitors (cycloserine), dictyostatin, discodermolide, eleutherobin, epothilone, ethambutol, etoposide, faropenem, fusidic acid, furazolidone, isoniazid, laulimalide, metronidazole, mupirocin, mycolactone, NAM synthesis inhibitors (e.g., fosfomycin), nitrofurantoin, paclitaxel, platensimycin, pyrazinamide, quinupristin / dalfopristin, rifampicin (rifampin), tazobactamcinidazole, uvaricin;
[0182] 4) Antiviral drugs: a) Entry / fusion inhibitors: aplaviroc, maraviroc, vicriviroc, gp41( enfuvirtide), PRO140, CD4 (ibalizumab); b) Integrase inhibitors: Raltegravir, Elvitegravir, Globoidnan A; c) Maturation inhibitors: Bevirimat, Vivecon; d)Neuraminidase inhibitors: oseltamivir, zanamivir, peramivir; e) Nucleosides and Nucleotides: Abacavir, Acyclovir, Adefovir, Amdoxovir, Apricitabine, Brivudine, Cidofovir, Clevudine, Dexerbucitabine, Didanosine (DDI), Elvucitabine, Emtricitabine (FTC), Entecavir, Famciclovir, Fluorouracil (5-FU), 3'-Fluoro-substituted 2',3'-deoxynucleoside analogues (3'-fluoro-2',3'-dideoxythymidine (FLT) and 3'-fluoro-2',3'- dideoxyguanosine (FLG), fomivirsen, ganciclovir, idoxuridine, lamivudine (3TC), L-nucleosides (β-L-thymidine and β-L-2'-deoxycytidine), penciclovir, rasvir, ribavirin, stampidine, stavudine (d4T), taribavirin (viramidine), telbivudine, tenofovir, trifluridine, valacyclovir, valganciclovir, zalcitabine (ddC), zidovudine (AZT); f) Non-nucleosides: amantadine, ateviridin, capravirine, diarylpyrimidines (etravirine, rilpivirine), delavirdine, docosanol, emivirine, efavirenz, foscarnet (phosphoryl formate), imiquimod, interferon alpha, loviride, rhodenosine, methisazone, nevirapine, NOV-205, peginterferon alpha, podophyllotoxin, rifampicin, rimantadine, resiquimod (R-848), tromantadine; g) Protease inhibitors: amprenavir, atazanavir, boceprevir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, pleconaril, ritonavir, saquinavir, telaprevir (VX-950), tipranavir; h) Other antiviral drugs: Abzyme, arbidol, calanolide A, ceragenin, cyanovirin-N, diarylpyrimidine, epigallocatechin gallate (EGCG), foscarnet, griffithsin, taribavirin (viramidine), hydroxyurea, KP-1461, miltefosine, pleconaril, portmanteau inhibitors, ribavirin, seliciclib.
[0183] 5) Radioisotopes used in radiation therapy. Examples of radioisotopes (radionuclides) are: 3 H, 11 C. 14 C. 18 F, 32 P, 35 S, 64 Cu, 68 Ga, 86 Y, 99 Tc, 111 In, 123 I, 124 I, 125 I, 131 I, 133 Xe, 177 Lu, 211 At, or 213Radioisotope-labeled antibodies are useful for receptor-targeted imaging experiments and can also be used for targeted therapy using antibody-radioisotope conjugates (Wu et al. (2005) Nature Biotechnology 23(9):1137-46). Cell-binding molecules, such as antibodies, can be labeled with ligand reagents that bind, chelate, or complex with radioisotope metals using techniques described in Current Protocols in Immunology, Volumes 1 and 2, Coligen et al., Ed. Wiley-Interscience, New York, Pubs. (1991). Chelating ligands capable of complexing metal ions include DOTA, DOTP, DOTMA, DTPA, and TETA (Macrocyclics, Dallas, Texas, USA).
[0184] 6) Other cell-binding molecule-drug conjugates as synergistic treatments. Preferred synergistic conjugates are tubulysin analogs, maytansinoid analogs, taxane analogs, CC-1065 analogs, daunorubicin and doxorubicin compounds, amanitaxin analogs, benzodiazepines. Dimers (e.g., dimers of pyrrolobenzodiazepines (PBD), tomaymycin, anthramycin, indolinobenzodiazepines, imidazobenzothiadiazepines, or oxazolidinodibenzodiazepines), calicheamicin and enediyne antibiotic compounds, actinomycin, azaserine, bleomycin, epirubicin, tamoxifen, idarubicin, dolastatins, auristatins (e.g., monomethyl auristatin E, MMAE, MMAF, auristatin PYE, auristatin The conjugates may be cytotoxic agents such as benzodiazepines (BMP), ...
[0185] 7) Pharmaceutically acceptable salts, acids, or derivatives of any of the above drugs.
[0186] In yet another embodiment, immunotoxins can be conjugated to cell-binding molecules via the conjugates of the present invention. Here, immunotoxins are macromolecular drugs, typically cytotoxic proteins derived from bacterial or plant proteins, such as diphtheria toxin (DT), cholera toxin (CT), trichosanthin (TCS), dianthin, Pseudomonas exotoxin A (ETA'), erythrogenic toxin, diphtheria toxin, AB toxin, and type III exotoxin. They may also be highly toxic bacterial pore-forming protoxins that require proteolytic processing for activation. Examples of such protoxins include proerolysin and its recombinant form, topsalysin. Topsalysin is a modified recombinant protein designed to be selectively activated by prostate enzymes, causing localized cell death and tissue destruction without damaging adjacent tissues and nerves.
[0187] In another synergistic immunotherapy, checkpoint inhibitors, TCR (T cell receptor) T cells, or CAR (chimeric antigen receptor) T cells, or B cell receptor (BCR), natural killer (NK) cells, or cytotoxic antibody cells, or anti-CD3, CD4, CD8, CD16 (FcγRIII), CD19, CD20, CD22, CD25, CD27, CD30, CD33, CD37, CD38, CD40, CD40L, CD45RA, CD45RO, CD56, CD57, CD57bright, CD70, CD79, CD79b, CD123, CD125, CD138, TNFβ, Fas ligand, MHC class I molecules (HLA-A, B, C), VEGF, or NKR-P1 antigens are preferably used together with the conjugates of the present patent for synergistic therapy.
[0188] Prescription and Application
[0189] The conjugates of the present application are suitable for formulation into liquids or for lyophilization and subsequent reconstitution into liquid formulations. The conjugate in a liquid formulation or in a formulated lyophilized powder may comprise 0.01% to 99% by weight of the major component in the formulation. Generally, pre-lyophilized liquid formulations containing the conjugate active ingredient at a concentration of 0.1 g / L to 300 g / L for delivery to patients without high levels of antibody aggregation may contain one or more polyols (e.g., sugars), a buffer having a pH of 4.5 to 7.5, surfactants (e.g., polysorbate 20 or 80), antioxidants (e.g., ascorbic acid and / or methionine), tonicity agents (e.g., mannitol, sorbitol, or NaCl), chelating agents such as EDTA, metal complexes (e.g., Zn-protein complexes), biodegradable polymers such as polyesters, preservatives (e.g., benzyl alcohol), and / or free amino acids.
[0190] Buffers suitable for use in the formulation include, but are not limited to, citric acid, ascorbic acid Organic acid salts such as sodium, potassium, ammonium, or trihydroxyethylamino salts of gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid; Tris, tromethamine hydrochloride, sulfate, or phosphate buffers. Additionally, amino acid cationic components can also be used as buffers. Examples of such amino acid components include, but are not limited to, arginine, glycine, glycylglycine, and histidine. Arginine buffers include arginine acetate, arginine chloride, arginine phosphate, arginine sulfate, arginine succinate, and the like. In one embodiment, the arginine buffer is arginine acetate. Examples of histidine buffers include histidine chloride-arginine chloride, histidine acetate-arginine acetate, histidine phosphate-arginine phosphate, histidine sulfate-arginine sulfate, histidine succinate-arginine succinate, and the like. The pH of the buffer formulation is 4.5 to 7.5, preferably about 4.5 to about 6.5, and more preferably about 5.0 to about 6.2. In some embodiments, the concentration of the organic acid salt in the buffer is about 10 mM to about 500 mM.
[0191] "Polyols," optionally included in formulations, are substances with multiple hydroxyl groups. Polyols can be used as stabilizing excipients and / or isotonicity agents in both liquid and lyophilized formulations. Polyols can protect biopharmaceuticals from physical and chemical degradation pathways. Preferentially excluded cosolvents increase the effective surface tension of the solvent at the protein interface, thereby ensuring that the most energetically favorable structural conformation is the one with the smallest surface area. Polyols include sugars (reducing and nonreducing sugars), sugar alcohols, and sugar acids. "Reducing sugars" contain a hemiacetal group that can reduce metal ions or covalently react with lysine and other amino groups in proteins, while "nonreducing sugars" lack these properties of reducing sugars. Examples of reducing sugars are fructose, mannose, maltose, lactose, arabinose, xylose, ribose, rhamnose, galactose, and glucose. Nonreducing sugars include sucrose, trehalose, sorbose, melezitose, and raffinose. The sugar alcohol is selected from mannitol, xylitol, erythritol, maltitol, lactitol, erythritol, threitol, sorbitol, and glycerol. Sugar acids include L-gluconate and its metal salts. The polyol content in the liquid formulation or the resulting lyophilized solid can be 0.0% to 20% by weight. Preferably, a non-reducing sugar, sucrose or trehalose, at a concentration of about 0.1% to 15% is selected in the formulation, with trehalose being preferred over sucrose due to its solution stability.
[0192] Surfactants optionally included in the formulation include polysorbates (such as polysorbate 20, polysorbate 40, polysorbate 65, polysorbate 80, polysorbate 81, and polysorbate 85), poloxamers (such as poloxamer 188, poly(ethylene oxide)-poly(propylene oxide), poloxamer 407, and polyethylene-polypropylene glycol); Triton; sodium dodecyl sulfate (SDS); sodium lauryl sulfate; sodium octyl glycoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl-, or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamidopropyl betaine;
[0033] Suitable surfactants include camidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmimidopropyl-, or isostearamidopropyl-betaine (e.g., lauramidopropyl); myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl or sodium methyl oleyl taurate; dodecyl betaine, dodecyl dimethylamine oxide, cocamidopropyl betaine, and cocoamphoglycinate, the "MONAQUAT" (trademark) series (e.g., isostearyl ethylimidonium ethosulfate); polyethyl glycol, polypropylene glycol, and copolymers of ethylene and propylene glycol (e.g., Pluronics, PF68, etc.); and polyoxyethylene glycols such as polysorbate 20, 40, 60, or 80 (Tween 20, 40, 60, or 80). The surfactant is an ethylene sorbitan fatty acid ester. The surfactant concentration in the formulation ranges from 0.0% to about 2.0% by weight. In certain embodiments, the surfactant concentration is about 0.01% to about 0.2%. In one embodiment, the surfactant concentration is about 0.02%.
[0193] A "preservative" optionally included in the formulation is a compound that substantially reduces bacterial activity. Examples of potential preservatives include octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride (a mixture of alkylbenzyldimethylammonium chlorides in which the alkyl groups are long-chain compounds), and benzethonium chloride. Other types of preservatives include aromatic alcohols such as phenol, butyl, and benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol. The preservative content in the liquid formulation or the prepared lyophilized powder can be 0.0% to 5.0% by weight. In one embodiment, the preservative herein is benzyl alcohol.
[0194] Suitable free amino acids for use as tonicity or osmolality adjusters in bulk materials or formulations include, but are not limited to, arginine, cystine, glycine, lysine, histidine, ornithine, isoleucine, leucine, alanine, glycerol, glutamic acid, or aspartic acid. Basic amino acids, i.e., arginine, lysine, and / or histidine, are preferred. When histidine is included in a composition, it can function as both a buffer and a free amino acid; however, when a histidine buffer is used, a non-histidine free amino acid, e.g., histidine buffer and lysine, are typically included. Amino acids may be D- and / or L-, but are usually L-forms. Amino acids may be present as any stable salt, e.g., hydrochloride salts such as arginine-HCl. The amino acid content in a liquid formulation or prepared lyophilized powder can range from 0.0% to 30% by weight.
[0195] The antioxidant in the formulation can optionally be selected from methionine, glutathione, cysteine, cystine, or ascorbic acid at a concentration of up to about 5 mg / ml in the liquid formulation or 0.0 to 5.0 wt% in the formulated lyophilized powder. The formulation can optionally include a metal chelator, such as EDTA or EGTA, at a concentration of up to about 2 mM in the liquid formulation or 0.0 to 0.3% in the formulated lyophilized powder.
[0196] The final formulation can be adjusted to a desired pH with a buffer adjuster (e.g., acids such as HCl, H2SO4, acetic acid, H3PO4, citric acid, etc., or bases such as NaOH, KOH, NH4OH, ethanolamine, diethanolamine, or triethanolamine, sodium phosphate, potassium phosphate, trisodium citrate, or tromethamine). The formulation must be controlled to be "isotonic," meaning that the formulation has essentially the same osmotic pressure as human blood. Isotonic formulations generally have an osmotic pressure of approximately 250-350 mOsm. Isotonicity can be measured, for example, using a vapor pressure or ice-type osmometer. Isotonicity agents are selected from mannitol, sorbitol, sodium acetate, potassium chloride, sodium phosphate, potassium phosphate, trisodium citrate, or NaCl. Generally, both the buffer salt and the isotonicity agent can account for up to 30% by weight of the formulation.
[0197] Other excipients that may be useful in either the liquid or lyophilized formulations of the patent application include, for example, fucose, cellobiose, maltotriose, melibiose, octulose, ribose, xylitol, arginine, histidine, glycine, alanine, methionine, glutamic acid, lysine, imidazole, glycylglycine, mannosylglycerate, Triton X-100, Pluoronic F-127, cellulose, cyclodextrin, (2-hydroxypropyl)-β-cyclodextrin, dextran (10, 40, or 70 kD), polydextrose, maltodextrin, ficoll, gelatin, hydroxybenzoates ... hydroxypropyl methacrylate, sodium phosphate, potassium phosphate, ZnCl2, zinc, zinc oxide, sodium citrate, trisodium citrate, tromethamine, copper, fibronectin, heparin, human serum albumin, protamine, glycerin, glycerol, EDTA, metacresol, benzyl alcohol, phenol, polyhydric alcohols, or hydrogenated forms of carbohydrates having a carbonyl group reduced to a primary or secondary hydroxyl group.
[0198] Other contemplated excipients that may be utilized in the aqueous pharmaceutical compositions of the patent application include, for example, flavoring agents, antimicrobial agents, sweeteners, antioxidants, antistatic agents, lipids such as phospholipids or fatty acids, steroids such as cholesterol, protein excipients such as serum albumin (human serum albumin), recombinant human albumin, gelatin, casein, salt-forming counterions such as sodium, etc. These and additional known pharmaceutical excipients and / or additives suitable for use in the formulations of the present invention are described in, for example, "The Handbook of Pharmaceutical Excipients, 4 th edition, Rowe et al., Eds., American Pharmaceuticals Association (2003); and Remington: The Science and Practice of Pharmacy, 21 th edition, Gennaro, Ed., Lippincott Williams & Wilkins (2005).”
[0199] Pharmaceutical containers or containers are used to hold pharmaceutical formulations of any of the conjugates of the patent application. The containers may be vials, bottles, prefilled syringes, prefilled syringes, or autoinjector syringes. Liquid formulations can be freeze-dried or drum-dried into cake or powder form in borosilicate or soda-lime glass vials. Solid powders can also be prepared by efficient spray drying and then packaged in vials or pharmaceutical containers for storage and distribution.
[0200] In a further embodiment, the present invention provides a method for preparing a formulation, comprising the steps of: (a) lyophilizing a formulation comprising a conjugate, excipients, and a buffer system; and (b) reconstituting the lyophilized mixture of step (a) in a reconstitution medium such that the reconstituted formulation is stable. The formulation of step (a) may further comprise a stabilizer and one or more excipients selected from the group including bulking agents, salts, surfactants, and preservatives described above. The reconstitution medium may be any of several diluted organic acids or water, i.e., sterile water or bacteriostatic water for injection (BWFI). The reconstitution medium may be selected from the group consisting of water, i.e., sterile water, bacteriostatic water for injection (BWFI), or acetic acid, propionic acid, succinic acid, sodium chloride, magnesium chloride, an acidic solution of sodium chloride, an acidic solution of magnesium chloride, and an acidic solution of arginine, in an amount of about 10 to about 250 mM.
[0201] Liquid pharmaceutical formulations of the present conjugates must exhibit various predefined properties. One of the main concerns for liquid pharmaceuticals is stability, as proteins / antibodies tend to form soluble and insoluble aggregates during manufacturing and storage. Furthermore, various chemical reactions (e.g., deamination, oxidation, clipping, isomerization) can occur in solution, leading to increased levels of degradation products and loss of biological activity. Preferably, the conjugates in liquid or lyophilized formulations should exhibit a shelf life of greater than 6 months at 25°C. More preferably, the conjugates, either in liquid or lyophilized formulations, should exhibit a shelf life of greater than 12 months at 25°C. Most preferably, liquid formulations should exhibit a shelf life of approximately 24-36 months at 2-8°C, and lyophilized formulations should exhibit a shelf life of up to approximately 60 months at 2-8°C. Both liquid and lyophilized formulations should exhibit a shelf life of at least 2 years at -20°C or -70°C.
[0202] In some embodiments, the formulations can be frozen (e.g., at −20° C. or −70° C.) and, after thawing, e.g., Stability after one, two, or three freeze-thaw cycles can be assessed qualitatively and / or quantitatively by a variety of methods, including assessment of drug / antibody (protein) ratio and aggregate formation (e.g., by UV or size-exclusion chromatography, turbidity measurement, and visual inspection); assessment of charge heterogeneity using cation-exchange chromatography, electrofocusing, or capillary zone electrophoresis (e.g., image capillary); amino- or carboxyl-terminal sequence analysis; mass spectrometry, matrix-assisted laser desorption / ionization / time-of-flight mass spectrometry (MALDI / TOF MS), or HPLC-MS / MS; SDS-PAGE analysis for comparison of antibody reduction or integrity; peptide map analysis (e.g., trypsin or lysine-carbon); and assessment of antibody biological activity or antigen-binding function. The instability can include any one or more of aggregation, deamidation (e.g., Asn deamidation), oxidation (e.g., Met oxidation), isomerization (e.g., Asp isomerization), shearing / hydrolysis / cleavage (e.g., hinge rupture), succinimide formation, unpaired cysteine, N-terminal extension, C-terminal processing, and catabolic glycosylation.
[0203] A stable conjugate should also "retain its biological activity" in the pharmaceutical formulation, e.g., the biological activity of the conjugate at a particular time, e.g., 12 months, should be within about 20%, preferably within about 10% (within the error of the assay) of the biological activity at the time the pharmaceutical formulation was prepared, as determined by, e.g., antigen binding assays and / or in vitro cytotoxicity assays.
[0204] For in vivo clinical use, the conjugates of the present invention are provided as solutions or as lyophilized solids that can be redissolved in sterile water for injection. A suitable conjugate administration protocol is as follows: the conjugate is administered intravenously as a bolus once daily, weekly, every two weeks, every three weeks, every four weeks, or once monthly for 8 to 54 weeks. The bolus dose is dissolved in 50 to 1000 mL of saline, to which human serum albumin can optionally be added (e.g., 0.5 to 1 mL of concentrated human serum albumin solution at 100 mg / mL). The drug dosage is approximately 50 μg to 20 mg / kg body weight per week, administered intravenously (each injection ranging from 10 μg to 200 mg / kg). After 4 to 54 weeks of treatment, patients can receive a second course of treatment. The exact treatment method, including the route of administration, excipients, diluents, dosage, and duration of treatment, can be determined by an experienced surgeon.
[0205] Examples of conditions that can be treated by selectively killing cell populations by in vivo or ex vivo methods include any type of cancer, autoimmune diseases, transplant rejection, and infectious diseases (including viral, bacterial, or parasitic).
[0206] The amount of conjugate required to achieve a desired biological effect will vary depending on many factors, including the chemical properties, potency and bioavailability of the conjugate, the type of disease, the patient's race, the patient's pathological condition, the route of administration, and all factors that determine the required dosage, delivery and regimen.
[0207] In general terms, the formulations of the present invention may be formulations for parenteral administration, containing the conjugate dissolved in a physiological buffer solution at a concentration of 0.1 to 10% w / v. Typical dosage ranges are 1 μg / kg body weight to 0.1 g / kg body weight daily, weekly, biweekly, triweekly, or monthly, with preferred dosage ranges being 0.01 mg / kg body weight to 20 mg / kg body weight weekly, biweekly, triweekly, or monthly. The preferred drug dosage may depend appropriately on variables such as the type and extent of progression of the disease or disorder, the overall health of the individual patient, the relative biological activity of the selected drug, the compound dosage form, the mode of administration (intravenous, intramuscular, or other), the pharmacokinetic properties of the drug in the selected mode of administration, and the administration rate (single injection or continuous infusion) and schedule (frequency of administration over a given period of time).
[0208] The conjugates of the present invention via a linker can also be administered in unit doses. Here, "unit dose" refers to a single dose administered to a single patient. This unit dose can be easily and conveniently packaged and maintains a physically and chemically stable unit dose, either as the active conjugate itself or as a pharmaceutically acceptable composition, as described below. Therefore, a typical daily dose range is 0.01 to 100 mg / kg body weight. Generally, the unit dose ranges from 1 to 3,000 mg per day, week, 2 weeks, 3 weeks, or month. A preferred unit dose is 1 mg to 500 mg administered 1 to 4 times per month, and more preferably 1 mg to 100 mg administered once per week, 2 weeks, or 3 weeks. The conjugates provided herein can be prepared by adding one or more pharmaceutically acceptable excipients to a pharmaceutical composition. The unit dosage of the drug can be administered as a tablet, simple capsule or soft capsule for oral administration; as a powder, nose drops or aerosol for intranasal administration; or as an ointment, cream, lotion, gel or spray or skin patch for dermal administration.
[0209] In yet another embodiment, a pharmaceutical composition comprising a therapeutically effective amount of a conjugate of Formula (I), (II), or (III) or any conjugate described in this patent can be administered simultaneously with other therapeutic agents such as chemotherapeutic agents, radiation therapy, immunotherapy agents, autoimmune disease agents, anti-infective agents, or other conjugates for the synergistically effective treatment or prevention of cancer, autoimmune diseases, or infectious diseases. The synergist is preferably selected from one or several of the following drugs: abatacept, abiraterone acetate, abraxane, acetaminophen / hydrocodone, acalabrutinib, aducanumab, adalimumab, ADXS31-142, ADXS-HER2, afatinib dimalate, aldesleukin, alectinib, alemtuzumab, alitretinoin, alpelisib, ado-trastuzumab emtansine, amphetamine / dextroamphetamine, analotinib, anastrozole, apalutamide, aripiprazole, anthracyclines, aripiprazole, atazanavir, atezolizumab, atorvastatin, avelumab, axicabtagene Ciloreucel, axitinib, belinostat, live BCG, bevacizumab, bexarotene, blinatumomab, bortezomib, bosutinib, brentuximab, vedotin, brigatinib, budesonide, budesonide / formoterol, buprenorphine, cabazitaxel, cabozatinib, camrelizumab, cammatinib, capecitabine, carfilzomib, chimeric antigen receptor-modified T (CAR-T) cells, celecoxib, ceritinib, cetuximab, chidamide, cyclosporine, cinacalcet, crizotinib, cobimetinib, Cosentyx, crizotinib, CTL019, dabigatran, dabrafenib, dacarbazine, daclizumab, dacomitinib, dacomitinib, daprazolam ... tomycin, daratumumab, darbepoetin alfa, darolutamide, darunavir, dasatinib, denileukin diftitox, denosumab, depakote, dexlansoprazole, dexmethylphenidate, dexamethasone, DigniCap Cooling System, dinutuximab, doxycycline, duloxetine, duvelisib, dalumabumab, elotuzumab, emtricibine / rilpivirine / tenofovir, disoproxil fumarate, emtricibine / tenofovir / efavirenz, enfortumabVedotin-ejfv, enoxaparin, ensartinib, entrectinib, enzalutamide, epoetin alfa, erlotinib, erdafitinib, esomeprazole, eszopiclone, etanercept, everolimus, exemestane, everolimus, exenatide ER, ezetimibe, ezetimibe / simvastatin, fam-trastuzumab Dulaxtecan, fenofibrate, filgrastim, fingolimod, fluticasone propionate, fluticasone / salmeterol, fulvestrant, Gadiva, gefitinib, glatiramer, goserelin acetate, icotinib, imatinib, ibritumomab tiusetan, ibrutinib, idelalisib, ifosfamide, infliximab, imiquimod, ImmuCyst, ImmunoBCG, iniparib, insulin aspart, insulin detemir, insulin glargine, insulin lispro, interferon alfa, interferon Interferon alfa-1b, interferon alfa-2a, interferon alfa-2b, interferon beta, interferon beta-1a, interferon beta-1b, interferon gamma-1a, lapatinib, ipilimumab, ipratropium bromide / salbutamol, ixazomib, Kanumab, lanreotide acetate, lenalidomide, lenalidomide, lenvatinib mesylate, letrozole, levothyroxine, lidocaine, linezolid, liraglutide, lisdexamfetamine, LN-144, loratinib, memantine, methylphenidate, metoprolol, mekinist, melicitabine / Rilpivirine / tenofovir, modafinil, mometasone, Mycidac-C, necitumumab, neratinib, nilotinib, niraparib, nivolumab, ofatumumab, obinutuzumab, olaparib, olmesartan, olmesartan / hydrochlorothiazide, omalizumab, omega-3 fatty acid ethyl esters, oncoline, oseltamivir, osimertinib, oxycodone, palbociclib, palivizumab, panitumumab, panobinostat, pazopanib, pembrolizumab, pexidartinib hydrochloride, PD-1 antibody, PD-L1 antibody, pemetrexed, pertuzumab, pneumococcal conjugate vaccine, polatuzumabVedotin, pomalidomide, pregabalin, ProscaVax, propranolol, quetiapine, rabeprazole, radium-223 chloride, raloxifene, raltegravir, ramucirumab, ranibizumab, relugolix, regorafenib, rituximab, rivaroxaban, romidepsin, rosuvastatin, ruxolitinib phosphate, salbutamol, savolitinib, semaglutide, selinexor, sevelamer, sildenafil, siltuximab, sipuleucel-T sel-T), sitagliptin, sitagliptin / metformin, solifenacin, solanezumab, sonidegib, sorafenib, sunitinib, tacrolimus, tadalafil, tamoxifen, Tafinlar, talimogenela herparepvec, talazoparib, telaprevir, talazoparib, temozolomide, tensirolimus, tenofovir / emtricitabine, tenofovir disoproxil fumarate, testosterone gel, thalidomide, TICE BCG, tiotropium bromide, tisagenlecleucel, toremifene, trametinib, trastuzumab, trastuzumab / hyaluronidase-oysk, trabectin (ecteinascidin 743), trametinib, tremelimumab, trifluridine / tipiracil, tretinoin, tislelizumab, uro-BCG, ustekinumab, valsartan, veliparib, vandetanib, vemurafenib, venetoclax, vorinostat, zanubrutinib, dib-aflibercept, and zostavax, and analogs, derivatives, pharmaceutically acceptable salts, carriers, diluents, or excipients thereof, or combinations thereof.
[0210] The drug / cytotoxic agent used in conjugation via the branched linkers of the present invention can be any analog and / or derivative of the amatoxins described herein. Those skilled in the art of drugs / cytotoxic agents will readily understand that each of the amatoxins described herein can be modified so that the resulting compound still retains the specificity and / or activity of the starting compound. Those skilled in the art will also understand that many of these analog or derivative compounds can be used in place of the drugs described herein. Thus, the drug analogs of the present invention include many analogs and derivatives not described in detail herein.
[0211] All references cited herein and in the examples below are expressly incorporated by reference in their entirety. [Example]
[0212] The present invention is further illustrated in the following examples, which are not intended to limit the scope of the invention. The cell lines described in the following examples were grown under conditions specified by the American Type Culture Collection (ATCC), the German Collection of Microbial and Cell Cultures (DSMZ), Braunschweig, Germany, or the Shanghai Institute of Cell Culture, Chinese Academy of Sciences, unless otherwise stated. Cells were maintained in culture medium. Unless otherwise stated, all cell culture reagents were provided by Invitrogen. All anhydrous reagents were commercially available and stored in nitrogen-sealed Sure-Seal bottles. PEG compounds were purchased from Biomatrik Inc., Jiaxing, China. Topotecan, maytansinol, MMAE, MMAF, exatecan, eribulin, and their derivatives or main components were purchased from several commercial sources, including Chengdu Tianyuan Natural Products Co., Ltd., Chengdu, China, and Brightgene Biomedical Co., Ltd., Suzhou, China. Experimental animals were provided by the National Resource Center through GemPharmatech Co., Ltd., Nanjing, China, and Shanghai SLAC Laboratory Animal Co., Ltd., Shanghai, China. T-DM1 was purchased from Roche via a pharmacy in Hong Kong, China. All other reagents and solvents were purchased according to the highest standards and used without further purification. Preparative HPLC separations were performed using Varain PreStar HPLC was performed. NMR spectra were recorded on a Bruker 500 MHz Instrument. Chemical shifts (Δ) are in ppm, referenced to tetramethylsilane at 0.00, and coupling constants (J) are in Hz. Mass spectrometry data were acquired on a Waters Xevo QTOF mass spectrometer equipped with a Waters Acquity UPLC separator and an Acquity TUV detector. Typically, UPLC separations were performed on a C8 column using mobile phase A: 1% formic acid and mobile phase B: 100% CH3CN.
[0213] Example 1: Synthesis of tert-butyl 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-oate (1) [ka]
[0214] To a solution of mPEG8-OH (38.4 g, 100 mmol) in THF (1.0 L) was added NaH (60%, 8.0 g, 200 mmol). After stirring at room temperature for 30 minutes, tert-butyl 2-bromoacetate (48.8 g, 250 mmol) was added and stirred at room temperature for 1 hour. The mixture was then poured into ice water and extracted with DCM. The organic layer was washed with brine and dried over anhydrous sodium sulfate. Purification by column chromatography (0% to 5% methanol / dichloromethane) afforded compound 1 as a yellow oil (27.6 g, 59% yield). ESI MS m / z 499.40 ([M + H] + ).
[0215] Example 2: Synthesis of 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-oic acid (2) [ka]
[0216] Compound 1 (29.4 g, 59.0 mmol) was dissolved in DCM (400 mL), and then formic acid (600 mL) was added. The resulting solution was stirred overnight at 25° C. All volatiles were The HCl was removed under vacuum to give the title product as a yellow oil (26.1 g, >100% yield). ESI m / z calculated C 19 H 39 O 11 [M+H] + : 443.24, measured value 443.25.
[0217] Example 3: Synthesis of Compound 3 [ka]
[0218] To a solution of compound 2 (59.0 mmol) in DCM (600 mL) was added (COCl) (100 mL) and DMF (41 g, 0.59 mmol). The resulting solution was stirred at room temperature for 4 hours. All volatiles were removed in vacuo to give the title product as a yellow oil. ESI MS m / z 461.38 ([M+H] + ).
[0219] Example 4: Synthesis of Compound 4 [ka]
[0220] ZL-Lys-OH (33.1 g, 118.0 mmol), Na2CO3 (18.7 g, 177.1 mmol), and NaOH (4.7 g, 118.0 mmol) were dissolved in water (700 mL). The mixture was cooled to 0 °C, and a THF solution (20 mL) of compound 3 (59.0 mmol) was added. The resulting mixture was stirred at room temperature for 1 h. THF was removed under vacuum, and concentrated HCl was added to the aqueous solution under ice cooling until the pH reached 3. After extraction with DCM, the organic layer was washed with brine, dried over sodium sulfate, and concentrated to give the title product as a yellow oil (44 g, 99% yield). ESI m / z calculated C 33 H 57 N2O 14 [M+H] + : 705.40, measured value 705.39.
[0221] Example 5: Synthesis of Compound 5 [ka]
[0222] Compound 4 (20 g, 28.4 mmol, 1.0 equiv.) was dissolved in 350 mL of anhydrous DCM and cooled in an ice-water bath. NHS (3.9 g, 34.1 mmol, 1.2 equiv.) and EDTA were added. C (27 g, 142.0 mmol, 5.0 equiv) was added in turn. The reaction was allowed to stand at room temperature overnight. The mixture was stirred, then washed with water (200 mL x 2), brine (200 mL x 1), dried over anhydrous sodium sulfate, and concentrated. The residue was dissolved in a small amount of DCM, loaded onto a silica gel column, and eluted with MeOH / EA / DCM / 2:49:49 to 4:48:48. The product was obtained as a yellow oil (14.2 g, 62% yield). ESI m / z calculated C 37 H 60 N3O 16 [M+H] + : 802.4,Actual value: 802.4.
[0223] Example 6: Synthesis of (2S,4R)-5-(3-amino-4-hydroxyphenyl)-4-((tert-butoxycarbonyl)-amino)-2-methylpentanoic acid (Compound 7) [ka]
[0224] A mixture of (2S,4R)-4-((tert-butoxycarbonyl)amino)-5-(4-hydroxy-3-nitrophenyl)-2-methylpentanoic acid (compound 6) (15 g, 0.041 mol, 1.0 equiv.) and palladium on carbon (2.0 g, 10 wt %) in 150 mL of methanol was stirred under a H balloon for 4 hours at room temperature. The catalyst was filtered off and washed with methanol. The filtrate was concentrated to give 13.8 g of crude material, which was used directly in the next step (yield >100%). ESI m / z calculated C 17 H 27 N2O5[M+H] + : 339.2, Actual value: 339.2.
[0225] Example 7: Synthesis of Compound 9 [ka]
[0226] To the crude product from the previous step (13.8 g, 0.041 mol, 1.0 equiv.) dissolved in 2 mL of ethanol and 0.2 mL of 0.1 M NaH2PO4, 2,5-dioxopyrrolidin-1-yl 4-(((benzyloxy)-carbonyl)amino)-butanoate (15.0 g, 0.054 mol, 1.1 equiv.) was added. The reaction mixture was stirred overnight, concentrated, redissolved in DCM, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column (0-5% MeOH / DCM) to give a yellow oil (14.9 g, 66% yield). ESI m / z calculated C 29 H 40 N3O8[M+H] + : 558.3, Actual value: 558.3.
[0227] Example 8: Synthesis of Compound 10 [ka]
[0228] Compound 9 (8.7 g, 15.08 mmol, 1.0 equiv.) and palladium on carbon (1.0 g, 10 wt.%) in 100 mL of methanol were stirred overnight at room temperature under a H balloon. The catalyst was filtered off and washed with methanol. The filtrate was evaporated in vacuo to give 6.4 g of crude material, which was used directly in the next step (yield >100%). ESI m / z calculated C 21 H 34 N3O6[M+H] + : 424.2, Actual value: 424.2.
[0229] Example 9: Synthesis of Compound 11 [ka]
[0230] To compound 10 (6.4 g, 15.1 mmol, 1.0 equiv.) in a mixture of 40 mL of ethanol and 10 mL of 0.1 M NaH2PO4 was added compound 5 (12.7 g, 15.9 mmol, 1.05 equiv.). The reaction mixture was stirred overnight, concentrated, dissolved in DCM, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column (3-5% MeOH / DCM) to give a white foam (11.7 g, 70% yield). ESI m / z calculated C 54 H 88 N5O 19 [M+H] + : 1110.6, Actual value: 1110.6.
[0231] Example 10: Synthesis of Compound 12 [ka]
[0232] A mixture of compound 11 (4.2 g, 3.79 mmol, 1.0 equiv.) and palladium on carbon (0.4 g, 10 wt.%) in 5 mL of methanol was stirred overnight at room temperature under a H balloon. The catalyst was filtered off and washed with methanol. The filtrate was evaporated to give 0.32 g of crude product, which was used directly in the next step (87% yield). ESI m / z calculated C 46 H 82 N5O 17 [M+H] + : 1997.1, Actual value: 1997.1.
[0233] Example 11: Synthesis of meso-2,3-bis(benzylamino)succinic acid (Compound 13) [ka]
[0234] To a solution of meso-2,3-dibromosuccinic acid (50 g, 181 mmol) in EtOH (400 mL) was added dropwise benzylamine (150 mL). After the addition was complete, the mixture was heated to 90° C. and stirred overnight. The mixture was cooled to room temperature and diluted with water. 6N HCl was added until a pH of 4 was reached, resulting in a white precipitate. The precipitate was filtered, rinsed with water, and dried to give meso-2,3-bis(benzylamino)succinic acid (50 g, 152 mmol, 84%).
[0235] Example 12: Synthesis of meso-2,3-diaminosuccinic acid [ka]
[0236] To a solution of meso-2,3-bis(benzylamino)succinic acid (18 g, 55 mmol) in AcOH (100 mL) and HCl (100 mL) was added Pd / C (3 g, 10 wt%), and the mixture was stirred at 50°C under 1 atm of hydrogen for 48 hours. The catalyst was removed by filtration and washed with water. The filtrate was concentrated, and the residue was dissolved in 1N NaOH (200 mL). Acetic acid was added until a pH of 5 was reached, giving a white precipitate. The precipitate was filtered, rinsed with water, and dried to give meso-2,3-diaminosuccinic acid (8.7 g, >100%).
[0237] Example 13: Synthesis of meso-2,3-bis(((benzyloxy)carbonyl)amino)succinic acid [ka]
[0238] To a solution of meso-2,3-diaminosuccinic acid (31.74 g, 214 mmol) in THF (220 mL) and 4N NaOH (214 mL) at 0°C, benzyl chloroformate (61 mL, 428 mmol) was added dropwise. After the addition was complete, the mixture was warmed to room temperature and stirred for 2 hours. The reaction was diluted with water (1600 mL) and washed with ethyl acetate (2 x 1500 mL). The aqueous layer was separated and acidified with concentrated HCl until a pH of 2 was reached. The resulting solution was stirred for 1 hour and allowed to stand at 5°C to give a white precipitate. The precipitate was filtered, rinsed with water, and dried to give meso-2,3-bis(((benzyloxy)carbonyl)amino)succinic acid (52.2 g, 125 mmol, 59%).
[0239] Example 14: Synthesis of dibenzyl ((3R,4S)-2,5-dioxotetrahydrofuran-3,4-diyl) dicarbamate [ka]
[0240] A solution of meso-2,3-bis(((benzyloxy)carbonyl)amino)succinic acid (5.0 g, 12 mmol) in AcO (37.5 mL) was refluxed for 20 min, cooled, and concentrated to give the anhydride. The diastereomeric mixture was treated with CHCl (37 mL), the insoluble meso isomer was filtered, and the filtrate was treated with petroleum ether to give crystals of dibenzyl ((3R,4S)-2,5-dioxotetrahydrofuran-3,4-diyl)dicarbamate (racemic mixture, 2.0 g, 5 mmol, 42%).
[0241] Example 15: Synthesis of Compound 17 [ka]
[0242] To a mixture of compound 16 (4.25 g, 10.68 mmol, 1.0 equiv.) and DMAP (13 mg, 0.11 mmol, 0.01 equiv.) in 20 mL of dry DCM was added t-butylaminobutyrate (1.78 g, 11.21 mmol, 1.05 equiv.) in 10 mL of anhydrous DCM. After the addition was complete, compound 16 was completely dissolved and the reaction was stirred overnight at room temperature. The crude product was loaded onto a silica gel column and eluted with 3-5% MeOH / DCM. The fractions were combined and evaporated, and the residue was triturated with PE / DCM (1:1) to give 3.3 g of a white solid (55.9% yield). ESI m / z calculated C 28 H 36 N3O9[M+H] + : 558.2, Actual value: 558.2.
[0243] Example 16: Synthesis of Compound 18 [ka]
[0244] In a 500 mL flask, H2N-PEG4-CH2CH2CO2H (3.0 g, 11.3 mmol, 1.0 equiv) and K2CO3 (4.7 g, 33.93 mmol, 3.0 equiv) were dissolved in 50 mL of water and cooled in an ice-water bath. Boc2O (3.2 g, 14.7 mmol, 1.3 equiv) in 50 mL of THF was added dropwise. The reaction was allowed to warm to room temperature and stirred overnight. The reaction mixture was adjusted to pH 4-5 with 1 N KHSO4, extracted with DCM (200 mL x 1, 100 mL x 3), washed with water (500 mL x 1) and brine (500 mL x 1), dried over anhydrous sodium sulfate, and concentrated. The residue was dissolved in a small amount of DCM and then loaded onto a silica gel column and eluted with 2-4% MeOH / DCM. The fractions were combined and concentrated to give 3.8 g of a colorless oil (93% yield). ESI m / z calculated C 16 H 32 NO8[M+H] + : 366.2, Actual value: 366.2.
[0245] Example 17: Synthesis of Compound 19 [ka]
[0246] In a 50 mL single-neck flask, BocHN-PEG-CHCHCOH (0.81 g, 2.22 mmol, 1.0 equiv.), KCO (0.92 g, 6.66 mmol, 3.0 equiv.), and NaI (0.033 g, 0.222 mmol, 0.1 equiv.) were mixed in 10 mL of DMF and cooled on an ice-water bath. BnBr (0.57 g, 3.33 mmol, 1.5 equiv.) was added dropwise, and the mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was diluted with 100 mL of water, extracted with DCM (100 mL × 2), washed with water (200 mL × 1) and brine (200 mL × 1), dried over anhydrous sodium sulfate, and concentrated. The residue was dissolved in a small amount of DCM, loaded onto a silica gel column, and eluted with 70-90% EA / PE to give 0.69 g of a colorless oil (69% yield).
[0247] Example 18: Synthesis of Compound 20 [ka]
[0248] A solution of BocHN-PEG-CHCHCOBn (0.69 g, 1.5 mmol, 1.0 equiv.) in 6 mL of DCM and 3 mL of TFA was stirred at room temperature for 30 min. The solvent was removed and the residue was co-evaporated with DCM three times and placed on a high vacuum pump. The crude product was used directly in the next reaction. ESI m / z calculated C 18 H 30 NO6[M+H] + : 356.2, Actual value: 356.2.
[0249] Example 19: Synthesis of Compound 21 [ka]
[0250] To a solution of BocHN-PEG-CHCHCOH (3.8 g, 10.4 mmol, 1.0 equiv.) in dry DCM (50 mL) was added NHS (1.4 g, 12.5 mmol, 1.2 equiv.) and EDC (10.0 g, 52.0 mmol, 5.0 equiv.). The reaction was stirred overnight at room temperature and then washed with water (50 mL x 2), brine (100 mL x 1), dried over anhydrous sodium sulfate, and concentrated. The crude product was used directly in the next step. ESI m / z calcd. C 20 H 35 N2O 10 [M+H] + : 463.2, Actual value: 463.2.
[0251] Example 20: Synthesis of Compound 22 [ka]
[0252] In a 300 mL flask, H2N-PEG4-CH2CH2CO2H (2.8 g, 10.4 mmol, 1.0 equiv.) and K2CO3 (4.3 g, 31.2 mmol, 3.0 equiv.) were dissolved in 40 mL of water and cooled in an ice-water bath. A solution of the crude NHS ester (3.8 g, 10.4 mmol, 1.0 equiv.) in THF (40 mL) was added dropwise, and the mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was adjusted to pH 4-5 using 1 N KHSO4, extracted with DCM (150 mL x 1, 100 mL x 2), and diluted with water (200 mL x 1) and brine. The residue was washed with 200 mL of HCl, dried over anhydrous sodium sulfate, and concentrated. The residue was dissolved in a small amount of DCM, loaded onto a silica gel column, and eluted with 4-6% MeOH / DCM to give a colorless oil (5.18 g, 81% yield). ESI m / z calculated C 27 H 53 N2O 13 [M+H] + : 613.3, Actual value: 613.3.
[0253] Example 21: Synthesis of Compound 23 [ka]
[0254] H2N-PEG4-CH2CH2CO2Bn (crude product from the previous step) was dissolved in 3 mL of DMF and cooled in an ice / water bath. DIPEA (0.78 g, 6.0 mmol, 4.0 equiv.) was added dropwise, followed by the addition of compound 22 (0.93 g, 1.5 mmol, 1.0 equiv.) and HATU (1.72 g, 4.5 mmol, 3.0 equiv.) in 7 mL of DMF. The reaction was stirred on an ice bath for 2 h, diluted with 100 mL of water, extracted with DCM (100 mL x 3), washed with 1 N KHSO4 (200 mL x 1), saturated sodium bicarbonate (200 mL x 1), and brine (200 mL x 1), dried over anhydrous sodium sulfate, and concentrated. The residue was dissolved in a small amount of DCM and loaded onto a silica gel column, eluting with 0-5% MeOH / DCM. The fractions were combined and concentrated to give 1.0 g of a pale yellow oil (71% yield). ESI m / z calculated C45 H 80 N3O 18 [M+H] + : 950.5, Actual value: 950.5.
[0255] Example 22: Synthesis of Compound 24 [ka]
[0256] A solution of compound 23 (1.0 g, 1.03 mmol, 1.0 equiv) in 6 mL of DCM and 3 mL of TFA was stirred at room temperature for 1 h. The solvent was removed and the residue was coevaporated with DCM three times and placed on a high vacuum pump.
[0257] The crude product was redissolved in 10 mL of DMF and cooled in an ice-water bath. DIPEA (0.53 g, 4.12 mmol, 4.0 equiv.), compound 17 (0.56 g, 1.03 mmol, 1.0 equiv.), and HATU (1.17 g, 3.09 mmol, 3.0 equiv.) were added sequentially. After stirring in the ice bath for 1 h, 100 mL of water was added, and a solid precipitated. The solid was collected by filtration, washed with water, dissolved in DCM, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was dissolved in a small amount of DCM, loaded onto a silica gel column, and diluted with 0-10% M HCl. Elution with eOH / DCM. Fractions were combined and concentrated to give 0.93 g of a pale yellow foam (65% yield). ESI m / z calculated C 68 H 107 N8O 26 [M+H] + : 1451.7, Actual value: 1451.7.
[0258] Example 23: Synthesis of Compound 25 [ka]
[0259] A solution of compound 24 (0.93 g, 0.67 mmol, 1.0 equiv) in 6 mL of DCM and 3 mL of TFA was stirred at room temperature for 1 h (reaction completion was monitored by LC-MS). The solvent was removed, and the residue was co-evaporated with DCM three times and placed on a high vacuum pump. The crude product was dissolved in a small amount of DCM, loaded onto a silica gel column, and then eluted with 15-20% MeOH / DCM. The fractions were combined and concentrated to give 0.53 g of the product as a white foam (60% yield). ESI m / z calculated C 64 H 99 N8O 26 [M+H] + : 1395.7, Actual value: 1395.7.
[0260] Example 24: Synthesis of Compound 26 [ka]
[0261] To compound 25 (0.53 g, 0.40 mmol, 1.0 equiv.) in 10 mL of DCM was added pentafluorophenol (0.081 g, 0.44 mmol, 1.1 equiv.) and EDC (0.38 g, 2.0 mmol, 5.0 equiv.). The reaction mixture was stirred overnight at room temperature, washed with cold water (5 mL x 2) and brine (10 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was used directly in the next step. ESI m / z calcd. C 70 H 98 F5N6O 26 [M+H] + : 1561.6, Actual value: 1561.6.
[0262] Example 25: Synthesis of Compound 27 [ka]
[0263] The crude product from the previous step (0.4 mmol, 1.0 equiv) was dissolved in 10 mL of DMF and cooled in an ice-water bath. To this was added compound 12 (0.39 g, 0.4 mmol, 1.0 equiv) and DIPEA (0.15 g, 1.2 mmol, 3.0 equiv) in sequence. After stirring in the ice bath for 1 h, the reaction was concentrated, redissolved in a small amount of DCM, loaded onto a silica gel column, and eluted with 0-20% MeOH / DCM to give a colorless oil (0.53 g, 58% yield). ESI m / z calculated C 110 H 176 N 11 O 40 [M+H] + : 2291.2, Actual value: 2291.2.
[0264] Example 26: Synthesis of Compound 28 [ka]
[0265] Compound 27 (0.53 g, 0.23 mmol, 1.0 equiv.) and dry palladium on carbon (0.1 g, 10% wt.) in 10 mL of methanol were stirred overnight at room temperature under a H balloon. The reaction mixture was filtered and the filtrate was evaporated to give 0.35 g of crude material, which was used directly in the next reaction (80% yield). ESI m / z calculated C 87 H 158 N 11 O 36 [M+H] + : 1933.1, Real Measurement: 1933.1.
[0266] Example 27: Synthesis of Compound 29 [ka]
[0267] The crude product from the previous step (0.35 g, 0.18 mmol, 1.0 equiv.) was redissolved in a mixture of 3 mL of ethanol and 0.2 mL of 0.1 M NaH2PO4, and N-(4-maleimidobutyryloxy)succinimide (0.20 g, 0.72 mmol, 4.0 equiv.) was added. The reaction mixture was stirred overnight at room temperature, then concentrated, redissolved in DCM, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was dissolved in a small amount of DCM, loaded onto a silica gel column, and eluted with 0-20% MeOH / DCM to give a colorless oil product (0.13 g, 33% yield). ESI m / z calculated C 103 H 172 N 13 O 42 [M+H] + : 2263.2, Actual value: 2263.2.
[0268] Example 28: Synthesis of Compound 30 [ka]
[0269] Compound 29 (0.13 g, 0.0574 mmol, 1.0 equiv) was dissolved in 2 mL of DCM and stirred with 2 mL of TFA at room temperature for 3 h. The solvent was removed, and the residue was coevaporated with DCM three times and placed on a high vacuum pump.
[0270] The crude product was redissolved in DMF and cooled on an ice-water bath. Pentafluorophenol (0.048 g, 0.0690 mmol, 1.0 equiv.) was added to the bath, followed by DIPEA (0.022 g, 0.172 mmol, 3.0 equiv.). The reaction was stirred on the ice bath for 1 h and then adjusted to pH 4-5 using formic acid. The mixture was concentrated, redissolved in a small amount of DCM, loaded onto a silica gel column, and eluted with PE / EA and MeOH / DCM (all containing 0.1% formic acid). The fractions were combined and concentrated to give 0.1 g of a yellow foam (70% yield). The product was further purified by preparative HPLC (45-50% MeCN / HO with 0.1% formic acid). The fractions were combined and concentrated to give a colorless oil (0.030 g, yield). The calculated ESI m / z value was C 123 H 204 N 17 O 45 S [M+H] + : 2671.4, Actual value: 2671.4.
[0271] Example 29: Synthesis of Compound 31 [ka]
[0272] To mPEG8-OH (10 g, 26 mmol, 1.0 equiv.) in 100 mL of anhydrous DCM was added, in order, TEA (10.5 g, 104 mmol, 4.0 equiv.), DMAP (32 mg, 0.26 mmol, 0.01 equiv.), and TsCl (14.9 g, 78 mmol, 3.0 equiv.) in an ice-water bath. The reaction was stirred at 0 °C for 10 min, then warmed to room temperature and stirred overnight. The reaction was washed with 1 N HCl (100 mL × 1), water (100 mL × 1), and brine (100 mL × 1), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was dissolved in a small amount of DCM, loaded onto a silica gel column, and eluted with EA / PE (5-100%) and 1-3% MeOH / DCM. The combined fractions were concentrated to give a yellow oil (11.6 g, 83% yield). ESI m / z calculated C 24 H 43 O 11 S [M+H] + : 539.2, measured Value: 539.2.
[0273] Example 30: Synthesis of Compound 32 [ka]
[0274] A mixture of compound 31 (11.6 g, 21.5 mmol, 1.0 equiv) and dibenzylamine (5.5 g, 27.8 mmol, 1.5 equiv) in 20 mL of anhydrous DMF was heated to 100 °C and stirred overnight. The reaction was diluted with 300 mL of DCM, washed with water (300 mL × 3) and brine (300 mL × 1), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified on a silica gel column (50-100% EA / PE) to give a pale yellow oil (8.2 g, 66% yield). ESI m / z calculated. ESI m / z calculated C 31 H 50 NO8[M+H] + : 564.3, Actual value: 564.3.
[0275] Example 31: Synthesis of Compound 33 [ka]
[0276] A solution mixture of compound 32 (8.6 g, 15.2 mmol, 1.0 equiv.) and dry palladium on carbon (0.9 g, 10 wt.%) in 100 mL of anhydrous methanol was refluxed overnight under a H balloon. The catalyst was filtered off and washed with methanol. The filtrate was evaporated to give 5.3 g of a colorless oil (90% yield). ESI m / z calculated for C17H38NO8 [M+H]+: 384.3, found: 384.3.
[0277] Example 32: Synthesis of Compound 34 [ka]
[0278] Compound 17 (1.6 g, 2.84 mmol, 1.0 equiv.) and compound 33 (1.2 g, 2.84 mmol, 1.0 equiv.) were dissolved in 5 mL of anhydrous DMF, and HATU (3.2 g, 8.52 mmol, 3.0 equiv.) and DIPEA (1.5 g, 11.36 mmol, 4.0 equiv.) were added sequentially in an ice-water bath. The reaction was stirred in the bath for 2 h, then 150 mL of water was added and extracted with DCM (150 mL x 1, 100 mL x 1). The organic phase was washed with 1 N HCl (200 mL x 1), saturated sodium bicarbonate (200 mL x 1), and brine (200 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was dissolved in a small amount of DCM, loaded onto a silica gel column, and eluted with 0-5% MeOH / DCM. The fractions were combined and concentrated to give 2.29 g of a white solid (87% yield). ESI m / z calculated C 45 H 71 N4O 16 [M+H] + : 923.5, Actual value: 923.5.
[0279] Example 33: Synthesis of Compound 35 [ka]
[0280] A solution of compound 34 (2.29 g, 2.48 mmol, 1.0 equiv) in a mixture of 5 mL of DCM and 5 mL of TFA was stirred at room temperature for 3 h. The solvent was removed, and the residue was coevaporated with DCM three times. The residue was dissolved in a small amount of DCM, loaded onto a silica gel column, and eluted with 5-8% MeOH / DCM. The fractions were combined and concentrated to give 2.09 g of a white solid (97% yield). ESI m / z calculated C 41 H 63 N4O 16 [M+H] + : 867.4, Actual value: 867.4.
[0281] Example 34: Synthesis of Compound 36 [ka]
[0282] To compound 35 (1.5 g, 1.73 mmol, 1.0 equiv.) in 10 mL of DCM on an ice-water bath, pentafluorophenol (0.35 g, 1.90 mmol, 1.1 equiv.) and EDC (1.7 g, 8.66 mmol, 5.0 equiv.) were added. The reaction was warmed to room temperature and stirred for 5 hours, then washed with water (10 mL x 2) and brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated to give 1.07 g of crude product (60% yield). ESI m / z calculated C 47 H 62 F5N4O 16 [M+H] + : 1033.4, Actual value: 1033.4.
[0283] Example 35: Synthesis of Compound 37 [ka]
[0284] To the above crude product (1.07 g, 1.0 mmol, 1.0 equiv) in 10 mL of DMF was added compound 12 (0.92 g, 1.0 mmol, 1.0 equiv) and DIPEA (0.39 g, 3.0 mmol, 3.0 equiv) in an ice-water bath. The reaction was stirred in the bath for 1 h, adjusted to pH 4-5 using 1N HCl, diluted with EA (100 mL), and extracted with water (30 mL x 5). The aqueous phase was concentrated, then redissolved in a small amount of DCM and loaded onto a silica gel column, eluting with 15-18% MeOH / DCM. The combined fractions were concentrated to give 0.88 g of a colorless oil (51% yield). ESI m / z calculated C 87 H 142 N9O 32 [M+H] + : 1825.0, Actual value: 1825.0.
[0285] Example 36: Synthesis of Compound 38 [ka]
[0286] A mixture of compound 37 (0.88 g, 0.48 mmol, 1.0 equiv.) and palladium on carbon (0.1 g, 10 wt.%) in 5 mL of methanol was stirred overnight at room temperature under a H balloon. The catalyst was filtered, and the filtered solution was concentrated to give 0.75 g of crude material, which was used directly in the next reaction (80% yield). ESI m / z calculated C 71 H 130 N9O 28 [M+H] + : 1556.9, Actual value: 1556.9.
[0287] Example 37: Synthesis of Compound 39 [ka]
[0288] The crude product from the previous step (0.75 g, 0.48 mmol, 1.0 equiv) was dissolved in a mixture of 2 mL of ethanol and 0.2 mL of 0.1 M NaH2PO4, and N-(4-maleimidobutyryloxy)succinimide (0.54 g, 1.92 mmol, 4.0 equiv) was added. The reaction mixture was stirred overnight at room temperature, then concentrated, redissolved in DCM, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was dissolved in a small amount of DCM, loaded onto a silica gel column, and eluted with 0-20% MeOH / DCM to give a colorless oil (0.26 g, 29% yield). ESI m / z calculated C 87 H 144 N 11 O 34 [M+H] + : 1887.0, Actual value: 1887.0.
[0289] Example 38: Synthesis of Compound 40 [ka]
[0290] Compound 39 (0.26 g, 0.138 mmol, 1.0 equiv) in 3 mL of DCM and 1 mL of TFA was stirred at room temperature for 1 h. The solvent was removed and the residue was coevaporated with DCM three times and placed on a high vacuum pump.
[0291] The crude product was redissolved in 5 mL of DMF and cooled in an ice-water bath. Tub-PFP (0.114 g, 0.166 mmol, 1.2 equiv.) and DIPEA (0.265 g, 2.07 mmol) were added. The reaction was stirred on the ice bath for 1 h and then adjusted to pH 4-5 using formic acid. The mixture was concentrated, redissolved in a small amount of DCM, loaded onto a silica gel column, and eluted with PE / EA and MeOH / DCM (all containing 0.1% formic acid). The combined fractions were concentrated to give 0.2 g of a yellow foam (63% yield). The product was further purified by preparative HPLC (45-50% MeCN / HO with 0.1% formic acid). The combined fractions were concentrated to give a colorless oil (0.10 g, 23% yield). ESI m / z calculated C 107 H 176 N 15 O 37 S [M+H] + : 2295.2, Actual value: 2295.2.
[0292] Example 39: Synthesis of Compound 41 [ka]
[0293] To a solution of benzyl 11-aminoundecanoate (2.91 g, 10.0 mmol) and Boc-Glu(OBzl)-OH (3.37 g, 10.0 mmol) in DMF (50 mL) was added EDC (1.91 g, 12.0 mmol) and TEA (3.5 mL, 25.0 mmol). The reaction was stirred at room temperature for 8 hours, diluted with water (100 mL), and extracted with EA (3 × 100 mL). The combined organic phase was washed once with 100 mL of brine, then dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by SiO column chromatography (EA / DCM, 1:15) to give the title compound as a colorless oil (5.37 g, 88% yield).
[0294] Example 40: Synthesis of Compound 42 [ka]
[0295] Compound 41 (0.64 g, 1.05 mmol, 1.0 equiv) in a mixture of 5 mL of DCM and 2 mL of TFA was stirred at room temperature for 2 hours and then concentrated. The residue was coevaporated with DCM three times and placed under high vacuum pump. ESI m / z calculated C 30 H 42 N2O5[M+H] + : 511.3, Actual value: 511.3.
[0296] The crude product from above was redissolved in 3 mL of DMF and cooled in an ice-water bath. To this was added a solution of compound 22 (0.64 g, 1.05 mmol, 1.0 equiv.) in 7 mL of DMF, followed by DIPEA (0.54 g, 4.20 mmol, 4.0 equiv.) and HATU (1.2 g, 3.15 mmol, 3.0 equiv.). The reaction was stirred on the bath for 1 h, then 100 mL of water was added and extracted with DCM (150 mL x 1, 100 mL x 1). The organic phase was washed with 1 N KHSO4 (200 mL x 1), saturated sodium bicarbonate (200 mL x 1), and brine (200 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was dissolved in a small amount of DCM, loaded onto a silica gel column, and then eluted with 0-10% MeOH / DCM. The fractions were combined and concentrated to give 0.94 g of a pale yellow oil (81% yield). ESI m / z calculated C 57 H 92 N4O 17 [M+H] + : 1104.6, Actual value: 1104.6.
[0297] Example 41: Synthesis of Compound 43 [ka]
[0298] Compound 42 (0.94 g, 0.458 mmol, 1.0 equiv) in a mixture of 7 mL of DCM and 3 mL of TFA was stirred at room temperature for 2 hours and concentrated. The residue was co-evaporated with DCM three times and then placed under high vacuum pump. ESI m / z calculated C 52 H 84 N4O 15 [M+H] + : 1004.6, real Measurement: 1004.6.
[0299] The crude compound from above was redissolved in 10 mL of DMF, cooled on an ice-water bath, and to this was added compound 17 (0.46 g, 0.85 mmol, 1.0 equiv.), DIPEA (0.44 g, 3.40 mmol, 4.0 equiv.), and HATU (0.97 g, 2.55 mmol, 3.0 equiv.). The reaction was stirred on the bath for 1 hour, then 100 mL of water was added, and a solid precipitated. The solid was collected by filtration, washed with water, dissolved in DCM, and dried over anhydrous sodium sulfate. The crude product was dried, filtered, and concentrated. The crude product was dissolved in a small amount of DCM, loaded onto a silica gel column, and eluted with 0-10% MeOH / DCM. The fractions were combined and concentrated to give 1.13 g of a pale yellow oil product (87% yield). ESI m / z calculated C 80 H 120 N9O 24 [M+H] + : 1590.8, Actual value: 1590.8.
[0300] Example 42: Synthesis of Compound 44 [ka]
[0301] Compound 43 (1.13 g, 0.73 mmol, 1.0 equiv) in a mixture of 7 mL of DCM and 3 mL of TFA was stirred at room temperature for 3 h and concentrated. The residue was coevaporated with DCM three times, dissolved in a small amount of DCM, loaded onto a silica gel column, and eluted with 5-15% MeOH / DCM. The combined fractions were concentrated to give 0.85 g of a white foam (78% yield). ESI m / z calculated C 76 H 112 N9O 25 [M+H] + : 1550.8, Actual value: 1550.8.
[0302] Example 43: Synthesis of Compound 45 [ka]
[0303] To compound 44 (0.85 g, 0.57 mmol, 1.0 equiv.) in 10 mL of DCM was added pentafluorophenol (0.11 g, 0.63 mmol, 1.1 equiv.) and EDC (0.55 g, 2.85 mmol, 5.0 equiv.) in an ice-water bath. The reaction mixture was warmed to room temperature and stirred overnight, then washed with ice water (10 mL × 2) and cold brine (20 mL × 1), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was used directly in the next step.
[0304] Example 44: Synthesis of Compound 46 [ka]
[0305] To the above crude product (0.94 g, 0.57 mmol, 1.0 equiv.) in 10 mL of DMF on an ice-water bath, compound 12 (0.56 g, 0.57 mmol, 1.0 equiv.) and DIPEA (0.22 g, 1.71 mmol, 3.0 equiv.) were added. The reaction mixture was stirred on the bath for 3 h and concentrated. It was then redissolved in a small amount of DCM, loaded onto a silica gel column, and eluted with 12-20% MeOH / DCM. The combined fractions were concentrated to give 1.00 g of a colorless oil (71% yield). ESI m / z calculated C 122 H 189 N 12 O 39 [M+H] + : 2446.3, Actual value: 2446.3.
[0306] Example 45: Synthesis of Compound 47 [ka]
[0307] Compound 46 (0.53 g, 0.23 mmol, 1.0 equiv) was dissolved in 5 mL of methanol, dried palladium on carbon (0.1 g, 10 wt%) was added, and the reaction was stirred overnight at room temperature under a H balloon. The catalyst was filtered, and the filtrate was evaporated to give 0.71 g of crude material (87% yield). ESI m / z calculated C 92 H 165 N 12 O 35 [M+H] + : 1997.1, Actual value: 1997.1.
[0308] The crude product from above (0.71 g, 0.355 mmol, 1.0 equiv) was redissolved in 2 mL of ethanol and 0.2 mL of 0.1 M NaH2PO4, N-(4-maleimidobutyryloxy)succinimide (0.40 g, 1.42 mmol, 4.0 equiv) was added, and the reaction mixture was stirred overnight at room temperature, concentrated, and purified on a preparative C-18 HPLC column eluting with 0-40% MeOH / HO to give a colorless oil (0.26 g, 33%). ESI m / z calculated C 108 H 179 N 14 O 41 [M+H] + : 2328.2, Actual value: 2328.2.
[0309] Example 46: Synthesis of Compound 48. [ka]
[0310] Compound 47 (0.26 g, 0.112 mmol, 1.0 equiv) in a mixture of 2 mL of DCM and 2 mL of TFA was stirred at room temperature for 3 h. The solvent was removed and the residue was co-evaporated with DCM three times and placed on a high vacuum pump. ESI m / z calculated C 103 H 171 N 14 O 39 [M+H] + : 2228.2, Actual value: 2228.2.
[0311] The crude product from above was redissolved in 5 mL of DMF and cooled in an ice-water bath. Tub-PFP (0.0.93 g, 0.134 mmol, 1.2 equiv) was added, followed by DIPEA (0.043 g, 0.336 mmol, 3.0 equiv). The reaction was stirred on the ice bath for 1 h and then adjusted to pH 4-5 using formic acid. The mixture was concentrated, redissolved in a small amount of DCM, loaded onto a silica gel column, and eluted with PE / EA and MeOH / DCM (with 0.1% formic acid). The combined fractions were concentrated to give 0.09 g of a yellow foam. The product was dissolved in 50:50 MeOH / HO (2 mL) and further purified by preparative HPLC (45-50% MeCN / HO with 0.1% formic acid). The combined fractions were concentrated to give a colorless oil (0.027 g, 15% yield). ESI m / z calculated C 128 H 211 N 18 O 44 S [M+H] + : 2736.4, Actual value: 2736.4.
[0312] Example 47: Synthesis of (S)-3,4-dimethyloxazolidine-2,5-dione (NCA) [ka]
[0313] (S)-2-((tert-butoxycarbonyl)(methyl)amino)propanoic acid (5.0 g, 24.6 mmol) was dissolved in dichloromethane (95 mL) and stirred in an ice / water bath for 15 minutes. After cooling, triphosgene (8.7 g, 29.6 mmol, 1.2 equiv.) was added dropwise over approximately 5 minutes. After the addition was complete, the ice bath was removed and the reaction was stirred at room temperature for an additional 4 hours. The reaction mixture was allowed to proceed. The solution was reduced under pressure and carbon tetrachloride (130 mL) was added to precipitate the product. The white precipitate was collected by filtration and washed with the remaining carbon tetrachloride. After a few minutes, the crystals turned yellow. The yellow crystals were redissolved in a small amount of dichloromethane and the yellow gunk was removed by filtration. The filtrate (product) was then precipitated with carbon tetrachloride and filtered. The crystals were dried on the filter at ambient temperature for 3 hours to give the title product (2.3 g, 69% yield). ESI MS, 130.05 (M+1) + .
[0314] Example 48: Synthesis of May-NMA [ka]
[0315] Maytansinol (200 mg, 0.354 mmol) was dissolved in DMF (5 mL) and THF (2.5 mL) and cooled in an ice / water bath. After several minutes, DIPEA (0.25 mL, 1.42 mmol, 4 equiv.) and zinc triflate (6 equiv.) were added using a magnetic stirrer, followed by NCA (183 mg, 1.42 mmol, 4 equiv.), and the reaction was stirred at room temperature under argon for 17 h. The reaction was diluted with 20 mL of EtOAc and treated with a solution of 1:1 brine:saturated sodium bicarbonate (4.4 mL). The resulting solution was stirred for 10 min. The white precipitate was filtered off, and the resulting aqueous solution was re-extracted with 20 mL of EtOAc. The organic layer was then washed with brine. The resulting organic layer was concentrated to give the crude product (210 mg, approximately 91% yield, 87% purity by HPLC) for the next step without further purification. ESI m / z calculated C 32 H 45 ClN3O9[M+H] + : 650.28, Actual value: 650.29.
[0316] Example 49: Synthesis of (S)-tert-butyl 34-(((benzyloxy)carbonyl)amino)-28,35-dioxo-2,5,8,11,14,17,20,23,26-nonaoxa-29,36-diazatetracontan-40-oate (210) [ka]
[0317] To a mixture of tert-butyl 4-aminobutanoate (1.03 g, 6.12 mmol) and compound 4 (3.91 g, 5.56 mmol) in DMF (18 mL) at 0 °C, HATU (2.32 g, 6.12 mmol) and TEA (1.2 mL, 8.34 mmol) were added sequentially. The reaction was stirred for 1 h, then diluted with water (300 mL) and extracted with ethyl acetate (3 × 250 mL). The organic solution was washed with brine and dried over anhydrous sodium sulfate. The mixture was then filtered, concentrated, and purified by silica gel column chromatography (32:1 dichloromethane / methanol) to give the title compound (210) (5.10 g, 99% yield). ESI MS m / z 846.50 ([M+H] + ).
[0318] Example 50: Synthesis of (S)-tert-butyl 34-amino-28,35-dioxo-2,5,8,11,14,17,20,23,26-nonaoxa-29,36-diazatetracontan-40-oate (211) [ka]
[0319] Compound 210 (1.0 g, 1.18 mmol) and Pd / C (10 wt%, 0.10 g) were added to a hydrogenation bottle containing methanol (50 mL). The mixture was shaken for 2 h, filtered through Celite (filter aid), and the filtrate was concentrated to give compound 211 (0.93 g, >100% yield). ESI MS m / z 712.50 ([M+H] + ).
[0320] Example 51: Synthesis of (S)-tert-butyl 34-(4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanamido)-28,35-dioxo-2,5,8,11,14,17,20,23,26-nonaoxa-29,36-diazatetracontan-40-oate (212) [ka]
[0321] To a solution of compound 211 (0.93 g, 1.18 mmol) in 95% EtOH (50 mL) and NaH2PO4 solution (0.1 M, pH 5.0, 10 mL) was added N-succinimidyl 4-maleimidobutyrate (0.50 g, 1.77 mmol, 1.5 equiv.). The mixture was stirred overnight, then concentrated, diluted with water (50 mL), extracted with dichloromethane (80 mL x 3), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (25:1 dichloromethane / methanol) to give the title compound as a pale yellow oil (0.82 g, 80%). ESI MS m / z 877.52 ([M+H] + ).
[0322] Example 52: Synthesis of (S)-34-(4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanamido)-28,35-dioxo-2,5,8,11,14,17,20,23,26-nonaoxa-29,36-diazatetracontan-40-oic acid (213) [ka]
[0323] Compound 212 (0.82 g, 0.94 mmol) was dissolved in HCOOH (50 mL) and stirred at room temperature for 1 h. The reaction mixture was concentrated and coevaporated twice with toluene, and the residue was placed on a vacuum pump to give compound 213 (0.80 g, crude). ESI MS m / z 820.45 ([M+H]+ ).
[0324] Example 53: Synthesis of (S)-2,5-dioxopyrrolidin-1-yl 34-(4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanamide)-28,35-dioxo-2,5,8,11,14,17,20,23,26-nonaoxa-29,36-diazatetracontan-40-oate (214) [ka]
[0325] To a solution of compound 213 (0.80 g, crude, 0.94 mmol) in DMA (5.0 mL) were added NHS (0.12 g, 1.03 mmol) and EDC·HCl (0.27 g, 1.41 mmol). The reaction was stirred at room temperature for 2 h, then diluted with water (15 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic phase was washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified on a silica gel column (10-50% ethyl acetate / petroleum ether) to give a colorless oily compound (0.67 g, 78% yield). ESI MS m / z 918.55 ([M+H] + ).
[0326] Example 54: Synthesis of tert-butyl (2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)carbamate (215) [ka]
[0327] A mixture of N-Boc-ethylenediamine (5.6 mL, 35.4 mmol, 1.1 equiv.) and saturated NaHCO3 (60 mL) was cooled to 0 °C, and N-methoxycarbonylmaleimide (5.00 g, 32.2 mmol, 1.0 equiv.) was added portionwise. After stirring at 0 °C for 30 min, the reaction was warmed to room temperature and stirred for 1 h. The precipitate was collected by filtration, washed with cold water, then dissolved in ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, and concentrated to give a white solid (6.69 g, 87% yield). ESI MS m / z 241.12 ([M+H] + ).
[0328] Example 55: Synthesis of tert-butyl (2-(1,3-dioxo-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindol-2(3H)-yl)ethyl)carbamate (216) [ka]
[0329] In a high-pressure tube, a solution of compound 215 (6.00 g, 25.0 mmol) and furan (18.0 mL) in toluene (120 mL) was heated to reflux and stirred for 16 hours. The colorless solution turned yellow during the reaction. The mixture was then cooled to room temperature and concentrated. The resulting white solid was triturated with ethyl ether to give compound 216 (6.5 g, 84% yield). ESI MS m / z 309.13 ([M+H] + ).
[0330] Example 57: Synthesis of 2-(2-aminoethyl)-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione hydrochloride (217) [ka]
[0331] A solution of compound 216 (9.93 g, 32.2 mmol) in dioxane (15 mL) was treated with concentrated HCl (15 mL) at room temperature for 3 hours. The reaction was concentrated, and the resulting solid was collected by filtration. The filter cake was washed with ethyl acetate. The solid was dried in an oven (50 °C) overnight to give compound 217 (6.94 g, 88% yield). ESI MS m / z 206.05 ([M+H] + ).
[0332] Example 58: Synthesis of Compound 218 [ka]
[0333] To a solution of compound 217 (1.22 g, 5 mmol) in THF (10 mL) was added POCl3 (0.47 mL, 5 mmol) at -10 °C. After stirring for 10 min, 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-amine (2.14 g, 5 mmol) was added, followed by DIPEA (0.87 mL, 5 mmol). The reaction was warmed to 0 °C and stirred for 3 h, then concentrated. The residue was diluted with dichloromethane (10 mL), filtered through Celite, and the filtrate was used directly in the next step. ESI MS m / z 716.29 ([M+H] + ).
[0334] Example 59: Synthesis of methyl 4-(bis(2-hydroxyethyl)amino)-4-oxobutanoate (219) [ka]
[0335] Dimethyl succinate (20.0 g, 136.9 mmol) and dihydroxyethylamine (7.20 g, 68.7 mmol) in a mixture of anhydrous toluene (500 mL) and pyridine (50 mL) were heated at 150 °C for 28 h. The mixture was concentrated and purified on a silica gel column eluted with 5-25% ethyl acetate / dichloromethane to give the title compound (12.5 g, 83% yield). ESI MS m / z 242.42 [M+Na] + .
[0336] Example 60: Synthesis of methyl 4-(bis(2-((methylsulfonyl)oxy)ethyl)amino)-4-oxobutanoate (220) [ka]
[0337] To a solution of methyl 4-(bis(2-hydroxyethyl)amino)-4-oxobutanoate (12.0 g, 49.56 mmol) in anhydrous pyridine (350 mL) was added methanesulfonyl chloride (20.0 g, 175.4 mmol). After stirring overnight, the mixture was concentrated, diluted with ethyl acetate (350 mL), and washed with cold 1 M NaH2PO4 (2 x 300 mL). The crude product was used in the next step without further purification. ESI MS m / z 376.06 ([M+H] + ).
[0338] Example 61: Synthesis of 3,6-endoxo-Δ-tetrahydrophthalimide (221) [ka]
[0339] To a solution of maleimide (10.0 g, 103.0 mmol) in toluene (200 mL) was added furan (10.0 mL, 137.4 mmol). The mixture was heated at 100° C. in a 1 L autoclave bomb for 8 hours. The bomb was cooled to room temperature, and the solid was rinsed with methanol, concentrated, and crystallized from ethyl acetate / hexane to give 16.7 g (99%) of the title compound. 1 H NMR (CDCl3): 11.12 (s, 1H), 6.68-6.64 (m, 2H), 5.18-5.13 (m, 2H), 2.97-2.92 (m, 2H). ESI MS m / z [M + Na] + 188.04.
[0340] Example 62: Synthesis of methyl 4-((2-((3aR,4R,7S,7aS)-1,3-dioxo-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindol-2(3H)-yl)ethyl)(2-((4R,7S,7aS)-1,3-dioxo-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindol-2(3H)-yl)ethyl)amino)-4-oxobutanoate (222) [ka]
[0341] To a solution of methyl 4-(bis(2-((methylsulfonyl)oxy)ethyl)amino)-4-oxobutanoate (220, freshly prepared, 90% purity, 8.5 g, ~20 mmol) in DMA (350 mL) was added 3,6-endo-oxo-Δ-tetrahydrophthalimide (10.2 g, 61.8 mmol), sodium carbonate (8.0 g, 75.5 mmol), and sodium iodide (0.3 g, 2.0 mmol). The mixture was stirred overnight at room temperature, concentrated, diluted with ethyl acetate (350 mL), and washed with saturated NaHCO3 solution (300 mL), saturated NaCl solution...
Claims
1. Side-chain linked conjugate compounds of formula (I): 【Chemistry 1】 During the ceremony, 【Chemistry 2】 represents a single bond; n is 1 to 30; T is a cell binding agent / molecule selected from the group consisting of an antibody; a single chain antibody; an antibody fragment that binds to a target cell; a monoclonal antibody; a single chain monoclonal antibody; or a monoclonal antibody fragment that binds to a target cell; a chimeric antibody; a chimeric antibody fragment that binds to a target cell; a domain antibody; a domain antibody fragment that binds to a target cell; L 1 and L 2 are independently the same or different, O, NH, N, S, P, NNH, NHNH, N(R 12 ), N(R 12 ) N (R 12’ ), CH, CO, C(O)NH, C(O)O, NHC(O)NH, NHC(O)O, formula (OCH 2 CH 2 ) p OR 12 , (OCH 2 CH-(CH 3 )) p OR 12 , NH(CH 2 CH 2 O) p R 12 , NH(CH 2 CH (CH 3 ) O) p R 12 , N[(CH 2 CH 2 O) p R 12 ]-[(CH 2 CH 2 O) p’ R 12’ ], (OCH 2 CH 2 ) p COOR 12 , or C.H. 2 CH 2 (O.C.H. 2 CH 2 ) p COOR 12 where p and p′ are independently an integer selected from 0 to about 1000, or a combination thereof; 1 -C 8 Alkyl; C 2 -C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 -C 8 Aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or (Aa)r, where r=1-12 (1 to 12 amino acid units) composed of natural or unnatural amino acids, or the same or different dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, decapeptide, undecapeptide, or dodecapeptide units; W is a C 1 -C 8 extension unit including a peptide unit, hydrazone, disulfide, thioether, ester, or amide bond; w is 1, 2, or 3; V 1 and V 2 are independently spacer units, O, NH, S, C 1 -C 8 Alkyl, C 2 -C 8 Heteroalkyl, alkenyl, or alkynyl, C 3 -C 8 aryl, heterocycle, carbocycle, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroaralkyl, heteroalkylcycloalkyl, or alkylcarbonyl, or (Aa) r (r=1-12 (1 to 12 amino acid units) and composed of natural or unnatural amino acids, or the same or different dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, decapeptide, undecapeptide, or dodecapeptide units); or (CH 2 CH 2 O) p (p; 0-1000); and v 1 and v 2 is independently 0, 1, or 2, 1 and v 2 is simultaneously 0; 1 Or v 2 is 0, it means that one of the side chains Q1 or Q2 fragments is absent; Q 1 and Q. 2 are independently represented by formula (I-q1): 【Chemistry 3】 During the ceremony, 【Chemistry 4】 L 1 Or L 2 is the binding site for G 1 and G 2 are each independently OC(O), NHC(O), C(O), or CH 2 , NH, OC(O)NH, NHC(O)NH, O, S, B, P(O)(OH), NHP(O)(OH), NHP(O)(OH)NH, CH 2 P(O)(OH)NH, OP(O)(OH)O, CH 2 P(O)(OH)O, NHS(O) 2 , N.H.S. (O) 2 N.H., C.H. 2 S (O) 2 NH, OS (O) 2 O, C.H. 2 S (O) 2 O, Ar, ArCH 2 , ArO, ArNH, ArS, ArNR12, or (Aa) q1 is; G 3 は、OH、SH、OR 12 、SR 12 、OC(O)R 12 、NHC(O)R 12 、C(O)R 12 、CH 3 、NH 2 、NR 12 、 + NH(R 12 )、 + N(R 12 )(R 12’ )、C(O)OH、C(O)NH 2 、NHC(O)NH 2 、BH 2 、BR 12 R 12’ 、P(O)(OH) 2 、NHP(O)(OH) 2 、NHP(O)(NH 2 ) 2 、S(O) 2 (OH)、(CH 2 ) q1 C(O)OH、(CH 2 ) q1 P(O)(OH) 2 、C(O)(CH 2 ) q1 C(O)OH、OC(O)(CH 2 ) q1 C(O)OH、NHC(O)(CH 2 ) q1 C(O)OH、CO(CH 2 ) q1 P(O)(OH) 2 、NHC(O)O(CH 2 ) q1 C(O)OH、OC(O)NH(CH 2 ) q1 C(O)OH、NHCO(CH 2 ) q1 -P(O)(OH) 2 、NHC(O)(NH)(CH 2 ) q1 C(O)OH、CONH(CH 2 ) q1 P(O)(OH) 2 、NHS(O) 2 (CH 2 ) q1 C(O)OH, CO(CH 2 ) q1 S (O) 2 (OH), NHS (O) 2 NH (CH 2 ) q1 C(O)OH, OS(O) 2 NH (CH 2 ) q1 C(O)OH, NHCO(CH 2 ) q1 S (O) 2 (OH), NHP(O)(OH)(NH)(CH 2 ) q1 C(O)OH, CONH(CH 2 ) q1 S(O)(OH), OP(O)(OH) 2 , (CH 2 ) q1 P(O)(NH) 2 , N.H.S. (O) 2 (OH), NHS (O) 2 N.H. 2 , C.H. 2 S (O) 2 N.H. 2 , OS(O) 2 OH, OS (O) 2 OR12, CH 2 S (O) 2 OR 12 , Ar, ArR 12 , ArOH, ArNH 2 , ArSH, ArNHR 12 Or (Aa) q1 (Aa) q1 is a peptide containing the same or different natural or unnatural amino acids; X 1 and X 2 are independently O, CH 2 , S, S(O), NHNH, NH, N(R 12 ), + NH (R 12 ), + N (R 12 ) (R 12’ ), C(O), OC(O), OC(O)O, OC(O)NH, NHC(O)NH; Y 2 O, NH, NR 12 , C.H. 2 , S, NHNH, Ar; 1 , p 2 , and p 3 are independently 0 to 100, but p 1 and p 3 are not 0 at the same time; q 1 and q 2 are independently 0 to 24; R 12 , R 12’ , R 13 , and R 13’ are independently H, C 1 ~C 8 Alkyl; C 2 ~C 8 Heteroalkyl or heterocycle; C 3 ~C 8 Ar is aryl, Ar-alkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, carbocycle, or alkylcarbonyl; Or, Q. 1 and Q. 2 are independently linear or branched, C 2 -C 100 Polycarboxylic acids, C 2 -C 90 Polyalkylamines, C 6 -C 90 C consisting of oligosaccharides or polysaccharides, quaternary ammonium cations and / or sulfonate anions 6 -C 100 zwitterionic betaine or zwitterionic poly(sulfobetaine)) (PSB), or poly(lactic / glycolic acid) (PLGA), poly(acrylate), chitosan, copolymers of N-(2-(2-hydroxypropyl)methacrylamide, poly[2-(methacryloyloxy)ethylphosphorylcholine] (PMPC), poly-L-glutamic acid, poly(lactide-co-glycolide) (PLG), poly(lactide-co-glycolide), poly(ethylene glycol) (PEG), poly(propylene glycol) (PPG), poly(lactide-co-glycolide), poly(ethylene glycol) modified peptides, poly(ethylene and poly(ethylene glycol)-modified alkyl esters, poly(ethylene glycol)-modified phosphates, poly(ethylene glycol)-modified quaternary ammonium salts, poly(ethylene glycol)-modified phosphate ... 6 -C 100 It is a biodegradable polymer; Or W, Q 1 , Q 2 , L 1 , L 2 , V 1 , or V 2 Any one or more of may be independently absent, 1 and Q. 2 but at the same time not non-existent; D is a cytotoxic agent independently selected from calicheamicins, maytansinoids, camptothecins, taxanes, anthracyclines (daunorubicin / doxorubicin), vinca alkaloids, auristatins, eribulins, (pyrrolo)benzodiazepines (PBDs), CC-106 / duocarmycins, tubulysins, amatoxins, protein kinase inhibitors, MEK inhibitors, KSP inhibitors, nicotinamide phosphoribosyltransferase (NAMPT) inhibitors, and immunotoxins.
2. Side-chain linked conjugate compounds of formula (II) or (III): 【Chemistry 5】 In the formula, D, W, L 1 , L 2 , Q 1 , Q 2 , V 1 , V 2 , v 1 , v 2 , n, T are defined as in claim 1; w and w′ are independently 1, 2, or 3; and 【Chemistry 6】 is a single bond, a double bond, or is absent; D 1 and D. 2 are the same or different and have the same definition as D.
3. A side chain linked compound of formula (IV): 【Chemistry 7】 During the ceremony, D, W, w, L 1 , L 2 , Q 1 , Q 2 , V 1 , V 2 , v 1 , and v 2 has the same definition as in claim 1; Lv 1 represents a leaving group capable of reacting with a thiol, amine, carboxylic acid, selenol, phenol, or hydroxyl group on a cell-binding molecule; Lv 1 represents a leaving group selected from OH; F; Cl; Br; I; nitrophenol; N-hydroxysuccinimide (NHS); phenol, dinitrophenol, pentafluorophenol, tetrafluorophenol; difluorophenol; monofluorophenol; pentachlorophenol; triflate; imidazole; dichlorophenol; tetrachlorophenol; 1-hydroxybenzotriazole; tosylate; mesylate; and 2-ethyl-5-phenylisoxazolium-3'-sulfonate.
4. A side chain-linked compound of formula (V) or (VI): 【Chemistry 9】 wherein, D, D 1 , D 2 , W, w, w', L 1 , L 2 , Q 1 , Q 2 , V 1 , V 2 , v 1 , v 2 , and 【Chemistry 10】 is the same as defined in claims 1 and 2; Lv 1 and Lv 2 are independently Lv of claim 3 1 This is the same as the definition of
5. The side chain linked conjugate compound according to claim 1 or 2, or the side chain linked compound according to claim 3 or 4, wherein Q 1 and Q 2 are independently selected from the following Iq-01 to Iq-36: 【Chemistry 11】 【change】 In the formula, R 25 and R 25’ are independently H; HC(O), CH 3 C(O), CH 3 C(NH), NHCH 3 , COOH, CONH 2 , CONHC 3 , C 1 -C 18 Alkyl, C 1 -C 18 Alkyl, alkyl-Y 1 -SO 3 H.C. 1 -C 18 Alkyl-Y 1 -PO 3 H 2 , C 1 -C 18 Alkyl-Y 1 -CO 2 H.C. 1 -C 18 Alkyl-Y 1 -N + R 12 R 13 R 13’ R 14 , C 1 -C 18 Alkyl-Y 1 -CONH 2 , C 2 -C 18 Alkylene, C 2 -C 18 Estelle, C. 2 -C 18 Ether, C 2 -C 18 Amine, C 2 -C 18 Alkyl carboxylamide, C 3 -C 18 Aryl, C 3 -C 18 Cyclic alkyl, C 3 -C 18 Heterocyclic, 1-24 amino acids; C 2 -C 18 lipid, C 2 -C 18 Fatty acid, or C 2 -C 18 Fatty ammonium lipids; X 1 and X 2 are independently NH, N(R 12’ ), O, C.H. 2 , S, C(O), S(O), S(O 2 ), P(O)(OH), NHNH, CH=CH, Ar, or (Aa) q1 (q 1 = 0 to 24 (0 to 24 amino acids, q 1 X is selected from the group consisting of: 1 , X 2 , X 3 , X 4 , Y 1 , Y 2 , and Y 3 are independently NH, N(R 12’ ), O, C(O), CH 2 , S, S(O), NHNH, C(O), OC(O), OC(O)O, OC(O)NH, NHC(O)NH, Ar, or (Aa) q1 is selected from the following: 1 , X 2 , X 3 , X 4 , Y 1 , Y 2 , and Y 3 may independently be absent; 1 , p 2 , and p 3 are independently 0 to 100, but not 0; q 1 , q 2 , and q 3 are independently 0 to 24. 12 , R 13 , R 13’ , and R 14’ are independently H and C 1 -C 6 alkyl; Aa is a natural or unnatural amino acid; Ar or (Aa) q1 are peptides of the same or different sequence; q 1 = 0 is (Aa) q1 means that it does not exist.
6. D,D 1 , and D 2 or a pharma- ceutically acceptable salt, hydrate, or hydrated salt thereof; or a polymorphic crystal structure of these compounds; or an optical isomer, racemate, diastereomer, or enantiomer thereof; (A) Calicheamicin analogues: 【Chemistry 12】 (B) Maytansinoids: 【Chemistry 13】 (C) Camptothecin (CPT) and its derivatives: 【Chemistry 14】 【change】 【change】 During the ceremony, 【Chemistry 15】 is the attachment site; R 1 , R 2 , and R 4 are independently H, F, Cl, Br, CN, NO 2 , C 1 ~C 8 Alkyl; O-C 1 ~C 8 Alkyl; NH-C 1 ~C 8 Alkyl; C 2 -C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl of C 3 -C 8 Ar is selected from aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or an ester, ether, amide, carbonate, urea, or carbamate having 2 to 8 carbon atoms; R 3 is H, OH, NH 2 , C 1 ~C 8 Alkyl; O-C 1 ~C 8 Alkyl; NH-C 1 ~C 8 Alkyl; C 2 -C 8 or an ester, ether, amide, carbonate, urea, or carbamate having 2 to 8 carbon atoms; or R 1 R 2 , R 2 R 3 , and R 3 R 4 independently form a 5- to 7-membered carbocyclic, heterocyclic, heterocycloalkyl, aromatic, or heteroaromatic ring system; P 1 is H, OH, NH 2 , COOH, C(O)NH 2 , O.C.H. 2 OP(O)(OR 18 ) 2 ,OC(O)OP(O)(OR 18 ) 2 , OPO (OR 18 ) 2 , NHPO (OR 18 ) 2 , O.C.(O)R 18 , OP(O)(OR 18 ) OP (O) (OR 18 ) 2 , O C (O) NHR 18 , O C (O) N (C 2 H 4 ) 2 NCH 3 , OSO 2 (OR 18 ), O-(C 4 -C 12 -glycosides), OC(O)N(C 2 H 4 ) 2 CH 2 N (C 2 H 4 ) 2 CH 3 , C 1 -C 8 Linear or branched alkyl or heteroalkyl of C 2 -C 8 Linear or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl of C 3 -C 8 Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 ) is; R 17 and R 18 are independently H, linear or branched alkyl or heteroalkyl; C 2 -C 8 Linear or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl of C 3 -C 8 Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 ). (D) Taxanes and their analogues: 【Chemistry 16】 (E) Anthracyclines and their analogues: 【Chemistry 17】 【change】 (F) Vinca alkaloids: 【Chemistry 18】 【change】 (G) Auristatins or dolastatin analogs, or pharma- ceutically acceptable salts, hydrates, or hydrated salts thereof; or polymorphic crystal structures of these compounds; or optical isomers, racemates, diastereomers, or enantiomers thereof: 【Chemistry 19】 In the formula, R 1 , R 2 , R 3 , R 4 , and R 5 are independently H; C 1 -C 8 linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester, ether, amide, amine, heterocycloalkyl, or acyloxylamine; or a peptide containing 1 to 8 amino acids, or a peptide of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p (p is an integer from 1 to about 5000). 1 R 2 , R 2 R 3 , R 1 R 3 , or R 3 R 4 can form a 3- to 8-membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group. 3 is H, CH 3 , or X 1’ R 1’ where X 1’ is NH, N(CH 3 ), NHNH, O, or S; R 1’ is H or C 1 -C 8 R is a straight or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, or acyloxylamine; 3’ is H or C 1 -C 6 is a straight chain or branched alkyl group of the formula: 3’ H, COOR 1 , N.H. 2 , N.H.R. 1 , OR 1 , C.O.N.R. 1 , NHCOR 1 , O.C.O.R. 1 , OP(O)(OM 1 ) (O.M. 2 ), O.C.H. 2 OP(O)(OM 1 ) (O.M. 2 ), OSO 3 M 1 , R 1 , or O-glycosides (glucosides, galactosides, mannosides, glucuronosides / glucuronides, allosides, fructosides, etc.), NH-glycosides, S-glycosides, or CH 2 - is a glycoside; M 1 and M. 2 are independently H, Na, K, Ca, Mg, NH 4 , N.R. 1 R 2 R 3 is; Y 1 and Y 2 is the connection site 【Chemistry 20】 and independently O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 2 ), C(O)NHNHC(O), and C(O)NR 1 Also, the connection site 【Chemistry 21】 and independently, OH, NH 2 , N.H.N.H. 2 , N.H.R. 5 , SH, C(O)OH, C(O)NH 2 , OC(O)NH 2 , OC(O)OH, NHC(O)NH 2 , NHC(O)SH, OC(O)NH(R 1 ), N(R 1 )C(O)NH(R 2 ), C(O)NHNHC(O)OH, and C(O)NHR 1 is; R 12 OH, NH 2 , N.H.R. 1 , N.H.N.H. 2 ,NHNHCOOH,OR 1 -COOH,NH-R 1 -COOH,NH-(Aa) n COOH, O(CH 2 CH 2 O) p CH 2 CH 2 OH, O(CH 2 CH 2 O) p CH 2 CH 2 N.H. 2 , NH(CH 2 CH 2 O) p CH 2 CH 2 N.H. 2 , N.R. 1 R 1’ , NHOH, NHOR 1 , O(CH 2 CH 2 O) p CH 2 CH 2 COOH,NH(CH 2 CH 2 O) p CH 2 CH 2 COOH, NH-Ar-COOH, NH-Ar-NH 2 , O(CH 2 CH 2 O) p CH 2 CH 2 H. 3 H,NH(CH 2 CH 2 O) p CH 2 CH 2 P.S. 3 H 1 -NHSO 3 H 1 -NHSO 3 H、O(CH 2 CH 2 O) p CH 2 -CH 2 P. 3 H 2 NH(CH 2 CH 2 O) p CH 2 CH 2 P. 3 H 2 OR 1 、R 1 -NHPO 3 H 2 、R 1 -OPO 3 H 2 O(CH 2 CH 2 O) p CH 2 CH 2 OPO 3 H 2 OR 1 -NHPO 3 H 2 NH-R 1 -NHPO 3 H 2 NH(CH 2 CH 2 NH) p CH 2 -CH 2 NH 2 NH(CH 2 CH 2 S) p CH 2 CH 2 NH 2 NH(CH 2 CH 2 NH) p CH 2 CH 2 OH, NH(CH 2 CH 2 S) p CH 2 -CH 2 OH, NH-R 1 -NH 2 , or NH(CH 2 CH 2 O) p CH 2 CH 2 N.H.P.O. 3 H 2 where Aa is 1 to 8 identical or different amino acids; p is 1-5000; R 1 , R 2 , R 3 , R 4 , R 5 , R 5’ , Z 1 , Z 2 , and n have the same definition as above. (H) Eribulin: 【Chemical 22】 (I) A nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, or a pharma- ceutically acceptable salt, hydrate, or hydrate salt thereof; or a polymorphic crystal structure of these compounds; or an optical isomer, racemate, diastereomer, or enantiomer thereof: 【Chemistry 23】 During the ceremony, 【Chemistry 24】 and X 1 has the same definition as in claim 5. 5 is F, Cl, Br, I, OH, OR 1 , R 1 , O.P.O. 3 H 2 , OSO 3 H, N.H.R. 1 , O.C.O.R. 1 , NHCOR 1 is; (J) Benzodiazepine dimers and analogs thereof, or pharma- ceutically acceptable salts, hydrates, or hydrated salts thereof; or polymorphic crystal structures of these compounds; or optical isomers, racemates, diastereomers, or enantiomers thereof: 【Chemistry 25】 【change】 【change】 In the formula, X 1 , X 2 , Y 1 , and Y 2 are independently O, N, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 1 ), CH, C(O)NHNHC(O), or C(O)NR 1 is; R 1 , R 2 , R 3 , R 1’ , R 2’ , and R 3’ are independently H; F; Cl; =O; =S; OH; SH; C 1 -C 8 Linear or branched alkyl, aryl, alkenyl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester (COOR 5 or -OC(O)R 5 ), Ether (OR 5 ), amide (CONR 5 ), carbamate (OCONR 5 ), amine (NHR 5 , N.R. 5 R 5’ ), heterocycloalkyl, or acyloxylamine (-C(O)NHOH, -ONHC(O)R 5 ); or a peptide comprising 1 to 20 natural or unnatural amino acids, or a peptide of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p (p is an integer from 1 to about 5000); 1 R 2 , R 2 R 3 , R 1 R 3 , R 1’ R 2’ , R 2’ R 3’ , or R 1’ R 3’ can independently form a 3- to 8-membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group; X 3 and Y 3 are independently N, NH, CH 2 , or C.R. 5 where R 4 , R 5 , R 6 , R 12 , and R 12’ are independently H, OH, NH 2 , NH(CH 3 ), N.H.N.H. 2 , COOH, SH, OZ 3 , S.Z. 3 , F, Cl, or C 1 -C 8 linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, acyloxylamine; Z 3 is H, OP(O)(OM 1 ) (O.M. 2 ), O.C.H. 2 OP(O)(OM 1 ) (O.M. 2 ), OSO 3 M 1 , or O-glycosides (glucosides, galactosides, mannosides, glucuronosides / glucuronides, allosides, fructosides, etc.), NH-glycosides, S-glycosides, or CH 2 - is a glycoside; M 1 and M. 2 are independently H, Na, K, Ca, Mg, NH 4 , N.R. 1 R 2 R 3 It is. (K) CC-1065 analogs and duocarmycin analogs: 【Chemistry 26】 In the formula, X 1 , X 2 , Y 1 , and Y 2 is the connection site 【Chemistry 27】 and independently O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 2 ), C(O)NHNHC(O), and C(O)NR 1 Also, the connection site 【Chemistry 28】 and independently, OH, NH 2 , N.H.N.H. 2 , N.H.R. 1 , SH, C(O)OH, C(O)NH 2 , OC(O)NH 2 , OC(O)OH, NHC(O)NH 2 , NHC(O)SH, OC(O)NH(R 1 ), N(R 1 )C(O)NH(R 2 ), C(O)NHNHC(O)OH, and C(O)NHR 1 is; Z 3 H, PO(O)(OM 1 ) (O.M. 2 ), S.O. 3 M 1 , C.H. 2 PO(O)(OM 1 ) (O.M. 2 ), C.H. 3 N (CH 2 CH 2 ) 2 NC(O)-, O(CH 2 CH 2 ) 2 N-C(O)-, R 1 or a glycoside; R 1 , R 2 , R 3 , M. 1 , M. 2 , and n have the same definition as above. (L) Tubulysin and its analogs, or pharma- ceutically acceptable salts, hydrates, or hydrated salts thereof; or polymorphic crystal structures of these compounds; or optical isomers, racemates, diastereomers, or enantiomers thereof: 【Chemical 29】 【change】 In the formula, X 1 and Y 1 are independently O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 1 ), CH, C(O)NHNHC(O), and C(O)NR 1 mAb is an antibody, preferably a monoclonal antibody; R 12 OH, NH 2 , N.H.R. 1 , N.H.N.H. 2 ,NHNHCOOH,OR 1 -COOH,NH-R 1 -COOH,NH-(Aa) n COOH, O(CH 2 CH 2 O) p CH 2 CH 2 OH, O(CH 2 CH 2 O) p CH 2 CH 2 N.H. 2 , NH(CH 2 CH 2 O) p CH 2 CH 2 N.H. 2 , N.R. 1 R 1’ , NHOH, NHOR 1 , O(CH 2 CH 2 O) p CH 2 CH 2 COOH,NH(CH 2 CH 2 O) p CH 2 CH 2 COOH, NH-Ar-COOH, NH-Ar-NH 2 , O(CH 2 CH 2 O) p CH 2 CH 2 NH-SO 3 H,NH(CH 2 CH 2 O) p CH 2 CH 2 P.S. 3 H 1 -NHSO 3 H 1 -NHSO 3 H、O(CH 2 CH 2 O) p CH 2 -CH 2 P. 3 H 2 NH(CH 2 CH 2 O) p CH 2 CH 2 P. 3 H 2 OR 1 、R 1 -NHPO 3 H 2 、R 1 -OPO 3 H 2 O(CH 2 CH 2 O) p CH 2 CH 2 OPO 3 H 2 OR 1 -NHPO 3 H 2 NH-R 1 -NHPO 3 H 2 NH(CH 2 CH 2 NH) p CH 2 -CH 2 NH 2 NH(CH 2 CH 2 S) p CH 2 CH 2 NH 2 NH(CH 2 CH 2 NH) p CH 2 CH 2 Hmm, Hmm 2 CH 2 S) p CH 2 -CH 2 OH, NH-R 1 -NH 2 , or NH(CH 2 CH 2 O) p CH 2 CH 2 N.H.P.O. 3 H 2 where Aa is 1 to 8 amino acids; n and m 1 is independently 1 to 20; p is 1 to 5000; R 1 , R 1’ , R 2 , R 3 , and R 4 are independently H, C 1 -C 8 linear or branched alkyl, amide, or amine of 2 -C 8 aryl, alkenyl, alkynyl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester, ether, heterocycloalkyl, or acyloxylamine; or a peptide containing 1 to 8 amino acids, or a peptide of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p (p is an integer from 1 to about 5000); 1 R 2 , R 2 R 3 , R 1 R 3 , or R 3 R 4 can independently form a 3- to 8-membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group; X 3 is H, CH 3 , C.H. 2 CH 3 , C 3 H 7 , or X 1’ R 1’ where X 1’ is NH, N(CH 3 ), NHNH, O, or S; R 1’ is H or C 1 -C 8 R is a straight or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, or acyloxylamine; 3’ is H or C 1 -C 6 is a straight chain or branched alkyl group of the formula: 3 H, COOR 1 , N.H. 2 , N.H.R. 1 , OR 1 , C.O.N.R. 1 , NHCOR 1 , O.C.O.R. 1 , OP(O)(OM 1 ) (O.M. 2 ), O.C.H. 2 OP(O)(OM 1 ) (O.M. 2 ), OSO 3 M 1 , R 1 , or O-glycosides (glucosides, galactosides, mannosides, glucuronosides / glucuronides, allosides, fructosides, etc.), NH-glycosides, S-glycosides, or CH 2 - is a glycoside; M 1 and M. 2 are independently H, Na, K, Ca, Mg, NH 4 , N.R. 1 R 2 R 3 It is. (M) amatoxin and its analogs, or pharma- ceutically acceptable salts, hydrates, or hydrated salts thereof; or polymorphic crystal structures of these compounds; or optical isomers, racemates, diastereomers, or enantiomers thereof: 【Chemistry 30】 In the formula, X 1 and Y 1 are independently O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 1 ), CH, C(O)NHNHC(O), and C(O)NR 1 is; R 7 , R 8 , and R 9 are independently H, OH, OR 1 , N.H. 2 , N.H.R. 1 , C 1 -C 6 alkyl, or absent; Y 2 Yes, O 2 , N.R. 1 , NH, or absent; R 10 is CH 2 , O., N.H., N.R. 1 , NHC(O), NHC(O)NH, NHC(O)O, OC(O)O, C(O), OC(O), OC(O)(NR 1 ), (NR 1 ) C(O)(NR 1 ), C(O)R 1 , or absent; R 11 OH, NH 2 , N.H.R. 1 , N.H.N.H. 2 ,NHNHCOOH,OR 1 -COOH,NH-R 1 -COOH,NH-(Aa) n COOH, O(CH 2 CH 2 O) p CH 2 CH 2 OH, O(CH 2 CH 2 O) p CH 2 CH 2 N.H. 2 , NH(CH 2 CH 2 O) p CH 2 CH 2 NH 2 NR 1 R 1’ 、NHOH、NHOR 1 O(CH 2 CH 2 O) p CH 2 CH 2 COOH, NH(CH 2 CH 2 O) p CH 2 CH 2 COOH、NH-Ar-COOH、NH-Ar-NH 2 O(CH 2 CH 2 O) p CH 2 CH 2 H. 3 H,NH(CH 2 CH 2 O) p CH 2 CH 2 P.S. 3 H 1 -NHSO 3 H 1 -NHSO 3 H、O(CH 2 CH 2 O) p CH 2 -CH 2 P. 3 H 2 NH(CH 2 CH 2 O) p CH 2 CH 2 P. 3 H 2 OR 1 、R 1 -NHPO 3 H 2 、R 1 -OPO 3 H 2 O(CH 2 CH 2 O) p CH 2 CH 2 OPO 3 H 2 OR 1 -NHPO 3 H 2 , N.H.-R. 1 -NHPO 3 H 2 , NH(CH 2 CH 2 N.H. p CH 2 -CH 2 N.H. 2 , NH(CH 2 CH 2 S) p CH 2 CH 2 N.H. 2 , NH(CH 2 CH 2 N.H. p CH 2 CH 2 OH, NH(CH 2 CH 2 S) p CH 2 -CH 2 OH, NH-R 1 -NH 2 , or NH(CH 2 CH 2 O) p CH 2 CH 2 N.H.P.O. 3 H 2 where Aa is 1 to 8 amino acids; n and m 1 is independently 1 to 20; p is 1 to 5000; R 1 and Ar have the same definition as in claim 1. (N) Protein kinase inhibitors: 【Chemistry 31】 【change】 【change】 【change】 【change】 (O) MEK inhibitors: 【Chemistry 32】 During the ceremony, Z 5 is O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 2 ), C(O)NHNHC(O), and C(O)NR 1 Selected from: (P) Proteinase inhibitors: 【Chemical 33】 (Q) An immunotoxin, which is a macromolecular drug that is a cytotoxic protein, usually derived from a bacterial or plant protein, selected from diphtheria toxin (DT), cholera toxin (CT), trichosanthin (TCS), dianthin, Pseudomonas exotoxin A (ETA'), erythrogenic toxin, diphtheria toxin, AB toxin, type III exotoxin, proerolysin, and topsalisin, and is attached via a side chain linker by an amino acid bearing an amine, thiol, or carboxylic acid group.
7. W, L 1 , L 2 , V 1 , and V 2 comprises independently one or more linker moieties of the following structures: 【Chemical 34】 【change】 【change】 【change】 or an L- or D-, natural or non-natural peptide containing from 1 to 20 identical or different amino acids; During the ceremony, 【Chemistry 35】 is a linking site; X 2 , X 3 , X 4 , X 5 , or X 6 are independently NH; NHNH; N(R 12 );N(R 12 ) N (R 12’ );O;S;C 1 -C 6 Alkyl; C 2 -C 6 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 -C 8 Aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; CH 2 OR 12 , C.H. 2 S.R. 12 , C.H. 2 NHR 12 or 1 to 8 amino acids; 12 and R 12’ are independently H; C 1 -C 8 Alkyl; C 2 -C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 -C 8 Aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or an ester, ether, or amide having 1 to 8 carbon atoms; or a group of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p where p is an integer from 0 to about 1000, or a combination thereof;
8. W, L 1 , L 2 , V 1 , and V 2 wherein each of the side chain linked conjugate compounds of claims 1 or 2 or the side chain linked compound of claims 3 or 4 independently comprises the structure: (B) a non-self-immolative linker moiety comprising any of the following structures: 【Chemical 37】 【change】 In the formula, ( * The atom labeled with X is the point of attachment to an additional spacer or releasable linker unit, a cytotoxic agent, and / or a binding molecule; 1 , Y 1 , U 1 , R 5 , R 5’ is as defined above; r is 0 to 100; m and n are independently 0 to 20; (C) at least one bond capable of being broken down under physiological conditions; a releasable component comprising a pH-labile, acid-labile, base-labile, oxidatively labile, metabolically labile, biochemically labile, or enzymatically labile bond and having one of the following structures: -(CR) 15 R 16 ) m (A) r (CR) 17 R 18 ) n (OCH) 2 CH 2 ) t -、-(CR 15 R 16 ) m (CR) 17 R 18 ) n (A) r (OCH) 2 CH 2 ) t -、-(A]) r -(CR) 15 R 16 ) m (CR) 17 R 18 ) n (OCH) 2 CH 2 ) t -、-(CR 15 R 16 ) m (CR) 17 R 18 ) n (OCH) 2 CH 2 ) r (A) t -、-(CR 15 R 16 ) m (CR) 17 =CR 18 )(CR 19 R 20 ) n (A) t (OCH) 2 CH 2 ) r -、-(CR 15 R 16 ) m (NR) 11 CON t (CR) 19 R 20 ) n (OCH) 2 CH 2 ) r -、-(CR 15 R 16 ) m (A) t (NR) 21 CR) 19 R 20 ) n (OCH) 2 CH 2 ) r -、-(CR 15 R 16 ) m (O) (A) t (CR) 19 R 20 ) n (OCH) 2 CH 2 ) r -、-(CR 15 R 16 ) m (OCNR) 17 )(Aa) t (CR) 19 R 20 ) n (OCH) 2 CH 2 ) r -、-(CR 15 R 16 ) m (C) (A) t -(CR) 19 R 20 ) n (OCH) 2 CH 2 ) r -、-(CR 15 R 16 ) m (NR) 21 CON t (CR) 19 R 20 ) n (OCH) 2 CH 2 ) r -、-(CR 15 R 16 ) m (O) (A) t (CR) 19 R 20 ) n -(OCH 2 CH 2 ) r -、-(CR 15 R 16 ) m (OCNR 17 ) (Aa) t (CR 19 R 20 ) n (O.C.H. 2 CH 2 ) r -, - (CR 15 R 16 ) m (CO) (Aa) t (CR 19 R 20 ) n (O.C.H. 2 CH 2 ) r -, - (CR 15 R 16 ) m -phenyl-(CO)(Aa) t (CR 17 R 18 ) n -, - (CR 15 R 16 ) m -furyl-(CO)(Aa) t (CR 17 R 18 ) n -, - (CR 15 R 16 ) m -oxazolyl-(CO)(Aa) t (CR 17 R 18 ) n -, - (CR 15 R 16 ) m -Thiazolyl-(CO)(Aa) t (CR 17 R 18 ) n -, - (CR 15 R 16 ) t -Thienyl-(CO)(CR 17 R 18 ) n -, - (CR 15 R 16 ) t -imidazolyl-(CO)(CR 17 R 18 ) n -, - (CR 15 R 16 ) t -Morpholino-(CO)(Aa) t (CR 17 R 18 ) n -, - (CR 15 R 16 ) t -piperazino-(CO)(Aa) t (CR 17 R 18 ) n -, - (CR 15 R 16 ) t -N-methylpiperazine-(CO)(Aa) t (CR 17 R 18 ) n -, - (CR 15 R 16 ) m -(Aa) t Phenyl-, -(CR 15 R 16 ) m -(Aa) t Frill-,-(CR 15 R 16 ) m -Oxazolyl (Aa) t -, - (CR 15 R 16 ) m -Thiazolyl (Aa) t -, - (CR 15 R 16 ) m -Thienyl (Aa) t -, - (CR 15 R 16 ) m -Imidazolyl (Aa) t -, - (CR 15 R 16 ) m -Morpholino-(Aa) t -, - (CR 15 R 16 ) m -Piperazino- (Aa) t -, - (CR 15 R 16 ) m -N-methylpiperazino- (Aa) t -, -K(CR 15 R 16 ) m (A) r (CR) 17 R 18 ) n (OCH) 2 CH 2 ) t -、-K(CR 15 R 16 ) m (CR) 17 R 18 ) n (A) r (OCH) 2 CH 2 ) t -、-K(Aa) r (CR) 15 R 16 ) m (CR) 17 R 18 ) n (OCH) 2 CH 2 ) t -、-K(CR 15 R 16 ) m (CR) 17 R 18 ) n (OCH) 2 CH 2 ) r (A) t -、-K(CR 15 R 16 ) m (CR) 17 =R 18 )(CR 19 R 20 ) n (A) t (OCH) 2 CH 2 ) r -、-K(CR 15 R 16 ) m (NR) 11 CON t (CR) 19 R 20 ) n (OCH) 2 CH 2 ) r -、-K(CR 15 R 16 ) m (A) t (NR) 21 CR) 19 R 20 ) n (OCH) 2 CH 2 ) r -、-K(CR 15 R 16 ) m (O) (A) t (CR) 19 R 20 ) n (OCH) 2 CH 2 ) r -、-K(CR 15 R 16 ) m (OCNR) 17 )(Aa) t (CR) 19 R 20 ) n (OCH) 2 CH 2 ) r -、-K(CR 15 R 16 ) m (C) (A) t (CR) 19 R 20 ) n (OCH) 2 CH 2 ) r -、-K(CR 15 R 16 ) m (NR) 21 CON t (CR) 19 R 20 ) n (OCH) 2 CH 2 ) r -、-K(CR 15 R 16 ) m (O) (A) t (CR) 19 R 20 ) n (OCH) 2 CH 2 ) r -、-K(CR 15 R 16 ) m (OCNR 17 ) (Aa) t (CR 19 R 20 ) n (O.C.H. 2 CH 2 ) r -, -K(CR 15 R 16 ) m (CO) (Aa) t (CR 19 R 20 ) n (O.C.H. 2 CH 2 ) r -, -K(CR 15 R 16 ) m -phenyl-(CO)(Aa) t (CR 17 R 18 ) n -, -K(CR 15 R 16 ) m -furyl-(CO)(Aa) t (CR 17 R 18 ) n -, -K(CR 15 R 16 ) m -oxazolyl-(CO)(Aa) t (CR 17 R 18 ) n -, -K(CR 15 R 16 ) m -Thiazolyl-(CO)(Aa) t (CR 17 R 18 ) n -, -K(CR 15 R 16 ) t -Thienyl-(CO)(CR 17 R 18 ) n -, -K(CR 15 R 16 ) t -imidazolyl-(CO)(CR 17 R 18 ) n -, -K(CR 15 R 16 ) t -Morpholino-(CO)(Aa) t (CR 17 R 18 ) n -, -K(CR 15 R 16 ) t -piperazino-(CO)(Aa) t (CR 17 R 8 ) n -, -K(CR 15 R 16 ) t -N-methylpiperazine-(CO)(Aa) t (CR 17 R 18 ) n -, -K(CR 15 R 16 ) m -(Aa) t Phenyl-, -K(CR 15 R 16 ) m -(Aa) t Frill-, -K (CR 15 R 16 ) m -Oxazolyl (Aa) t -, -K(CR 15 R 16 ) m -Thiazolyl (Aa) t -, -K(CR 15 R 16 ) m -Thienyl (Aa) t -, -K(CR 15 R 16 ) m -Imidazolyl (Aa) t -, -K(CR 15 R 16 ) m -Morpholino-(Aa) t -, -K(CR 15 R 16 ) m -Piperazino- (Aa) t G-, -K (CR 15 R 16 ) m -N-methylpiperazino- (Aa) t ; In the formula, m, Aa, m, n, R 13 , R 14 , and R 15 is defined as above; t and r are independently 0 to 100. R 16 , R 17 , R 18 , R 19 , and R 20 are independently H; halide; C 1 ~C 8 Alkyl or heteroalkyl; C 2 ~C 8 Aryl, alkenyl, alkynyl, ether, ester, amine, or amide; or one or more halides, CN, NR 12 R 12’ , C.F. 3 , OR 12 , aryl, heterocycle, S(O)R 12 , S.O. 2 R 12 , -CO 2 H, -SO 3 H, -OR 12 , -CO 2 R 12 , -CONR 12 , -PO 2 R 12 R 13 , -PO 3 H or P(O)R 12 R 12’ R 13’ C optionally substituted with 3 ~C 8 aryl; K is selected from NR 12 , -SS-, -C(=O)-, -C(=O)NH-, -C(=O)O-, -C=NH-O-, -C=N-NH-, -C(=O)NH-NH-, O, S, Se, B, Het(C 3 ~C 12 or a peptide containing 1 to 20 identical or different amino acids.
9. 3. The side chain-linked conjugate compound according to claim 1 or 2, which is a side chain-linked conjugate compound having the structure shown below, or a pharma- ceutically acceptable salt, hydrate, or hydrate salt thereof; or a polymorphic crystal structure of these compounds; or an optical isomer, racemate, diastereomer, or enantiomer thereof: 【Chemical 38】 In the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 , X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , Y 1 , Y 2 , Y 3 , Y 5 , R 12 , R 12’ , R 13 , R 13’ , R 25 , R 25’ , p 1 , p 2 , q 1 , q 2 , m, m 1 , n, and mAb are as described in claims 1, 2, 3, and 6; Aa is a natural or unnatural amino acid; r is 0 to 12; (Aa) r are peptides containing the same or different amino acid sequences when r>2, and when r=0, (Aa) r means that it does not exist.
10. 5. The side chain linked compound of claim 3 or 4, which is a side chain linked compound having the structure shown below, or a pharma- ceutically acceptable salt, hydrate, or hydrate salt thereof; or a polymorphic crystal structure of these compounds; or an optical isomer, racemate, diastereomer, or enantiomer thereof: 【Chemical 39】 In the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 , X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 8 , Y 1 , Y 2 , Y 3 , Y 5 , R 12 , R 12’ , R 13 , R 13’ , R 25 , R 25’ , Z 2 , Z 3 , p, p 1 , p 2 , p 3 , q 1 , q 2 , Lv 1 , Lv 2 , Lv 3 , Lv 3’ , m, m 1 , n, and mAb are as described in claims 3 and 6; Aa is a natural or unnatural amino acid; r is 0 to 12; (Aa) r is a peptide containing natural or unnatural amino acids, r>2; r=0 is (Aa) r means that it does not exist.
11. 10. The side chain linked conjugate compound of claim 1, 2, or 9, wherein the cell binding agent / molecule (T or mAb) is selected from: (A) the group consisting of antibodies, proteins, probodies, nanobodies, vitamins (including folic acid), peptides, polymeric micelles, liposomes, lipoprotein-based drug carriers, nanoparticle drug carriers, dendrimers, and the above molecules or particles conjugated to or coated with cell-binding ligands, or combinations thereof; (B) an antibody-like protein, a full-length antibody (polyclonal antibody, monoclonal antibody, dimer, multimer), or a multispecific antibody (selected from a bispecific antibody, a trispecific antibody, or a tetraspecific antibody); a single chain antibody, an antibody fragment that binds to a target cell, a monoclonal antibody, a single chain monoclonal antibody, a monoclonal antibody fragment that binds to a target cell, a chimeric antibody, a chimeric antibody fragment that binds to a target cell, a domain antibody, a domain antibody fragment that binds to a target cell, a resurfaced antibody, a single chain resurfaced antibody, a resurfaced antibody that binds to a target cell Constitutive antibody fragments, humanized antibodies or resurfaced humanized antibodies, single chain humanized antibodies or humanized antibody fragments that bind to target cells, anti-idiotypic (anti-Id) antibodies, CDRs, dimers, trimers, tetramers, miniantibodies, probodies, probody fragments, small immune proteins (SIPs), lymphokines, hormones, vitamins, growth factors, colony stimulating factors, nutrient transport molecules, large proteins, fusion proteins, kinase inhibitors, gene targeted drugs, and nanoparticles or polymers modified with antibodies or large proteins; (C) Cell-binding ligands or receptor agonists selected from the following: folic acid derivatives; glutamic acid urea derivatives; somatostatin and its analogs (selected from the group consisting of octreotide (Sandostatin) and lanreotide (Somatrin); aromatic sulfonamides; pituitary adenylate cyclase activating peptide (PACAP) (PAC1); vasoactive intestinal peptide (VIP / PACAP) (VPAC1, VPAC2); melanocyte stimulating hormone (α-MSH); cholecystokinin (CCK) / gastrin receptor agonists; bombesin (Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2 Neurotensin receptor ligands (NTR1, NTR2, NTR3); substance P (NK1 receptor) ligands; neuropeptide Y (Y1-Y6); homing peptides including RGD (Arg-Gly-Asp), NGR (Asn-Gly-Arg), dimeric and multimeric cyclic RGD peptides (cRGDfVc), TAASGVRSMH and LTLRWVGLMS (chondroitin sulfate proteoglycan NG2 receptor ligand) and F3 peptide; cell-permeable peptides luteinizing hormone releasing hormone (LHRH) agonists and antagonists, and gonadotropin releasing hormone (GnRH) agonists, which act by targeting follicle stimulating hormone (FSH) and luteinizing hormone (LH), as well as testosterone production, and include buserelin (Pyr-His-Trp-Ser-Tyr-D-Ser(OtBu)-Leu-Arg-Pro-NHEt), gonadorelin (Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH 2 ), goserelin (Pyr-His-Trp-Ser-Tyr-D-Ser(OtBu)-Leu-Arg-Pro-AzGly-NH2), histrelin (Pyr-His-Trp-Ser-Tyr-D-His(N-benzyl)-Leu-Arg-Pro-NHEt), leuprolide (Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt), nafarelin (Pyr-His-Trp-Ser-Tyr-2Nal-Leu-Arg-Pro-Gly-NH 2 ), Triptorelin (Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH 2 ), nafarelin, deslorelin, abarelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-(N-Me)Tyr-D-Asn-Leu-isopropyl-Pro-DAla-NH 2 ), Cetrorelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH 2 ), Degarelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-4-amioPhe(L-hydroorotyl)-D-4-amioPhe(carbamoyl)-Leu-isopropylLys-Pro-D-Ala-NH 2 ), and ganirelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-Tyr-D-(N9, N10-diethyl)-homoArg-Leu-(N9, N10-diethyl)-homoArg-Pro-D-Ala-NH 2 ); pattern recognition receptors (PRRs) selected from the group consisting of Toll-like receptor (TLR) ligands, C-type lectins, and Nod-like receptor (NLRs) ligands; calcitonin receptor agonists; integrin receptors and their receptor subtypes (α V β 1 , α V β 3 , α V β 5 , α V β 6 , α 6 β 4 , α 7 β 1 , α L β 2 , α IIb β 3 ) Agonists (GRGDSPK, cyclo(RGDfV)(L1) and its derivatives [cyclo(-N(Me)R-GDfV), cyclo(R-Sar-DfV), cyclo(RG-N(Me)D-fV), cyclo(RGD-N(Me)f-V), cyclo(RGDf-N(Me)V-) (Cilengitide)]; nanobodies (derivatives of VHH (camel Ig)); domain antibodies (dAb, derivatives of VH or VL domains), bispecific T cell induction (Bite, bispecific antibodies); dual affinity retargeting (DART, bispecific antibodies); tetravalent tandem antibodies (TandAb, dimerized bispecific antibodies); anticalins (derivatives of lipocalin); adnectins (tenth FN3 (fibronectin)); designed ankyrin repeat proteins (DARPins); avimers; EGF receptor and VEGF receptor agonists; (D) Small molecule or cell receptor agonist of cell binding molecule / ligand selected from the following: LB01 (folate conjugate), LB02 (PMSA ligand), LB03 (PMSA ligand), LB04 (PMSA ligand), LB05 (somatostatin), LB06 (somatostatin), LB07 (octreotide, somatostatin analog), LB08 (ramareotide, somatostatin analog), LB09 (vapreotide (sambar), somatostatin analog), L B10 (CAIX ligand), LB11 (CAIX ligand), LB12 (gastrin releasing peptide receptor (GRPr), MBA), LB13 (luteinizing hormone releasing hormone (LH-RH) ligand and GnRH), LB14 (luteinizing hormone releasing hormone (LH-RH) and GnRH ligand), LB15 (GnRH antagonist, abarelix), LB16 (cobalamin, vitamin B12 analog), LB17 (cobalamin, vitamin B12 analog), LB18 (α v β 3 for integrin receptors), LB19 (heterobivalent peptide ligand for VEGF receptors), LB20 (neuromedin B), LB21 (bombesin for G protein-coupled receptors), LB22 (TLR for Toll-like receptors), 2 ), LB23 (for androgen receptor), LB24 (α v Cilengitide / cyclo(-RGDfV-) for integrin receptors), LB23 (fludrocortisone), LB25 (rifabutin analog), LB26 (rifabutin analog), LB27 (rifabutin analog), LB28 (fludrocortisone), LB29 (dexamethasone), LB30 (fluticasone propionate), LB31 (beclomethasone dipropionate), LB32 (triamcinolone acetonide), LB33 (prednisone), LB34 (prednisolone), LB35 (methylprednisolone), LB36 (betamethasone), LB37 (irinotecan analog), LB3 8 (crizotinib analog), LB39 (bortezomib analog), LB40 (carfilzomib analog), LB41 (carfilzomib analog), LB42 (leuprolide analog), LB43 (triptorelin analog), LB44 (clindamycin), LB45 (liraglutide analog), LB46 (semaglutide analog), LB47 (retapamulin analog), LB48 (indibulin analog), LB49 (vinblastine analog), LB50 (lixisenatide analog), LB51 (osimertinib analog), LB52 (nucleoside analog), LB53 (erlotinib analog), or LB54 (lapatinib analog); 【Chemistry 40】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 (E): One or more of DNA, RNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA), and PIWI-interacting RNA (piRNA): 【Chemistry 41】 (F): Immunotoxins: diphtheria toxin (DT), cholera toxin (CT), trichosanthin (TCS), dianthin, Pseudomonas exotoxin A (ETA'), erythrogenic toxin, diphtheria toxin, AB toxin, type III exotoxin; During the ceremony, 【Chemistry 42】 is the linking site for the side chain linker of this patent; 【Chemistry 43】 is single-stranded or double-stranded DNA, RNA, mRNA, siRNA, miRNA, or piRNA; X 4 and Y 1 are independently O, NH, NHNH, NR 1 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 1 ), C.H. 2 , C(O)NHNHC(O), and C(O)NR 1 is; 1 is H, CH 2 , OH, O, C(O), C(O)NH, C(O)N(R 1 ), R 1 , N.H.R. 1 , N.R. 1 , C(O)R 1 or C(O)O; X 5 is H, CH 3 , F, or Cl; 1 and M. 2 are independently H, Na, K, Ca, Mg, NH 4 , N(R 12 R 12’ R 13 R 13’ ) is; R 12 , R 12’ , R 13 , and R 13’ is defined in claim 1.
12. The side chain linked conjugate compound of claim 1, 2, or 11, having one or more of the following bond structures: 【Chemistry 44】 【change】 In the formula, R 20 and R 21 is independent, C 1 ~C 8 Alkyl; C 2 ~C 8 Heteroalkyl or heterocycle; C 3 ~C 8 Aryl, Ar-alkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, carbocycle, or alkylcarbonyl; or (CH 2 CH 2 O) p C having the formula 2 ~C 100 It is polyethylene glycol.
13. The side chain linked conjugate compound of any one of claims 1, 2, 9, or 11, wherein the cell binding agent / molecule is capable of targeting tumor cells, virus-infected cells, microbial-infected cells, parasite-infected cells, autoimmune disease cells, activated tumor cells, bone marrow cells, activated T cells, affected B cells, or melanocytes, or cells expressing one or more of the following antigens or receptors: CD1, CD1a, CD1b, CD1c, CD1d, CD1e, CD2, CD3, CD3d, CD3e, CD3g, CD4, CD5, CD6, CD7, CD8, CD8a, CD8 b, CD9, CD10, CD11a, CD11b, CD11c, CD12w, CD14, CD15, CD16, CD16a, CD16b, CDw17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD 29, CD30, CD31, CD32, CD32a, CD32b, CD33, CD34, CD35, CD36, CD37, CD38, CD 39, CD40, CD41, CD42, CD42a, CD42b, CD42c, CD42d, CD43, CD44, CD45, CD46, C D47, CD48, CD49b, CD49c, CD49c, CD49d, CD49f, CD50, CD51, CD52, CD53, CD5 4, CD55, CD56, CD57, CD58, CD59, CD60, CD60a, CD60b, CD60c, CD61, CD62E, C D62L, CD62P, CD63, CD64, CD65, CD65s, CD66, CD66a, CD66b, CD66c, CD66d, C D66e, CD66f, CD67, CD68, CD69, CD70, CD71, CD72, CD73, CD74, CD74, CD75, CD 75s, CD76, CD77, CD78, CD79, CD79a, CD79b, CD80, CD81, CD82, CD83, CD84, C D85, CD85a, CD85b, CD85c, CD85d, CD85e, CD85f, CD85g, CD85g, CD85i, CD85j , CD85k, CD85m, CD86, CD87, CD88, CD89, CD90, CD91, CD92, CD93, CD94, CD95 , CD96, CD97, CD98, CD99, CD100, CD101, CD102, CD103, CD104, CD105, CD106,CD107、CD107a、CD107b、CD108、CD109、CD110、CD111、CD112、CD113、CD114、CD115、CD116、CD117、CD118、CD119、CD120a、CD120b、CD121、CD121a、CD121b、CD122、CD123、CD123a、CD124、CD125、CD126、CD127、CD128、CD129、CD130、CD131、CD132、CD133、CD134、CD135、CD136、CD137、CD138、CD139、CD140、CD140a、CD140b、CD141、CD142、CD143、CD144、CD145、CDw145、CD146、CD147、CD148、CD149、CD150、CD151、CD152、CD153、CD154、CD155、CD156a、CD156b、CD156c、CD156d、CD157、CD158、CD158a、CD158b1、CD158b2、CD158c、CD158d、CD158e1、CD158e2、CD158f2、CD158g、CD158h、CD158i、CD158j、CD158k、CD159、CD159a、CD159b、CD159c、CD160、CD161、CD162、CD163、CD164、CD165、CD166、CD167、CD167a、CD167b、CD168、CD169、CD170、CD171、CD172、CD172a、CD172b、CD172g、CD173、CD174、CD175、CD175s、CD176、CD177、CD178、CD179、CD179a、CD179b、CD180、CD181、CD182、CD183、CD184、CD185、CD186、CDw186、CD187、CD188、CD189、CD190、CD191、CD192、CD193、CD194、CD195、CD196、CD197、CD198、CDw198、CDw199、CD200、CD201、CD202(a,b)、CD203、CD203c、CD204、CD205、CD206、CD207、CD208、CD209、CD210、CDw210a、CDw210b、CD211、CD212、CD213、CD213a1、CD213a2、CD214、CD215、CD216、CD217、CD218、CDw218a、<h2 style=";text-align:left;direction:ltr">CD218、CD21b9、CD220、CD221、CD222、 CD223、CD224、CD225、CD226、CD227、C D228、CD229、CD230、CD231、CD232、CD 233、CD234、CD235a、CD235b、CD236、CD 235523 ... CD2445、CD246、CD247、CD248、CD249、CD250、CD251、CD252、CD253、CD254、CD2 55、CD256、CD257、CD258、CD259、CD260、CD261、CD262、CD263、CD264、CD265 、CD266、CD267、CD268、CD269、CD270、 CD271、CD272、CD273、CD274、CD275、CD 276、CD277、CD278、CD279、CD281、CD2 82、CD283、CD284、CD285、CD286、CD28 7、CD288、CD289、CD290、CD291、CD292、CD293、CD294、CD295、CD296、CD297、C D298、CD299、CD300、CD300a、CD300b、 CD300c、CD301、CD302、CD303、CD304、 CD305、CD306、CD307、CD307a、CD307b 、CD307c、CD307d、CD307e、CD307f、CD3 08、CD309、CD310、CD311、CD312、CD31 3、CD314、CD315、CD316、CD317、CD318 、CD319、CD320、CD321、CD322、CD323、 CD324、CD325、CD326、CD327、CD328、CD 3229、CD330、CD331、CD332、CD333、CD334、CD335、CD336、CD337、CD338、CD33 9、CD340、CD341、CD342、CD343、CD344 、CD345、CD346、CD347、CD348、CD349、C 535 ... 60、CD361、CD362、CD363、CD364、CD36 5、CD366、CD367、CD368、CD369、CD370、CD371, CD372, CD373, CD374, CD375, CD376, CD377, CD378, CD379, CD381, CD382, CD383, CD384, CD385, CD386, CD387, CD388, CD389, CRIPTO, CRIPTO, CR, CR1, CRGF, CRIPTO, CXCR5, LY64, TDGF1, 4-1BB, APO2, ASLG659, BMPR1B, 4-1BB, 5AC, 5T4 (trophoblast glycoprotein, TPBG, 5T4, inhibitor of Wnt activation 1 or WAIF1), adenocarcinoma antigen, AGS-5, AGS-22M6, activin receptor-like kinase 1, AFP, AKAP-4, ALK, α integrin, αvβ6, aminopeptidase N, amyloid beta, androgen receptor, angiopoietin 2, angiopoietin 3, annexin A1, anthrax toxin protective antigen, anti-transferrin receptor, AOC3 (VAP-1), B7-H3, anthrax, BAFF (B-cell activating factor), BCMA, B-lymphoma cells, bcr-abl, bombesin, BORIS, C5 , C242 antigen, CA125 (carbohydrate antigen 125, MUC16), CA-IX (or CAIX, carbonic anhydrase 9), CALLA, CanAg, canine IL31, carbonic anhydrase IX, cardiac myosin, CCL11 (C-C motif chemokine 11), CCR4 (CC chemokine receptor type 4, CD194), CCR5, CD3E (epsilon), CEA (carcinoembryonic antigen), CEACAM3, CEACAM5 (carcinoembryonic antigen), CFD (factor D), Ch4D5, cholecystokinin 2 (CCK2R), CLDN18 (crow din-18), CLDN18.1 (claudin-18.1), CLDN18.2 (claudin-18.2), clumping factor A, cMet, CRIPTO, FCSF1R (colony-stimulating factor 1 receptor, CD115), CSF2 (colony-stimulating factor 2, granulocyte-macrophage colony-stimulating factor (GM-CSF)), CSP4, CTLA4 (cytotoxic T-lymphocyte-associated protein 4), CTAA16.88 tumor antigen, CXCR4, CXC chemokine receptor type 4, cADP ribose hydrolase, Cyclin B1, CYP1B1, cytomegalovirus, cytomegalovirus glycoprotein B, dabigatran, DLL3 (delta-like ligand 3), DLL4 (delta-like ligand 4),DPP4 (dipeptidyl peptidase 4), DR5 (death receptor 5), E. coli Shiga toxin type 1, E. coli Shiga toxin type 2, ED-B, EGFL7 (EGF-like domain containing protein 7), EGFR, EGFRII, EGFRvIII, endoglin, endothelin B receptor, endotoxin, EpCAM (epithelial cell adhesion molecule), EphA2, episialin, ERBB2 (epidermal growth factor receptor 2), ERBB3, ERG (TMPRSS), S2ETS fusion gene), E. coli, ETV6-AML, FAP (fibroblast activation protein α), fibroblast surface antigen, FCGR1, α-fetoprotein, fibrin II, β chain, fibronectin ectodomain B, FOLR (folate receptor), folate receptor α, folate hydrolase, respiratory syncytial virus Fos-related antigen 1F protein, Frizzled receptor, fucosyl GM1, GD2 ganglioside, G-28 (cell surface glycolipid antigen Gen), GD3 idiotype, GloboH, glypican 3, N-glycolylneuraminic acid, GM3, GMCSF receptor α chain, growth differentiation factor, GP100, GPNMB (transmembrane protein NMB), GUCY2C (guanylate cyclase 2C, guanylate cyclase C (GC-C), intestinal guanylate cyclase, guanylate cyclase-C receptor, heat-stable enterotoxin receptor (hSTAR)), heat shock protein, hemocyte agglutinins, hepatitis B surface antigen, hepatitis B virus, HER1 (human epidermal growth factor receptor 1), HER2, HER2 / neu, HER3 (ERBB-3), IgG4, HGF / SF (stem cell growth factor / scatter factor), HHGFR, HIV-1, histone complex, HLA-DR (human leukocyte antigen), HLA-DR10, HLA-DRB, HMWMAA, human chorionic gonadotropin, HNGF, human scatter factor receptor kinase, HPV E6 / E7, Hsp90, hTERT, ICAM-1 (intercellular adhesion molecule 1), idiotype, IGF1R (IGF-1, insulin-like growth factor 1 receptor), IGHE, IFN-γ, influenza hemagglutinin, IgE, IgE Fc region, IGHE, interleukins (IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-6R, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-17A, IL-18, IL-19,IL-20, IL-21, IL-22, IL-23, IL-27, or IL-28), IL-31RA, ILGF2 (insulin-like growth factor 2), integrin (α4, α, IIIb β 3 , αvβ3, α 4 β 7 , α5β1, α6β4, α7β7, αIIβ3, α5β5, αvβ5), interferon-gamma-inducible protein, ITAGA2, ITGB2, KIR2D, Kappa Ig, LCK, Le, legumain, Lewis-Y antigen, LFA-1 (lymphocyte function-associated antigen 1, CD11a), LHRH, LINGO-1, lipoteichoic acid, LIV1A, LMP2, LTA, MAD-CT-1, MAD-CT-2, MAGE-1, MAGE-2, MAGE-3, MAGEA1, MAGEA3, MAGE4, MART1, MCP-1, MIF (macrophage migration inhibitory factor or glycosylation inhibitory factor (GIF)), MS4A1 (transmembrane 4 domain subfamily A member 1), MSLN (mesothelin), MUC1 (mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM)), MUC1-KLH, MUC16 (CA125), MCP1 (monocyte chemotactic protein 1), MelanA / MART1, ML-IAP, MPG, MS4A1 (transmembrane 4 domain subfamily A), MYCN, myelin-associated glycoprotein, myostatin, NA17, NARP-1, NCA-90 (granulocyte antigen), Nectin-4 (ASG-22ME), NGF, neuronal apoptosis-regulating proteinase 1, NOGO-A, Notch receptor, nucleolin, Neu oncogene product, NY-BR-1, NY-ESO-1, OX-40, OxLDL (oxidized low density lipoprotein), OY-TES1, P21, non-mutant p53, P9 7, Page 4, PAP, anti-(N-glycolylneuraminic acid) paratope, PAX3, PAX5, PCSK9, PDCD1 (PD-1, programmed cell death protein 1), PDGF-Rα, (platelet-derived growth factor receptor α), PDGFR-β, PDL-1, PLAC1, PLAP-like testicular alkaline phosphatase, platelet-derived growth factor receptor β, sodium phosphate cotransporter, PMEL17, polysialic acid, proteinase 3 (PR1), prostate cancer, PS (phosphatidylserine), prostate cancer cells, Pseudomonas aeruginosa, PSMA, PSA, PSCA, rabies virus glycoprotein, RHD (Rh polypeptide 1 (RhPI)), Rhesus factor, RANKL, PhoC,Ras mutants, RGS5, ROBO4, respiratory syncytial virus, RON, ROR1, sarcoma metastasis breakpoint, SART3, sclerostin, SLAMF7 (SLAM family member 7), selectin P, SDC1 (syndecan 1), sLe(a), somatomedin C, SIP (sphingosine-1-phosphate), somatostatin, sperm protein 17, SSX2, STEAP1 (six-transmembrane epithelial of the prostate 1) antigen), STEAP2, STn, TAG-72 (tumor-associated glycoprotein 72), survivin, T cell receptor, T cell transmembrane protein, TEM1 (tumor epithelial marker 1), TENB2, tenascin-C (TN-C), TGF-α, TGF-β (transforming growth factor beta), TGF-β1, TGF-β2 (transforming growth factor beta 2), Tie (CD202b), Tie2, TIM-1 (CDX-014), TN, TNF, TNF-α, TNFRSF8, TNFRSF10B (tumor necrosis factor receptor superfamily member 10B), TNFRSF13B (tumor necrosis factor receptor superfamily member 13B), TPBG (trophoblast glycoprotein), TRAIL-R1 (tumor necrosis-inducing ligand receptor 1), TRAILR2 (death receptor 5 (DR5)), tumor-associated calcium signaling Transducer 2, tumor-specific glycosylation of MUC1, TWEAK receptor, TYRP1 (glycoprotein 75), TRP-1 (Trop1), TRP-2 (Trop2), tyrosinase, VCAM-1, VEGF, VEGF-A, VEGF-2, VEGFR-1, VEGFR2, or vimentin, WT1, XAGE1, or any insulin growth factor receptor, or any epidermal growth factor receptor.
14. The side chain linked conjugate compound of claim 13, wherein the tumor cells are selected from lymphoma cells, myeloma cells, renal cells, breast cancer cells, prostate cancer cells, ovarian cancer cells, colorectal cancer cells, gastric cancer cells, squamous cell carcinoma cells, small cell lung cancer cells, non-small cell lung cancer cells, testicular cancer cells, or malignant cells.
15. 10. A pharmaceutical composition comprising a therapeutically effective amount of a side-chain linked conjugate compound of any one of claims 1, 2, or 9, and a pharma- ceutically acceptable salt, carrier, diluent, or excipient.
16. 16. The pharmaceutical composition of claim 15, which is a liquid formulation or a lyophilized solid / powder formulation, comprising: 0.01% to 99% by weight of one or more side-chain linked conjugate compounds according to any one of claims 1, 2, or 9; Polyol 0.0% to 20.0%; 0.0% to 2.0% of one or more surfactants; 0.0% to 5.0% of one or more preservatives; 0.0% to 30% of one or more amino acids; 0.0% to 5.0% of one or more antioxidants; 0.0% to 0.3% of one or more metal chelating agents; 0.0% to 30.0% of one or more buffer salts to adjust the pH of the formulation to 4.5 to 7.5; 0.0% to 30.0% of one or more tonicity agents to adjust the osmolality to between about 250 and 350 mOsm after reconstitution for administration to a patient; The polyol is selected from fructose, mannose, maltose, lactose, arabinose, xylose, ribose, rhamnose, galactose, glucose, sucrose, trehalose, sorbose, melezitose, raffinose, mannitol, xylitol, erythritol, maltitol, lactitol, erythritol, sorbitol, glycerol, or L-gluconate and its metal salts; The surfactant may be polysorbate 20, polysorbate 40, polysorbate 65, polysorbate 80, polysorbate 81, or polysorbate 85, poloxamer, poly(ethylene oxide)-poly(propylene oxide), polyethylene-polypropylene, Triton; sodium dodecyl sulfate (SDS), sodium lauryl sulfate; sodium octyl glucoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl-, or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamide propyl- myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl-, or disodium methyl oleyl-taurate; dodecyl betaine, dodecyl dimethylamine oxide, cocamidopropyl betaine, and cocoamphoglycinate; or isostearyl ethylimidonium ethosulfate; polyethyl glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol; The preservative is selected from benzyl alcohol, octadecyl dimethyl benzyl ammonium chloride, hexatonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, or m-cresol; The antioxidant is selected from ascorbic acid, glutathione, cystine, or methionine; The chelating agent is selected from EDTA or EGTA; The amino acids are selected from arginine, cystine, glycine, lysine, histidine, ornithine, isoleucine, leucine, alanine, glycine, glutamic acid, or aspartic acid; The buffer salt is selected from sodium, potassium, ammonium, or trihydroxyethylamino salts of citric acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetate, or phthalic acid; tris or tromethamine hydrochloride, phosphate, or sulfate; anionic acetate, chloride, phosphate, sulfate, or succinate of arginine, glycine, glycylglycine, or histidine; The tonicity agent is selected from mannitol, sorbitol, sodium acetate, potassium chloride, sodium phosphate, potassium phosphate, trisodium citrate, or sodium chloride.
